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ABSTRACT 
 
High Performance Lipoprotein Profiling for Cardiovascular Risk Assessment 
(August 2012) 
Craig Daniel Larner, B.S., Adrian College 
Chair of Committee: Dr. Ronald D. Macfarlane 
 
 With the severity of cardiovascular disease (CVD) and the related mortality rate 
to this disease, new methods are necessary for risk assessment and treatment prior to the 
onset of the disease.  The current paradigm in CVD risk assessment has shifted towards 
the multivariate approach over the individual use of traditional risk factors or lipid 
measurements.  Through a combination of analytical techniques and multivariate 
statistical analysis, a novel method of cardiovascular risk assessment was developed.  
The analytical techniques employed include density gradient ultracentrifugation (DGU) 
and matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) applied 
to human serum.  These techniques provided detailed information about the 
characterization of the lipoproteins and their structural components, specifically the 
apolipoproteins belonging to high density lipoproteins (HDL).  This information when 
combined with multivariate statistical analysis provided a method that accurately 
identified the presence of CVD in clinical studies between cohorts of subjects that had 
been previously diagnosed with CVD and cohorts of subjects that had been identified as 
healthy controls (CTRL) based on a clear angiography.   
iv 
 
 
 
  The lipoprotein density profiles were divided into subclasses based on their 
density and measured using a fluorescent probe to tag the lipoprotein particles.  Use of 
multiple ethylenediaminetetraacetic acid (EDTA) based solutes allowed for the 
manipulation of the density gradient formation in order to separate the lipoproteins by 
specific density ranges in order to achieve better baseline separation of the profiles.  
Application of the integrated fluorescence intensities for each subclass of lipoprotein to 
linear discriminant analysis/sliced inverse regression (LDA/SIR) and quadratic 
discriminant analysis (QDA) yielded an advanced and accurate form of risk assessment 
for CVD.  This method was found to be highly accurate as well as identify potential 
atherogenic lipoprotein subclasses through studying the LDA/SIR prediction equation 
generated.  It was also shown that the LDA/SIR equation could be used to monitor 
medical treatment and lifestyle change for their effects on the risk assessment model. 
Further study into the atherogenicity of HDL through analysis of the 
apolipoproteins using MALDI-MS led to identification of potential risk factors that 
could be added to the statistical analyses.  These risk factors included mass differences 
in the Apolipoprotein A-I (Apo A-I) and Apolipoprotein C-I (Apo C-I) between CVD 
and CTRL samples as well as the presence of specific mass peaks related to 
Apolipoprotein A-II (Apo A-II) that were primarily found in the CVD samples.  These 
differences, in addition to the lipoprotein density profile data, were found to increase the 
potential accuracy of CVD risk assessment.   The combination of these methods has 
shown great potential in the assessment of CVD risk as well as the ability to increase 
researchers’ understanding of the nature of VD and how to treat it. 
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1. INTRODUCTION 
 
1.1 Significance 
 With the significance of cardiovascular disease (CVD) and the related mortality 
rate, the current paradigm in risk assessment of CVD has been shifted to the use of 
multiple risk factors in the development of predictive algorithms.
1-7
  Current risk 
assessment methods have only been shown to be 80% accurate, at most, and they are 
widely inaccurate for subjects that show limited to no traditional risk factors and those 
subjects that either elderly or youthful.  In a recent report, the National Cholesterol 
Education Program (NCEP) recommended that lipid screening tests consisting of total 
cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein 
cholesterol (HDL-C), and triglyceride (TG) measurements be performed as a standard 
health assessment.
8
  While these measurements can be beneficial, they do not account 
for all the possible information that can be obtained from the lipoprotein particles.   
 Lipoproteins are a form of nanoparticle present in human serum that performs a 
major role in the metabolism and transportation of lipids, triglycerides, cholesterols, and 
cholesterol esters in the human body.  
9
  These nanoparticles can be separated and 
characterized based on their density through density gradient ultracentrifugation (DGU). 
 
________________ 
This thesis follows the style of Analytical Chemistry. 
2 
 
 
 
While other techniques such as nuclear magnetic resonance (NMR), chromatographic 
separations, and electrophoretic separations have been used to profile lipoproteins, DGU 
has long been considered the “gold standard” of lipoprotein characterization.9-11  
Through a combination of novel EDTA-based solutes
12,13
 and NBD C6-Ceramide 
(NBD), a lipoprotein-specific fluorophore, the self-forming density gradients have 
expanded the potential and analytical power of DGU.  Previously, application of this 
method has shown potential application for the risk assessment of CVD.
14
  Through 
enhancing the precision of the method, it became possible to increase the accuracy of the 
risk assessment and apply the methodology to larger clinical studies. 
 Mass spectrometry is another analytical tool that has shown use in the 
characterization of lipoproteins and their content.  Through soft ionization techniques 
such as MALDI-MS
15
, the apolipoprotein content of the HDL in serum has been studied 
and potential risk factors identified.
16
  Application of the mass/charge data obtained from 
this technique, coupled with the lipoprotein density profile data, has the potential to be 
added to the risk assessment methods as possible risk factors.  
 To develop the risk assessment algorithm, different multivariate statistical 
analyses can be used.  Linear discriminant analysis/sliced inverse regression 
(LDA/SIR)
17-20
 and quadratic discriminant analysis (QDA)
21
 are two different types of 
multivariate statistical analyses that can be applied to CVD risk assessment.  These 
methods inter-relate the variables used to generate the prediction equation in order to 
optimize the separation of the different sample groups.   
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 This work utilizes the techniques of DGU and MALDI-MS coupled with 
LDA/SIR and QDA statistical analyses in order to identify potential risk factors for CVD 
and generate a risk assessment algorithm for early detection of CVD. 
 
1.2 Cardiovascular Disease Risk Assessment Methods and Therapies 
 Cardiovascular disease is a class of diseases that affect the heart and arteries.  
Despite the advances in medical treatment, cardiovascular disease remains the leading 
cause of death worldwide.
22
  For this reason, current research in the field of 
cardiovascular disease includes identification of novel risk factors, development of 
advanced multivariate risk assessment methods
5,23-25
, and investigation into therapeutic 
methods for risk reduction. 
 
1.2.1 CVD Risk Assessment Methods 
Traditional risk factors (TRF) for preclinical screening of CVD include levels of 
Total Cholesterol, Triglycerides, High Density Lipoprotein Cholesterol (HDL-C), and 
Low Density Lipoprotein Cholesterol (LDL-C).  Other factors included in risk 
assessment are age, high blood pressure, diagnosis of diabetes, tobacco use, family 
history, and hypertension.
3,6,26
  The old paradigm of cardiovascular risk assessment using 
the presence of individual risk factors in an additive risk system has begun to shift to a 
multivariate approach of how all risk factors interrelate.
2,4,5,23,24,27
  Different multivariate 
methods that have been developed include the Framingham Risk Score, Reynolds Risk 
Score, and Systematic COronary Risk Evaluation (FRS, RRS, and SCORE, 
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respectively).
3,6,28
  These methods are regularly used to diagnose the risk of disease over 
a given period of time and are fairly accurate.   
FRS is a risk assessment tool developed from the Framingham Heart Study.  This 
study was established in 1948 and monitored 5,209 subjects between the ages of 28 to 62 
over time for risk factors related to CVD.  This study was broadened in 1971 to include 
the offspring of the original cohort as well as their spouses.
3
  The risk models developed 
from this study have been design to assess 5-year, 10-year, 30-year, and lifetime risk of 
CVD.
3,7,29
  These risk models are based on lipid concentrations, specifically total 
cholesterol (TC) and HDL cholesterol (HDL-C).  The c-statistics for FRS typically range 
from 0.7-0.8 indicating a 70-80% accuracy using this model.
2,30
  These risk scores, 
specifically the 10-year risk score, have weaknesses in diagnosing specific populations.  
These populations include young people and women.
31
  Other populations that have been 
inaccurately identified with/without risk include subjects with normal lipid levels
3
, 
subjects of varied ethnicity
32
, and those subjects with extensive forms of the disease in 
need of more aggressive treatments
33
.   
Based on the FRS, multiple different risk score methods have been developed 
using additional risk factors or new methods in order to increase the overall accuracy of 
risk assessment.  In an attempt to apply novel risk factors for CVD to diagnose women, 
the Reynolds Risk Score (RRS) was developed.
6
  In the RRS, hemoglobin A1c, high 
sensitivity c-reactive protein (hs-CRP), lipoprotein(a), apolipoproteins A-I and B-100, 
and parental history were included to improve the classical risk score.  This method was 
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found to reclassify 50% of the study population into new risk categories that more 
accurately assessed the level or risk for the population.   
Due to the difference in the definition of non-fatal end-points used in the FRS 
from other clinical studies, the SCORE method was developed to estimate risk in 
European populations.
28,34
  This method was based on the TC and the TC/HDL-C ratio.  
The results showed that the methods were able to estimate risk at a level suitable for 
clinical practice by achieving 71-84% accuracy.  The over-arching goal of these and 
other risk assessment methods is to have an accurate and cost efficient method which 
could be used for early diagnosis of CVD risk and allow for monitoring of therapeutic 
treatments in an effort to reduce risk in the early stages of the disease.
30
  With the 
identification of novel risk factors and enhanced methodologies, current research is 
aimed at developing risk assessment algorithms with higher accuracy which can be 
applied to clinical applications. 
 
1.2.2 CVD Therapies 
 Risk assessment methods for CVD are only clinically applicable if methods of 
therapeutic treatment can be monitored for risk reduction.  Many therapeutic methods 
have been studied over the course of CVD research.  The primary methods of therapy 
currently used include statin therapy, niacin therapy, and lifestyle modifications such as 
diet and exercise.
26
  These therapies are designed to modify lipoproteins in the subject’s 
serum in order to promote the “good” forms of lipoproteins and reduce the “bad” forms. 
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 Statins have been used in clinical applications in order to lower LDL-C and raise 
HDL-C.
35-37
  Statins work through inhibition of 3-hydroxy-3-methylclutaryl-coenzyme 
A (HMG-CoA) reductase which causes increased regulation of LDL-C receptors and 
results in enhanced removal of LDL-C from human blood.
37
  Statin therapy has currently 
formulated six different types of statins which all show different efficacies based on 
dosage and have different side effects.  Intensive statin therapy has been shown to reduce 
the rate or progression of atherosclerosis as well as decrease the levels of atherogenic 
lipoproteins and CRP.
38
 
 Niacin therapies have been coupled with statin therapy to show enhancements in 
the reduction of cardiovascular risk.
39,40
  Niacin has been shown to reduce LDL-C, TG, 
and lipoprotein(a) while increasing HDL-C.
41
  Like statins, there are multiple forms of 
niacin therapy, each with their own beneficial properties.  The formulations for niacin 
are based on their release times: immediate release, extended release, and long acting.
41
  
The different formulations control how the drug is metabolized in the body.  Niacin has 
been limited in use due to issues with patient tolerability related to dosage and 
formulation.   
 Due to the potential adverse effects related to medical therapies, lifestyle 
modification prior to the onset of CVD shows the most promise in risk reduction.  Some 
of the specific lifestyle characteristics related to the onset of CVD include tobacco 
usage, inactivity, and obesity.
26
  CVD preventative measures for these areas include the 
cessation of tobacco usage, dietary modification, and exercise.  These types of 
modification are considered primordial prevention.  Exercise and dietary changes are 
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targeted to control lipid levels
42,43
, reduce blood pressure and obesity
44
, and prevent 
onset of conditions that are precursory to CVD, such as diabetes and metabolic 
syndrome.
45
  For dietary changes, it has been recommended that one should increase 
fiber intake through fruits and vegetables while lowering the intake of saturated fats 
from meat and dairy products.
26
  For exercise, it is recommended that one should have at 
least 30-60 minutes of moderate to intense physical activity every day if possible.
26
  
 Despite the method of therapy chosen, risk reduction associated with lipids and 
lipoproteins is common to all of them.  This is due to the correlations made between 
lipid levels and risk of CVD.
8
  It is for this reason that risk assessment methodologies are 
focused around lipoprotein characterization. 
 
1.3 Lipoprotein Composition and Function 
 Lipoproteins are a distribution of nanoparticles (5-500nm) in serum that play a 
large role in the transportation and metabolism of lipids, triglycerides, cholesterols, and 
cholesterol esters.  Lipoproteins are made up of a hydrophilic exterior and a hydrophobic 
lipid core similar to the structure of micelles: they have a hydrophilic exterior and a 
hydrophobic core.  The outer shell is made up of phospholipids and cholesterol while the 
inner core is composed of triglycerides and cholesterol esters.  Surrounding the outer 
shell are apolipoproteins which are used in the recognition and transportation of the 
lipoproteins.  The basic structure of lipoproteins is shown in Figure 1.
9
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Figure 1: Basic Lipoprotein Structure 
 
1.3.1 Lipoprotein Properties  
Lipoproteins are primarily classified by their hydrated densities, but they can also 
be identified by their specific composition.  Lipoproteins in circulation throughout the 
human body are constantly modified through metabolic processes.  As a result of the 
metabolic changes, there is a distribution of particles with slightly different physical and 
chemical properties throughout the lipoprotein classes.
46,47
  The differences in the 
densities, composition, and size of the lipoprotein are used in identification of the 
different classes of lipoproteins: chylomicrons, VLDL, IDL, LDL, HDL, and Lp(a).  A 
summary of the main lipoprotein characteristics including density, size, lipid content, 
and apolipoprotein content is shown in Table 1.
9,48
 
 
Un-esterified  
Cholesterol 
Apolipoprotein Phospholipids 
Hydrophobic Core  
of Triacylglycerols  
& Cholesterol Esters 
(Inner Composition) 
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Table 1: Lipoprotein Characteristics 
Lipoprotein 
Type 
Density 
(g/mL) 
Size 
(nm) 
Major Lipids 
Major 
Apolipoproteins 
Chylomicrons < 0.93 100 - 500 Dietary TAGs B-48, C-II, E 
VLDL 0.93 -1.006 30 - 80 
Endogenous 
TAGs 
B-100, C-II, E 
IDL 1.006 -1.019 25 - 50 CEs and TAGs B-100, E 
LDL 1.019 -1.063 18 - 28 CEs and TAGs B-100 
HDL 1.063 -1.210 15-May PL 
A-I, A-II, C-I, 
C-II, E 
Lp(a) 1.040 -1.090 25 - 30 CEs B-100, Apo(a) 
 
1.3.2 Lipoprotein Function 
The density of lipoproteins is directly related to the biological function of the 
lipoproteins.  As the density of the lipoproteins decrease, the ratio of TAGs to the 
phospholipid and cholesterol content of the lipoproteins decreases.  This change in 
composition means that denser lipoproteins have higher protein composition.  For this 
reason, chylomicrons (CM) and VLDL are commonly paired together and labeled as 
triglyceride-rich lipoproteins (TRL).  The function of these TRLs is primarily to 
transport triglycerides throughout the body.
49
  TRLs exchange triglycerides with 
cholesteryl esters from nascent HDL using cholesterylester transfer protein (CETP) and 
interacts with lipoprotein lipase which causes for loss of lipid content and the 
transformation of TRL into IDL and then, eventually, LDL.  This change can be 
measured by the progressive change in density to more dense particles.   
IDL is a remnant of VLDL as it changes to LDL.  It is formed as a result of 
lipolysis of VLDL.  This particle’s lifetime is normally short lived as it is converted to 
LDL or cleared through the liver by receptor-mediated endocytosis.
50
  IDL is composed 
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of multiple apolipoproteins Apo E and a singular copy of Apo B-100.  Apo E is present 
until IDL is transformed into LDL when only Apo B-100 is present.
51
 
LDL is primarily made up of cholesterol esters and the apolipoprotein Apo B-
100.  LDL transports cholesterol and cholesteryl esters from the liver to different tissues 
throughout the body using LDL receptors to permeate the membrane.  LDL has been 
divided even further into five different subclasses labeled as LDL-1 (1.019 – 1.023 
g/mL), LDL-2 (1.023 – 1.029 g/mL), LDL-3 (1.029 – 1.039 g/mL), LDL-4 (1.039 – 
1.050 g/mL), and LDL-5 (1.050 – 1.063 g/mL) as identified by equilibrium density 
gradient ultracentrifugation.
9
 
HDL reverses the cholesterol transport process by transporting the cholesterol 
from the tissues back to the liver.  This process is known as reverse cholesterol transport.  
HDL has two main subclasses identified as HDL2 and HDL3.  Further division of these 
subclasses through sequential centrifugation and DGU identified fractions of these 
subclasses known as HDL2b (1.063-1.091 g/mL), HDL2a (1.091-1.110 g/mL), HDL3a 
(1.110 –1.133 g/mL), HDL3b (1.133 –1.156 g/mL) and HDL3c (1.156 –1.179 g/mL).
9
  A 
summary of the different lipoprotein subclasses is displayed in Table 2. 
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Table 2: Lipoprotein Subclass Densities 
Lipoprotein 
Subclass 
Density 
(g/mL) 
TRL <1.006 
IDL 1.006-1.019 
LDL-1 1.019-1.023 
LDL-2 1.023-1.029 
LDL-3 1.029-1.039 
LDL-4 1.039-1.050 
LDL-5 1.050-1.063 
HDL2b 1.063-1.091 
HDL2a 1.091-1.110 
HDL3a 1.110-1.133 
HDL3b 1.133-1.156 
HDL3c 1.156-1.179 
 
1.3.3 Lipoprotein Subclasses and Their Relation to CVD Risk 
 The classical view of the role lipoproteins play in the risk for cardiovascular 
disease is that LDL is the “bad” form of lipoprotein while HDL is the “good” form of 
lipoprotein.  The idea of LDL as the “bad” form of lipoprotein comes from the 
established direct correlation between LDL and CVD risk.  Small, dense LDL (sd-LDL) 
particles have been shown to stay in serum for longer periods of time compared to large, 
buoyant forms of LDL.  sd-LDL also exhibits increased oxidation rates, lower affinity to 
the LDL receptor, and increased penetration into the arterial wall.
52-55
  Oxidized LDL 
has been identified to possess pro-atherogenic and pro-inflammatory properties and has 
long been a target of medical therapies.
56,57
 
The idea of HDL as the “good” form of lipoprotein comes from the established 
inverse correlation between HDL cholesterol levels (HDL-C) and CVD risk.
58
  HDL has 
12 
 
 
 
been identified to have many athero-protective properties which reduce the risk of CVD.  
Through activation of lecithin-cholesterol acyltransferase (LCAT), HDL promotes a 
reduction in oxidized lipids.
59,60
  This activity has specifically been identified as a 
property of small, dense HDL.
61
  Apo A-I, the primary apolipoprotein of HDL, has the 
mimetic peptide ETC-642 that has been associated with the anti-inflammatory properties 
of HDL.
62
  HDL also promotes macrophage cholesterol efflux and reverse cholesterol 
transport which are two of the primary methods in which HDL protects against 
atherosclerosis.
63
 
This view of HDL as the “good” form of lipoprotein has evolved in recent years 
and current research has identified potential atherosclerotic properties of HDL.  This 
dysfunctional form of HDL has been correlated with inflammatory biomarkers.
64
  The 
dysfunctionality of HDL has also been linked to obesity.  In terms of the composition of 
HDL, glycation of Apo A-I in diabetes patients has been related to dysfunctional HDL.
64
  
Triglyceride-rich HDL cholesterol has been shown to reduce the efficacy of reverse 
cholesterol transport.
65
  The idea of dysfunctional HDL has promoted research into the 
importance of HDL function over the classical view of HDL quantity.
66
 
 
1.4 Methods for Lipoprotein Analysis 
 With the varied characteristics and composition of lipoproteins, several methods 
of chemical analysis have been developed for commercial use in order to study 
lipoproteins and their components.  These methods separate lipoproteins based on 
properties such as relative density, electrophoretic mobility, molecular weight, and 
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chemical composition.  Despite the continuing development and refinement of the 
techniques related to these characteristics, recent review articles have identified 
problems in inter-relating the use of the methods for identifying individuals who have 
treatable early stage CVD.
67,68
   
 
1.4.1 Density Gradient Ultracentrifugation (DGU) 
Ultracentrifugation has long been the ideal technique for separation, 
identification, and quantization of lipoproteins.
10,11,69
  Ultracentrifugal methods separate 
lipoproteins based on their hydrated densities.  The different forms of this technique 
include rate zonal ultracentrifugation and isopycnic separations
70,71
.  Rate zonal 
ultracentrifugation applies a layering method of preformed gradients over the sample.  
As the centrifugal force is applied to the sample, particles will move through the gradient 
relative to their densities.  Separation of the particles is halted and they are characterized 
by the zone in which they migrated to during the UC spin.  For isopycnic separations, 
the particles migrate to the specific density of the particles, or isopycnic point, relative to 
the density gradient formation during ultracentrifugation.  Separation of the particles in 
this method is specific to the density properties of the individual particles.  Each of these 
techniques has specific advantages and disadvantages including the accuracy of the 
separation, its use in fraction preparation, and the extent of skill needed to perform these 
techniques.   
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1.4.1.1 Sedimentation Theory and Gradient Mapping 
 DGU works through the principles of sedimentation theory.  There are two 
primary competing forces at work during the experiment: sedimentation and diffusion.  
The centrifugal force exerted on a particle is related to the mass of the particle, mp, 
angular velocity, ω, and the radius of the rotor, r.  The formula for calculating the 
centrifugal force is seen in Eq. 1
72
: 
 
                
          Eq. 1 
 
Diffusion forces can also be defined as the buoyancy of the solvent.  This force 
can be measured by the mass of the volume of solvent displaced.  This mass can be 
determined by using the mass of the particle, the density (ρ) of the solvent, and the 
partial specific volume of the particle (ῡ).  The resulting force from buoyancy is given in 
Eq. 3
72
: 
 
              
           Eq. 2 
 
A third force which acts on the particles during centrifugation is the frictional 
force between the solute particles and the solvent.  This force works in opposition to 
both the centrifugal and buoyant forces.  The frictional force can be calculated using the 
frictional coefficient, ƒ, and the velocity of the moving particle, ʋ.   
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Using gradient forming solutes beginning from a homogeneous solution, these 
density gradients reach a steady state in the form of an exponential curve relating density 
to the distance away from the meniscus.  In terms of tube coordinate, a lower tube 
coordinate is near the meniscus and therefore would have a lower density relative to a 
higher tube coordinate which is further away from the meniscus and has a larger density.  
The relation of tube coordinate to density can be seen in Eq. 3: 
 
     
 
                  Eq. 3 
 
In this equation, x is the position relative to the meniscus, A and B are coefficients, and 
y0 is the intercept.  The position of the measurement can be related to density through 
use of refractive index and calibration curves relating refractive index to density.
73
   
 Research into density gradient formation has shown a relationship between the 
molecular weight of the gradient-forming solute and the slope of the resulting density 
curve.
12,73
  At equilibrium, the free energy of centrifugation is equal to the free energy of 
diffusion.  Through relation of the free energy equations for each of the different acting 
forces in ultracentrifugation, a relationship between the molecular weight of the solute 
(Mw) and the resulting gradient formation is found.  The resulting equation relating the 
slope of the density gradient and molecular weight of the solute is shown in Eq. 4: 
 
   
               
           
    
   
       Eq. 4 
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In this equation, T represents the temperature of the UC spin, R is the gas constant, and 
c1/c2 represents the concentration ratio between two points at radii r1 and r2 in the sample 
tube, respectively. 
  
1.4.1.2 Methods of DGU 
The need for a rapid and straight forward method of lipoprotein density profiling 
which can provide the most precise information possible is necessary if lipoprotein 
density profiles are to be used in clinical studies.  Currently, the commercialized method 
of lipoprotein separation through density gradient ultracentrifugation is Vertical Auto 
Profiling (VAP) run by Atherotech.  This method involves the use of potassium bromide 
(KBr) as the salt present in the aqueous gradient.
74,75
  Use of this high ionic strength 
solution is problematic as it has been shown to create multi-component aggregates of the 
low-density lipoproteins.
76
  Fractioning the profile using this technique normally 
involves puncturing the sample tube at the bottom and using a continuous-flow analyzer 
to monitor and separate each elution.  This can allow lipoprotein to adhere to the sample 
tube walls causing for error in the measurement.  The VAP method measures 
composition of the different elution in terms of UV absorbance.  VAP results have been 
applied to CVD risk assessment, however, the results can vary and the precision for an 
individual patient is questionable.
77
 
Current research into DGU has introduced the viability of using EDTA salts to 
control the density gradient formation process under ultracentrifugation conditions.
12,78,79
  
In particular, use of the NaBiEDTA complex has been shown to generate a density 
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gradient for profiling the full density distribution of lipoproteins in 6 hours rather than 
the 48 hours required for traditional rate zonal ultracentrifugation
12
.  The gradient 
formation when using EDTA salts also has been shown to be modifiable based on the 
metal-ion complex used for the salt and the relative concentration of salt used in 
solution.
12
  These EDTA salt solutions have a low ionic strength which reduces the risk 
of aggregation in the low density lipoproteins mentioned previously.  However, there is 
some evidence that apolipoprotein A-1 (apo A-1) loss in the high density lipoproteins 
could be affected by the low ionic strength.
80
 
 
1.4.1.3 Fluorescence Analysis of Lipoproteins 
Fluorescent techniques for quantification studies have the advantage of being 
highly sensitive with reduced noise. Coupling the lipoprotein density separation with the 
use of NBD in order to image the intensity of the lipoprotein subclasses has provided a 
method for measurement of a subject’s lipoprotein density profile through 
fluorescence.
79
  NBD is a lipophilic molecule that has been shown useful in labeling 
lipoproteins.
81
  This fluorophore consists of a hydrophilic head and a hydrophobic tail 
(Figure 2).  For this reason, NBD has the advantage for lipoprotein studies in that it 
fluoresces in hydrophobic environments.  The lipid core of lipoprotein particles presents 
such an environment.  The excitation and emission spectra for NBD is shown in  
Figure 3. 
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Figure 2: NBD C6-Ceramide Structure 
 
 
Figure 3: Excitation and Emission Spectra of NBD C6-Ceramide 
 
Previous research into the association of NBD and lipoprotein for application to 
lipoprotein profiling has identified the optimum conditions to use in terms of quantifying 
the lipoprotein profile.
14,79
  By monitoring the fluorescence intensity for all lipoproteins, 
it was found that a 30 minute incubation time was necessary for the NBD to completely 
interact with all lipoproteins in serum.  It was also found that there was relatively a one-
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to-one volumetric relationship between the amount of NBD at a concentration of 
1mg/mL and serum volume in order to saturate the lipoproteins for all densities.  These 
conditions were selected to account for the speed and the quantity of fluorophore uptake 
in the different types of lipoproteins.  
 
1.4.2 Mass Spectrometry of Apolipoproteins 
 With the function of lipoproteins being targets as risk factors for CVD, 
characterization of the components of the lipoproteins, specifically the apolipoproteins 
which are directly related to the metabolic processes, is necessary.  To this end, mass 
spectrometry has recently been used to identify the apolipoprotein content of the 
different lipoproteins.  MALDI-MS is one of the forms of biological mass spectrometry 
that has been shown useful in the characterization of apolipoproteins.
16,82-86
  MALDI-MS 
is a soft-ionization technique developed in the late 1980’s which minimizes the 
fractioning of large macromolecules and results in primarily singly, sometimes doubly, 
charged ions.
87-89
  MALDI-MS is commonly paired with a time of flight (TOF) analyzer 
in a technique referred to as MALDI-TOF.  MALDI-MS is especially useful in the 
analysis and characterization of multi-component mixtures.  While MALDI-MS has 
been used in quantitative studies, it is primarily a qualitative method due to the potential 
error in signal intensity related to preparative techniques, ionization efficiencies, and ion 
suppression.
90,91
 
 MALDI-TOF mass spectrometry has been successful in the characterization of 
the protein and apolipoprotein content of HDL.  Specific proteomic signatures have been 
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identified in subjects with CVD using tryptic digestion of the HDL.
92
  Post-translational 
modifications (PTM) of apolipoproteins have been identified in HDL relative to 
CVD.
16,82
  While the nature of these PTMs and their impact on CVD are not fully 
understood, disease specific apolipoprotein signatures using MALDI-MS represent new 
potential risk factors in CVD risk assessment. 
  
1.4.3 Other Methods of Lipoprotein Analysis 
 The classical method for measuring lipoproteins is through measuring the 
cholesterol content.  The most used method of measuring cholesterol is currently the 
Friedewald method which has been used for over 30 years.
93
  This method uses 
enzymatic techniques to measure TC and TG, rapid precipitation to measure HDL-C, 
and then estimates the LDL-C using the following equation (Eq. 5): 
 
                      
    
      Eq. 5 
 
  Other methods of measuring lipoproteins include enzymatic assays to quantify 
apolipoprotein content
94
 as well as the bicinchoninic acid assay (BCA) 
95
 for protein 
quantification.  The enzyme-linked immunosorbent assays (ELISA) for apolipoprotein 
content use monoclonal or polyclonal antibodies to sandwich the apolipoprotein.  Then 
using a chromatic tag attached to one of the binding antibodies, the concentration of the 
solution is calculated based on a calibration curve relating absorbance to concentration.  
For BCA, the chemical reaction reduces Cu
2+
 to Cu
1+
 through interaction with the 
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proteins in an alkaline environment.  The Cu
1+
 cations are then chelated with 
bicinchoninic acid.  The absorbance of this BCA/Cu complex at 562nm is directly 
related to the protein concentration.  These methods just measure total content in a 
sample and give no information about the distribution or potential modification of the 
apolipoproteins. 
Due to the inherent time constraints and technical skill needed for analysis of 
density based lipoprotein separations, other analytical techniques such as nuclear 
magnetic resonance (NMR)
96-101
 and electrophoresis
81,102-108
 have been explored in order 
to qualify lipoproteins.  In these cases, it is not the hydrated densities, but the size of the 
lipoproteins as well as the electrophoretic mobility in a medium that are used to 
characterize the lipoproteins.  NMR, while useful in identifying multiple subclasses of 
lipoproteins through size differences, has some inherent problems including not being 
able to distinguish lipoprotein (a) ( Lp(a) ) from low density lipoproteins ( LDL ) and 
chylomicrons remnants from the very low density lipoproteins ( VLDL ).  There is also 
variability in the conversion of the peak areas into the cholesterol levels due to lipid 
composition variability.  While NMR profiles do give 15 different subclass 
measurements, only four subclasses of LDL are determined versus the five subclasses 
determined using hydrated densities.  The NMR profiles do have the advantage of 
identifying five subclasses of the VLDL.   
 Electrophoretic methods of lipoprotein separation include gel electrophoresis 
using agarose and analytical capillary isotachophoresis (ITP).
81,83
  Both of these 
techniques came about due to the problem of quantification of lipoproteins using 
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electrophoretic techniques.  Agarose gel electrophoresis has shown applicability in 
quantifying the VLDL-C, LDL-C, and HDL-C as well as the Lp(a)-C.
104
  Capillary ITP, 
in conjunction with NBD as a dye, has shown the ability to profile multiple subclasses 
for HDL and LDL and identify the VLDL and chylomicrons in a patient’s serum or 
plasma.
81
  This technique has a good correlation of peak intensity to cholesterol 
measurements and can be done rapidly.  However, this technique is limited by the 
number of subclasses that can be identified for each subclass.   
 Even with the advances in alternate techniques, the multiple subclasses and the 
differences in the hydrated densities of the lipoproteins make ultracentrifugation one of 
the best possible techniques for lipoprotein studies.  
 
1.5 Advanced Multivariate Statistical Analysis 
 Based on the paradigm shift in CVD risk assessment to a multivariable 
risk model, advanced statistical analysis such as linear discrimination analysis (LDA), 
sliced inverse regression (SIR)
17,109,110
, and quadratic discrimination analysis (QDA)
20,21
  
become available as statistical tools which can be used to develop an algorithm that can 
be used to separate defined groups by multiple variables.
20,111,112
  LDA separates groups 
through analysis of the mean values of variables and development of a linear algorithm 
using the selected variables.  SIR is a modern variation of R.A. Fisher’s original LDA 
method published in 1936.
19
  QDA separates the defined groups by using the mean, 
variance, and covariance between groups to develop a quadratic algorithm.  These 
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algorithms can be used to assess the positive or negative contributions that the risk 
factors play in classification. 
Application of the LDA/SIR and QDA analyses is tested in three steps: training 
set accuracy, cross validation accuracy, and accuracy on a holdout sample set.  The 
training set uses samples with known definitions to develop the mathematical algorithm 
in order to optimally separate the defined groups.  Cross validation is a method of data 
removal which systematically removes one sample’s data and re-develops a new 
algorithm.  This new algorithm is then tested on all samples, including the removed 
sample, for accuracy of definition.  This new accuracy, in comparison to the training set 
accuracy, represents the sample dependency of the training set algorithm for 
classification.  A small difference between the accuracy of the training set and the 
accuracy of the cross validation indicates a low sample dependency.  A large difference 
between the two accuracies indicates that the algorithm generated from the training set is 
highly sample-dependent.  Cross validation is traditionally used as a test of the 
significance of the separation between groups when only a small number of samples is 
available.  For larger sample libraries, the method of a holdout test is applied.  The 
holdout samples are a set of randomly selected samples from the library which are tested 
using the developed algorithm.  These samples are not used in the development of the 
algorithm and provide a real life sample set with which to test the accuracy of the 
prediction algorithm developed.    
Discriminant analyses have previously been used in the study of CVD diagnosis.  
LDA has been used in application to ejection fractions calculated from gated blood pool 
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studies to correctly classify coronary artery disease in 81% of the subjects.
18
  LDA has 
also been applied to cardiovascular risk variables such as HDL-C, LDL-C, TC, TG, Apo 
A-I, Apo B, and hs-CRP to show increased potential of risk assessment.
113
  These factors 
were shown to be highly accurate for the training set; however there were not enough 
samples to test a holdout.  Application of the LDA/SIR analysis has also been previously 
applied to the lipoprotein density profiles for small sample sets to show potential for risk 
assessment through just the integrated fluorescence intensities of the lipoprotein 
subclasses.
14
  Application of these discriminant analyses to CVD risk assessment using 
novel risk markers has the potential for improved risk classification as well as 
monitoring the effectiveness of therapeutic methods for risk reduction. 
 
1.6 Application of Methods 
 The goal of the research presented here is to develop an array of high precision 
analytical tools that can be used for clinical studies.  With traditional risk factors for 
CVD being present in roughly only 80% of the population,
114
 novel risk factors are still 
needed to enhance the accuracy of CVD risk assessment.  Using DGU as the primary 
tool for lipoprotein analysis, improved definition of the distribution of lipoprotein 
particles can be studied.  Through fluorescent tagging using NBD, the lipoprotein profile 
can be quantified and compared to the classical methods of cholesterol measurement.  
The NBD interaction with the lipoprotein particle acts as a probe into the chemical 
makeup and morphology of the individual particles.  DGU can also be used as a 
preparative separation technique for further characterization of the lipoproteins through 
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examination of their components.  MALDI-MS is a strong analytical tool through which 
the characterization of the lipoprotein components, specifically the apolipoproteins, can 
be performed.  The combination of these methods allow for the identification of new 
potential risk factors for CVD. 
 Use of these potential risk factors in application to multivariate statistical 
analyses can provide a novel approach to CVD risk assessment and classification.  
Through better medical definition of the presence of disease or lack thereof and through 
identification of significant risk factors, enhanced distinction between groups becomes 
possible.  Through use of the measured risk factors identified in this work as variables in 
the LDA/SIR and QDA analyses, a more accurate risk assessment algorithm can be 
generated.  The potential for this risk assessment algorithm to monitor the effectiveness 
of treatment provides a novel method of developing therapies that can be “personalized” 
based on the relevant risk factors.   
 The work presented here establishes high performance methods for lipoprotein 
characterization.  This work also establishes novel methods of CVD risk assessment 
through application of the data obtained from the lipoprotein characterization into 
multivariate statistical analyses.  These methods have clinical applications in the 
prescreening of the disease as well as the monitoring of therapeutic treatments aimed at 
reducing a patient’s risk.  
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2. MATERIALS AND METHODS 
 
2.1 Materials  
 
2.1.1 Chemicals and Supplies 
 NBD C6-ceramide (6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)hexanoyl)sphingosine, catalogue # N1154) and Fluorospheres (0.1 µm 
carboxylate modified red fluorescent microspheres, catalogue # F-8801) were purchased 
from Invitrogen, Carlsbad, CA.  Acetonitrile (ACN), dimethyl sulfoxide (DMSO) and 
hexane (>95%) were purchased from EM Science (Darmstadt, Germany).  
Trifluoroacetic acid (TFA), ethylenediaminetetraacetic acid (H4EDTA), cesium 
hydroxide, cadmium carbonate, sinipinic acid, Dextralip® 50, and magnesium chloride 
hexahydrate were purchased from Sigma-Aldrich (St. Louis, MO).  Sodium bismuth 
EDTA (C10H12N2O8NaBi4H2O) was purchased from TCI America (Portland, Oregon).  
Strata C18-E solid phase extraction cartridges and syringe adapter caps were purchased 
from Phenomenex (Torrance, CA).  Deionized water (DI H20) used in all experiments 
was from a Milli-Q water purification system (Millipore, Bedford, MA) 
HDL and LDL standards standards were purchased from Sigma-Aldrich (St. 
Louis, MO).  Apo A-I standards were purchased from Academy Biomedical (Houston, 
TX). 
Polycarbonate thick wall ultracentrifugation tubes (1.5 mL, 34 mm length, 
catalogue # 343778) were purchased from Beckman-Coulter (Palo Alto, CA).  Strata 
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C18-E solid phase extraction cartridges and syringe adapter caps were purchased from 
Phenomenex (Torrance, CA)  
 
2.1.2 Cs2CdEDTA Synthesis 
The Cs2CdEDTA complex was synthesized from H4EDTA, cesium hydroxide, 
and cadmium carbonate.
73
  The reagents were combined stoichiometrically in 500 mL of 
DI H2O, followed by a two hour reflux, yielding a clear solution.  The cesium hydroxide 
was added to the clear solution to bring the final pH range to 6-7.  The final solution 
volume was reconstituted to 500 mL to account for evaporation during reflux to give the 
desired final concentration for the solution.  The synthesis of the Cs2CdEDTA complex 
is shown in Eq. 6. 
 
                                            Eq. 6 
 
2.1.3 Serum Collection   
The serum used for these studies was acquired from multiple donors with 
informed consent.  The serum was collected in a 9.5mL Vacutainer treated with polymer 
gel and silica activator (366510, Beckton Dickinson Systems, Franklin Lakes, NJ).  The 
serum was separated from the red blood cells by centrifugation at 3200 rpm for 30 min 
at 5°C and then stored at -80°C prior to use.   
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The work described in this dissertation was carried out in accordance with The 
Code of Ethics of the World Medical Association (Declaration of Helsinki) for 
experiments involving humans. 
 
2.2 Analytical Methods 
 
2.2.1 Ultracentrifugation 
Ultracentrifugation was carried out using an Optima TLX ultracentrifuge and a 
TLA 120.2 fixed-angle rotor (Beckman-Coulter, Palo Alto, CA). Samples were spun 
using a rotor speed of 120,000 rpm. For the TLA120.2 rotor, these speeds correspond to 
average relative centrifugal force of 511000g.  Salt concentrations were selected to 
achieve the desired density gradient profiles. 
 
2.2.2 Density Gradient Measurement  
 
2.2.2.1 Properties of EDTA Solutions 
Serial dilutions for each of the EDTA solutions were made in order to construct 
calibration curves necessary for relating density, refractive index, and concentration.
14,73
  
Initial concentrations for each stock solution of EDTA salt were 0.4000M, calculated 
stoichiometrically.  Densities for each serial dilution were determined gravimetrically 
using a calibrated 10-mL glass pipet.  The refractive index for each dilution was 
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measured at 20°C using an Abbe 60/DR refractometer from Bellingham + Stanley 
(Lawrenceville, GA). 
 
2.2.2.2 Gradient Formation and Measurement 
Density gradient measurements were performed as previously described by 
Johnson et al.
14,73
  Briefly, the density gradients were formed in an Optima TLX 
ultracentrifuge, TLA 120.2 fixed-angle rotor.  All tubes contained 1150μL of the 
designated EDTA solution and were centrifuged as previously described (Section 2.2.1).  
After centrifugation, gradient formations were determined by removing 10μL aliquots 
from distinct positions throughout the formed gradient and measuring their respective 
refractive indexes. Aliquots were obtained sequentially from the top of the UC tube 
down in order to not disturb the density gradient below.  Images of the UC tube were 
taken using a digital color microscope camera (S99808, Optronics, Goleta, CA) while 
the sample was being removed so that the exact location of each aliquot could be 
determined by digital analysis.  The density of each aliquot was then mapped in relation 
to its orientation inside the tube (tube coordinate). 
 
2.2.3 Fluorescent Labeling of Serum Samples    
Serum samples were stained for imaging as follows: 6µL of serum were mixed 
with 10µL of NBD C6-ceramide (1mg/mL in DMSO) and diluted to 1300 µL using an 
aqueous solution of the density-forming solute (NaBiEDTA) followed by incubated for 
30 min to achieve saturation.
12,79 
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2.2.4 Fluorescence Image Analysis 
 Fluorescence imaging was used in monitoring the dynamics of the density 
gradient formation as well as the measurement of the sedimentation equilibrium density 
profile. An image of the tube containing the fluorophore-tagged lipoproteins or 
fluorescent nano-spheres was obtained and analyzed using a digital Optronics Microfire 
Camera (S99808, Goleta, CA) with a Fiber-Lite MH-100 Illuminator, a metal halide 
lamp, as a light source (MH100A, Edmund Industrial Optics, Barrington, NJ). A digital 
color microscope camera (S99808, Optronics, Goleta, CA) was used to record the image. 
The camera and light source were placed orthogonally to each other on an optical bench 
to illuminate the ultracentrifuge tube mounted in a custom-designed holder.  Two filters 
matching the excitation and emission characteristics of the fluorophore were chosen. 
Specific settings for the Microfire camera software were a gain of 1.000 and a target 
intensity of 30% to illuminate the tube.  The exposure time was optimized for sensitivity 
and to achieve linearity.   
The image of the polycarbonate ultracentrifuge tube was then converted to a 
density profile following the method described by Johnson et al.
12
  Briefly, the two-
dimensional pixel field generated by the camera software was converted to a digital 
matrix of intensity versus tube coordinate (6-33 mm length) using Origin 8.5 software to 
generate a graphical representation of the density profile.  The relationship between tube 
coordinate and density was then used to modify the x-axis in terms of density rather than 
tube coordinate. 
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2.2.5 Lipoprotein Density Profiling 
To obtain the lipoprotein density profile, the specific instrument set-up and 
settings is described here.  Following the UC spin, and layering depending on the 
respective study, an image of the sample tube was obtained and analyzed using the 
method for fluorescence imaging previously described.  Two filters matching the 
excitation and emission characteristics of NBD C6-ceramide from Schott Glass 
(Elmsford, NY) were chosen. A blue-violet filter (BG-12) with a bandwidth centered at 
455 nm and a yellow emission filter (OG-515) with a bandwidth centered at 570 nm 
were used as the excitation and emission filters, respectively.  Specific settings for the 
Microfire camera software were an exposure of 53.3 mS with a gain of 1.000 and a 
target intensity of 30% to illuminate the tube prior to image capture. 
 
2.2.6 NaBiEDTA Gradient Optimization Studies 
 
2.2.6.1 Spatial Separation of Lipoprotein Density Profiles 
 To test for the optimum volume that can be spun inside the UC tube, 1200µL 
samples of DI H2O were weighed and then spun inside the ultracentrifuge.  After being 
spun, the samples were weighed again to measure the sample loss inside the rotor.  By 
calculating the relationship of weight loss to volume of water, the optimum volume able 
to be used inside the tube without sample loss was determined.  This volume was then 
used as the standard volume in a spin for optimization of the method.  
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2.2.6.2 Density Gradient Development over Time 
The density gradient distribution for the 0.1800 M NaBiEDTA was measured for 
several different spin times ranging from 2 – 8 hours.  The method used follows a 
procedure and calibration method developed by Johnson et al where 10 aliquots (20 µL 
volumes) are withdrawn from well-defined positions within the gradient and their 
densities measured by refractive index.
12
 Gradient curves were then calculated by 
mapping the tube coordinate versus density using Origin 8.5.   
 
2.2.6.3 Precision of Density Measurements Using Nano-spheres 
Using the fluorospheres and following the method for density gradient 
measurements, the accuracy and precision of the density measurement were studied. 
Briefly, 1µL of the fluorosphere solution was mixed with 1299µL of 0.1800M 
NaBiEDTA.  A volume of 1150µL of this mixture was then spun as described 
previously and imaged using a green excitation filter (VG-6) with a bandwidth centered 
at 520 nm and a red emission filter (R-60) with a low cutoff at 600 nm (Edmund 
Industrial Optics, Barrington, NJ).  This was done for a set of 10 replicate samples for 
each spin condition.  Using Origin 8.5 graphing software, the images were mapped 
according to their tube orientation and relative densities.  The peak density (g/mL), full 
width at half maximum (mm), change in densities, and the density resolution were 
calculated for each replicate. 
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2.2.6.4 Polar Layering with H2O vs. Non-polar Layering with Hexane  
In preliminary studies, our laboratory used DI H2O as a layering medium for 
separation of the different TRL subclasses.
14
  Initial layering of the samples was done 
with 150µL DI H2O layered using gel loading tips (Sigma Aldrich, St. Louis, MO, 
Catalogue # CLS4853).  Hexane was chosen as the new layering medium in order to 
remove the meniscus interference from the TRL subclass measurement.  Following the 
UC spin, 240µL of hexane was slowly added on top of the spun samples without 
perturbing the density profile using gel loading tips (Sigma Aldrich, St. Louis, MO). 
 
2.2.6.5 Effects of Ultracentrifugation Spin Temperature 
The effect of the temperature in the ultracentrifuge chamber on the lipid profiles 
was studied when the samples were run using the pre-described method for the UC spin 
and varying the temperature at which the samples are run.  Specifically, the samples are 
run at 5, 15, and 25°C. 
 
2.2.6.6 Tube Orientation for Imaging 
 Each UC sample tube was marked to indicate its position inside the 
ultracentrifuge rotor.  After a standard spin at 5°C, the sample tube was rotated 360° 
using 90° increments inside the imaging station sample holder and imaged to test the 
effect that the tube orientation has on the lipoprotein profile.  Ten replicate samples were 
measured in order to assess the repeatability based on orientation in the tube holder. 
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2.2.6.7 Stability of the Lipoprotein Profile after UC Spin 
Stability of the lipoprotein profile was studied by taking an initial image of the 
spun sample as described previously and then taking consecutive images every 30 
minutes for a period of 90 minutes.  The images were then analyzed for the density 
profiles as described previously (Section 2.2.4). 
 
2.2.6.8 Precision and Normalization of the Density Profiles 
 Using serum from the single donor, ten replicate measurements were made of the 
lipoprotein density profile.  The ten profiles were overlaid using Origin 8.5 graphing 
software to identify any systematic error in the measurement.  A more quantitative and 
informative approach to measuring the inherent precision of the method was introduced 
that involves determining the integrated fluorescence intensities of the eleven subclasses 
based on density ranges as described in the literature.
9
  For each of the subclasses the 
mean value and standard deviation of the intensities of each of the subclasses was 
evaluated.   
While this analysis gave an overall estimate of the precision of the measurement 
related to sample preparation, an additional contribution of error comes from day-to-day 
variability in the intensity of the light source.  Consequently, two methods for measuring 
precision were established. The first method (referred to as Mode 1) determined the 
mean value and standard deviation of the absolute fluorescence intensities of each of the 
subclasses.  The second method (Mode 2) was a normalization of data where the 
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fluorescence intensity of each of the subclasses is given as a percent of the total 
integrated intensity.  In order to test the efficiency of Mode 2, sample tubes were imaged 
using exposure times of 53.3ms and 100ms.  The resulting profiles were normalized 
using Mode 2 analysis and the subclass percentages were compared.  This approach was 
designed to eliminate the day-to-day variability of the light source intensity. 
 
2.2.7 High Performance Lipoprotein Density Profiling (HPLDP) 
 Based on the previous studies, the optimum method for lipoprotein density 
profile using DGU was identified.  Serum samples were fluorescently tagged and 
prepared for the UC spin as follows: 6µL of serum were mixed with 10µL of NBD C6-
ceramide (1mg/mL in DMSO) and diluted to 1300µL using an aqueous solution of the 
desired EDTA salt concentration followed by incubation for 30min to achieve 
saturation.
12,79
   
 Using 1150µL of the serum/aqueous salt solution, the samples were then spun in 
the ultracentrifuge.  Ultracentrifugation was carried out as previously described with a 
spin temperature of 5°C and spin time of six hours.  Following the UC spin, samples 
were carefully layered with 240µL of hexane and images of the samples were obtained 
and analyzed using a digital Optronics Microfire Camera as previously described 
(Section 2.2.5).  Specific settings for the Microfire camera software were a gain of 1.000 
and a target intensity of 30% to illuminate the tube.  The exposure time was optimized 
for sensitivity and to achieve linearity.  The image of the polycarbonate ultracentrifuge 
36 
 
 
 
tube was then converted to a density profile following the method as previously 
described (Section 2.2.4). 
 
2.2.8 Lipoprotein Density Profiling of Commercial HDL/LDL Standards 
 Serial dilutions of the commercial standards for HDL and LDL were used to 
obtain lipoprotein density profiles using the HPLDP method.  The concentrations for 
each standard were reported in terms of total protein concentration.  For HDL, the serial 
dilutions were prepared in concentrations of 520µg/dL, 260µg/dL, 130µg/dL, 65µg/dL, 
and 32.5µg/dL.  For LDL, the serial dilutions were prepared in concentrations of 
160µg/dL, 120µg/dL, 80µg/dL, 40µg/dL, and 20µg/dL.  These concentrations for HDL 
and LDL represented four times and two times the average concentrations of protein 
present in a human sample
48
, respectively.  Calibration curves were developed relating 
the integrated fluorescence intensities to concentration.   
 
 2.2.9 Serum Viability Studies 
 The stability of the lipoprotein density profiles relative to storage conditions was 
studied in terms of time spent at room temperature and the effect that multiple 
freeze/thaw cycles would have on the density profiles.  Aliquots of a serum sample 
obtained from a volunteer were stored at room temperature for periods of 0.5, 2, 4, and 
24 hours prior to the UC spin.  Further aliquots of this serum were stored in a -80.0°C 
freezer.  These samples were thawed at room temperature for 30 minutes and then flash 
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frozen using liquid nitrogen for up to 12 cycles.  The serum samples were then profiled 
using the HPLDP method and compared to study the effects of each condition. 
 
2.2.10 Preparative Ultracentrifugation and Fraction Collection 
Preparative ultracentrifugation is a method developed in our laboratories in order 
to separate lipoproteins for further analysis using a variety of analytical techniques.
73
  
This method utilizes the density gradient separation applied to larger volumes of serum.  
Based on previously identified dysfunction forms of HDL, this work focused on 
isolation of HDL for further analysis. 
 
2.2.10.1 Dextran Sulfate Precipitation 
In order to eliminate interference from other lipoproteins, serum samples were 
first treated with dextran sulfate (DS) and magnesium chloride hexahydrate.  Dextran 
sulfate has been previously identified as method or removing all lipoproteins containing 
Apo B.
115,116
  A stock solution with the final concentration of 10.0g/L of DS and 0.500M 
magnesium chloride was formulated as follows: 
2.500g of the 50,000 molecular weight variant of dextran sulfate (Dextralip® 50) 
25.375g of dried magnesium chloride hexahydrate 
500mL of DI H2O 
This working solution was added to a serum sample at a volume of 10% of the serum 
volume. For these studies, 200µL of serum was combined with 20µL of the DS mixture.  
The serum/DS solution was mixed briefly through vortexing and incubated at room 
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temperature for 10 minutes. The precipitate was separated using a tabletop centrifuge 
spun at 12,000g for 5 minutes.  This resulted in the sedimentation of all Apo B 
containing lipoprotein particles.  The supernatant was then spun in the ultracentrifuge. 
 
2.2.10.2 Preparative Ultracentrifugation 
The recovered supernatant from the dextran sulfate precipitation reaction was 
spun in the UC.  For preparative methods, the 0.2500M concentration of the 
Cs2CdEDTA gradient forming solution was used due to its optimum separation of HDL 
over the length of the UC tube.  The samples were prepared as follows: 
~200µL of DS treated serum (supernatant) 
1100µL of 0.2500M Cs2CdEDTA solution 
NBD was not applied to the samples in order to reduce any effect it might have on the 
further analysis of HDL.  1150µL of this solution was added to the UC tube and spun 
using the standard spin conditions as previously described for the HPLDP method 
(Section 2.2.7). 
 
2.2.10.3 Freeze/Cut Method for Fraction Collection 
A freeze/cut method developed through our laboratory was used to fractionate 
lipoproteins following preparative UC spin.
73
  The spun samples were slowly frozen in 
their respective UC tubes using liquid nitrogen by placement into a custom 10-slot 
holder and lowering the holder into a Dewar of liquid nitrogen.  This method caused the 
liquid in the tubes to freeze from the bottom to the top as it was lowered into the Dewar.  
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The expansion of water as it turns to ice was accounted for by the following equation 
(Eq. 7): 
  
                          Eq. 7 
 
In the equation, mms corresponds to the relative tube coordinate when in the solid state 
and mml corresponds to the tube coordinate when in the liquid state, the state in which 
the image of the UC tube was captured.  The values for mml corresponded to the 
endpoints of the specific density range for lipoproteins to be studied.  In this case, for 
HDL, the densities were 1.063g/mL and 1.179g/mL which corresponded to tube 
coordinates of 10.63mm and 25.63mm, respectively. 
 The constant 1.058 represents the correction factor necessary relating the ratio 
water’s density in the liquid state to its corresponding density in the solid state.  Water is 
denser in its liquid state; therefore the ratio is greater than unity.  The subtraction of 
10.405mm was necessary to correct for the calibration of the micrometer/tube holder 
assembly that was used to dial in the correct cut points. This micrometer/tube holder 
assembly contained a micrometer head which functioned to advance the position of the 
UC tube relative to the location of the notch for the saw blade. A Dremel® scroll saw 
(Racine, WI) was fitted with 0.25mm blades for the cutting of the tubes. 
. 
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2.2.11 Solid Phase Extraction (SPE) 
 After preparative ultracentrifugation and fractionation, delipidation and desalting 
of the lipoproteins were accomplished using a Strata C18-E reversed phase solid phase 
extraction cartridge from Phenomenex (Torrance, CA).  Delipidation of samples was 
performed based on a published method.
117
  The method used was as follows: 
 
1) The cartridge was conditioned drop wise with three 1mL aliquots of 0.1% 
(v/v) TFA in acetonitrile (ACN), allowing no air to enter the cartridge.  
2) The cartridge was then conditioned drop wise with three 1mL aliquots of 
0.1% (v/v) TFA in DI H2O, allowing no air to enter the cartridge.  
3) The sample to be delipidated was first acidified with a volume of 0.1% (v/v) 
TFA in DI H2O equal to that of the sample volume.  This mixture was then 
slowly added to the cartridge, allowing no air to enter. 
4) The cartridge was then washed with three 1mL rinses of 0.1% (v/v) TFA in 
DI H2O to remove the salts, the non-specifically bound apolipoproteins, and 
the water soluble components from the serum sample. After the washes, one 
milliliter of air was pushed through the cartridge to remove any remaining 
liquid. 
5) Elution of the bound apolipoproteins was performed using six 100μL aliquots 
of 0.1% (v/v) TFA in acetonitrile and purging with 1mL of air in between 
each aliquot.  For each aliquot of the TFA solution, an incubation time of at 
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least one minute was giving for the sorbent to soak prior to purging with air.  
All six elutions were combined as the recovered apolipoproteins. 
 
Following SPE, the recovered samples were evaporated to dryness through the 
use of a SVC-100H Speed-Vac concentrator with a refrigerated condensation trap from 
Savant Instruments (Farmingdale, NY) which was connected to a 5KC36PN435AX 
vacuum pump from General Electric (Fort Wayne, IN).  The dried HDL apolipoprotein 
were then reconstituted in 0.1% (v/v) TFA in DI H2O for MS experiments.  The volume 
of the TFA/DI H2O solution used to reconstitute the sample was chosen based on the 
desired concentration relative to initial concentration in a subject’s serum.  For example, 
with 200µL of serum initially used, use of a 100µL volume to reconstitute the dried 
apolipoproteins would result in a concentration twice that of the initial serum 
concentration. 
 
2.2.12 Colorimetric Assays for Measuring Protein Concentration 
 
2.2.12.1 Bicinchoninic Acid Assay (BCA) 
 In order to determine the protein concentration of the serum samples, fractioned 
samples, and recovered apolipoproteins from SPE, a BCA Protein Assay Reagent kit 
from Pierce Biotechnology was used (Rockford, IL).
95
  This kit comes with three 
different reagents which need to be mixed in the proper ratios in order to make the 
working reagent (WR) for the assay and bovine serum albumin (BSA) to be used as a 
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standard to generate a calibration curve relating absorbance to concentration of protein.  
The three reagents are labeled A, B, and C and are composed of the following: 
 
A: Sodium carbonate, sodium bicarbonate, and sodium tartarate in 0.2M NaOH 
B: 4% (v/v) Bicinchoninic acid in H2O 
C: 4% (v/v) Cupric sulfate pentahydrate in H2O  
 
The volumetric ratio of reagents needed to create the WR is as follows (Eq. 8): 
 
                     Eq. 8 
 
150µL of the WR, followed by 150uL of the desired sample or standard to be analyzed, 
was pipetted into a 96 well microtitre plate.  The microtitre plate was then incubated in 
an over at 37°C for 2 hours, followed by a cool down period of 10 minutes at room 
temperature.  The plate was then placed on a µQuant spectrophotometer from Bio-Tek 
Instruments (Winooski, VT) and the absorbance at 562nm was recorded for all standards 
and sample replicates.  Each sample and standard was measured in triplicate to reduce 
the systematic error in analysis. 
 
2.2.12.2 Apo A-I ELISA 
 The commercial immunoassay for measuring Apo A-I concentrations in serum 
and plasma from Assaypro, LLC was applied to measuring the concentrations in serum, 
43 
 
 
 
recovered HDL, and recovered apolipoproteins (St. Charles, MO, Cat. # EA5201-1).  
The procedure provided by Assaypro was followed with few modifications.  Briefly, all 
samples were first diluted in 1:200 ratio of initial sample volume to final volume with 
the MIX Diluent provided in the assay kit.  For samples with higher concentrations, 
dilutions of up to 1:800 were necessary.  Incubation times were kept consistent with the 
provided procedure.  Absorbance for each sample was measured at 450nm and 570nm.  
The readings at 570nm were subtracted from the readings at 450nm to correct for 
background noise.  Samples and standards were run in triplicate to reduce systematic 
error. 
 
2.2.13 MALDI-TOF MS Analysis of HDL Apolipoproteins 
Matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) 
analysis was used to characterize the recovered apolipoproteins from the HDL fractions.  
A commercial Voyager-DE STR, MALDI-TOF mass spectrometer equipped with a 2m 
flight tube from Applied Biosystems (Foster City, CA, USA) and a mass range of 3000-
40,000 Da was used for the analyses.  The MALDI matrix used for the samples consisted 
of a 10mg/dL solution of sinapinic acid in a 1:1 mixture of acetonitrile and 0.1% TFA in 
water.  A thin-layer sample preparation method in which a MALDI plate was first 
spotted with the desired MALDI matrix and allowed to dry followed by a mixture of the 
sample and matrix (1:1 ratio) deposited atop the original spot was used for this analysis.  
Calibration of the instrument was performed with a mixture of bovine insulin, bovine 
serum albumin, and myoglobin as an external standard.  1μL of the standard was added 
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to 24μL of the matrix. For the MALDI analysis, the acceleration potential was held at 
25kV, the grid potential was at 93%, and the delay time was 575ns. Approximately 100 
shots per spectrum were collected.  
 
2.3 Clinical Studies 
Serum samples for each clinical study were selected from the serum libraries 
collected through collaboration of our laboratory with Scott & White Hospital (Temple, 
TX).  The complete adult serum library consists of CVD patients that were identified 
through patient histories of cardiovascular event and arterial blockage measured by 
angiography and control patients (CTRL) that were identified through arterial blockage 
of less than 10% measured by angiography.  Patient medical histories including 
information about ethnicity, family history of disease, diabetes, etc. were collected using 
a standard questionnaire for all subjects.  Standard lipid panel measurements for TC, TG, 
HDL-C, and LDL-C were performed by Scott & White clinicians and reported with the 
patient history data.  All serum libraries consist of donated serum from Scott & White 
patients. Informed consent was obtained from all donors.  
 
2.3.1 Statistical Methods of Analysis 
 Data for each clinical study was analyzed using multiple statistical methods. 
Linear discriminant analysis (LDA), sliced inverse regression (SIR), and quadratic 
discriminant analysis (QDA) were used to develop risk assessment algorithms for CVD.  
Analysis of Variance (ANOVA) and 2-sample T-tests were used to indentify factors 
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with statistical differences between selected cohorts.  LDA, QDA, ANOVA analyses, 
and T-tests were applied using Minitab 15 (State College, PA).  SIR was applied using 
the R statistical package (R Foundation for Statistical Computing, Vienna, Austria).   
The LDA and QDA analyses output the prediction accuracy of the training set, 
cross validation analysis (X-Val), and accuracy of a holdout sample.  The training set is 
a set of defined samples which are used for developing the prediction algorithm.  For 
large sample libraries, the training set is a group of randomly selected samples from the 
full library in order to remove any bias based on sample selection.  The X-Val is a 
method of removing one random sample from the sample set and then rerunning the 
analysis.  The resulting new equation is tested on the full sample set; including the 
sample that was removed.  The difference between the new prediction accuracy and the 
accuracy of the training set represents the level of dependence that the model has on the 
sample data that was removed.  For sample libraries that are large enough to use a 
randomly selected training set, the remaining samples are used for a holdout sample set.  
These are samples which were not used for development of the prediction algorithm.  
The accuracy of the holdout sample set using the prediction algorithm represents the real 
world application potential and statistical significance of the algorithm. 
SIR is a modern variation of R.A. Fisher’s original Linear Discriminant Analysis 
(LDA) method published in 1936 
19
.  SIR outputs the coefficients of each variable 
relative to the prediction algorithm.  These coefficients are relative to the coefficients 
from the LDA analysis with the inclusion of a scalar modification.  SIR also allows for 
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the calculation of the p-value which is a measurement of the statistical significance of 
the separation algorithm.   
 
2.3.2 Normal Lipidemic Serum Library 
Normal lipidemic serum samples were selected based on the following criteria: 
TC<200mg/dL, TG<150mg/dL, HDL-C >40mg/dL for men and >50mg/dL for women, 
and LDL-C<100mg/dL.  Twelve CTRL subjects were identified based on the criteria and 
through angiography (<10% arterial blockage).  Sixteen CVD patients were identified 
based on the criteria and having documented CVD.  
 
2.3.3 Comprehensive Serum Library 
 The comprehensive serum library study consisted of all adult serum samples 
collected through the Scott & White collaboration.  The library was made up of 100 
CVD subjects who were identified through patient histories of cardiovascular event and 
arterial blockage measured by angiography and 72 CTRL subjects who were identified 
to have less than 10% arterial blockage through angiography.  Of this library, 70 CVD 
and 40 CTRL subjects were selected using a random number generator (Minitab 15) to 
be used for the training set.  The remaining 30 CVD and 32 CTRL were used as a 
holdout sample set to test the generated algorithm.  The CVD serum library consisted of 
subjects from 34-83 years of age with varied racial backgrounds, primarily Caucasian.  
The CTRL serum library consisted of subjects from 29-83 years of age with varied racial 
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backgrounds, again primarily Caucasian.  The gender ratios for each library were 
approximately half male and half female. 
 
2.3.4 Hypercholesterolemia Serum Library 
 The hypercholesterolemia serum library was comprised of 30 children’s serum 
samples.  The subjects for this study ranged from ages 10 to 20. The definition of disease 
for these samples included children with a parental history of hypercholesterolemia or 
family history of premature CVD and also those children with two or more classical risk 
factors.  Eight healthy children samples were also collected.  The healthy children were 
defined as having normal lipid levels and no familial history of CVD or related risk 
factors.  These samples were similar in age range to the hypercholesterolemic children.  
This study was designed independent of gender and ethnicity.  
After dietary monitoring, hypercholesterolemic children with a fasting LDL-C 
remaining ≥ 130 mg/dl (e.g., high risk by NCEP guidelines) were randomized for 
simvastatin (20 mg) or placebo for 6 months.  The Scott & White inpatient pharmacy 
provided and dispensed compounded drug and placebo in identical forms.  Serum draws 
for each patient were taken every 12 weeks.   
 
2.3.5 Niacin Treatment Study 
 For this study, a single serum donor with documented CVD was treated with 
increasing amounts of niacin therapy from 0mg to 2000mg using increments of 500mg 
roughly every four weeks.  A baseline serum draw was performed prior to treatment and 
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then serum draws were performed after every treatment period.  A washout period of one 
week was performed after the last treatment to remove all drug effects.  A serum draw 
was performed after this washout period to assess the effect of stopping medical 
treatment.  The serum samples were analyzed using the HPLDP method of lipoprotein 
density profiling and the resulting integrated fluorescence intensities for the lipoprotein 
subclasses were applied to the risk assessment algorithm generated for the 
comprehensive serum library. 
 
2.3.6 Exercise Regime Study 
 For this study, a single volunteer underwent lifestyle modification in the form of 
increased exercise.  A baseline serum draw was performed prior to any change in 
exercise.  The first phase of the exercise program for this volunteer was made up of three 
to five 30 minute runs every week for 16 weeks.  This phase’s exercise was designed to 
keep the heart rate down to an optimal range for burning fat (60-70% of maximum heart 
rate).  After 16 weeks, the second phase was introduced.  This phase increased the 
exercise to include an extra 30 minute run each day at a pace that was set for 
cardiovascular training (70-80% of maximum heart rate) in addition to the fat burning 
run.  Serum draws were performed weekly through Scott & White (College Station, TX) 
to monitor the change in the lipoprotein density profiles relative to the exercise.  The 
serum samples were analyzed using the HPLDP method of lipoprotein density profiling 
and the resulting integrated fluorescence intensities for the lipoprotein subclasses were 
applied to the risk assessment algorithm generated for the comprehensive serum library. 
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3. RESULTS AND DISCUSSION 
 
 The overall objective of this study was to develop and enhance analytical 
techniques and methods which, when combined, could be used to assess the risk an 
individual has of developing cardiovascular disease.  The data from these techniques 
were combined with advanced statistical analysis methods for developing multivariate 
algorithms that not only determine classification, but also identify individual 
contributions and importance from the factors used in the analysis.  The first stage in 
completing this goal dealt with optimizing the methods to be used in the lipoprotein 
profile analysis in order to reduce error.  This was done through a fundamental 
understanding of the conditions and factors which have an effect on the reproducibility 
of the results.  After successful reduction of error in the measurements of lipoprotein 
profiles using density gradient ultracentrifugation and NaBiEDTA, the method was 
applied to multiple clinical studies with much success. 
 With the success of the NaBiEDTA-based density gradient system for lipoprotein 
profiles, further research was carried out employing a more versatile gradient based on 
the use of Cs2CdEDTA as the solute.  The higher solubility of Cs2CdEDTA allows for 
greater manipulation of the density gradient in order to isolate specific sections of the 
lipoprotein profile.  For this study, the selected concentrations were focused on the 
optimal separation of the main lipoproteins LDL and HDL.  HDL separation was a major 
interest due to the statistical analysis results from the previous clinical studies 
identifying the HDL subclasses as the largest contributor to risk classification.  While 
50 
 
 
 
the application of the Cs2CdEDTA profiles did not improve risk assessment, it did 
confirm the classification method and application of the LDA/SIR analysis for risk 
assessment using lipoprotein profiles.  Optimal separation of the HDL subclasses also 
allowed for application of the Cs2CdEDTA-based density gradient as an improved 
preparatory method for further analysis of the HDL profiles through mass spectrometry.  
Use of the Cs2CdEDTA gradient to isolate LDL allowed for the observation of a unique 
cationic interaction of the Cs
+ 
with the phospholipids on the surface of an LDL particle 
which affects the density of LDL in the profiles in comparison to the NaBiEDTA 
profiles. 
 Using the optimized Cs2CdEDTA gradient and dextran sulfate precipitation as a 
method for removal of LDL from serum, further studies were performed to test the 
viability of using mass spectra of HDL apolipoproteins for LDA/SIR analysis and risk 
assessment based on the earlier observation that HDL subclasses had highest 
contributions to the LDA/SIR classification.  This data was applied in addition to the 
lipoprotein profile data as well as being used as a separate method for risk assessment.  
Despite identification of differences in the masses of the major apolipoproteins present 
in HDL, the application of this data into the LDA/SIR analysis showed no improved risk 
assessment.  
 Overall, this research has advanced the field of cardiovascular risk assessment 
through application of high performance lipoprotein density profiling and further 
analysis through mass spectrometry.  Identification of distinct lipoprotein subclasses 
which can be used to assess risk and condition specific mass alterations of the 
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apolipoproteins specific to HDL have allowed for an 85% accurate risk assessment 
model for CVD which applies to the comprehensive serum library available through the 
collaboration of Scott & White Hospital and the Laboratory for Cardiovascular 
Chemistry at Texas A&M University. 
 
 3.1 Analytical Methods 
 
3.1.1 NaBiEDTA Lipoprotein Profile Optimization 
 The objective of this study was to identify sources of error in the NaBiEDTA-
based gradient system in order to focus on those features of the method that could be 
enhanced and therefore enhance the overall precision of the lipoprotein profile analysis.  
To accomplish this, several aspects of the gradient formation and lipoprotein profile 
were studied.  These factors included studies into the gradient formation, accuracy of the 
density measurement, lipoprotein propagation during the ultracentrifuge spin, spatial 
separation of the lipoproteins, layering methods, spin conditions, imaging conditions, 
and data analysis. 
 
3.1.1.1 Initial System Error Analysis 
 In order to identify components of the method where enhancements could be 
made and error reduced, a baseline analysis of the method was performed.  To 
accomplish this, a serum sample was spun and imaged in 10 replicate measurements 
using the 0.2000M NaBiEDTA-based density gradient with a 1000µL volume spin 
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previously described by Johnson et al.  The tubes were layered with 200µL of H2O and 
the resulting profiles were integrated based on the density profile and total intensity was 
calculated for each of the 12 lipoprotein subclasses.  The resulting profiles were overlaid 
as shown in Figure 4.  The average integrated intensities for each subclass and their 
respective errors, calculated based on the standard deviation, are graphed in Figure 5.   
The average error over the 12 subclasses was calculated based on the percent 
relative standard deviations (%RSD) and was found to be 23.39%.  As can be seen from 
the overlaid profiles and error bar analysis of the subclasses, the largest errors were in 
the buoyant TRL, dense TRL, and low density LDL subclasses.  There was also a larger 
amount of error at the dense region of the HDL subclasses.  The error in the TRL and 
LDL regions was associated with the H2O layering method.  The error in the HDL 
region was related to the curvature of the sample tube and the effect it has on the 
uniform exposure of the NBD fluorophore from the excitation source. 
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Figure 4: Overlaid Lipoprotein Profiles for Baseline Error Analysis 
 
bTRL dTRL LDL-1 LDL-2 LDL-3 LDL-4 LDL5 HDL-2b HDL-2a HDL-3a HDL-3b HDL-3c
0
10000
20000
30000
40000
50000
60000
In
te
n
s
it
y
Lipoprotein Subclass
 
Figure 5: Integrated Intensities and Error Bars for Baseline Error Analysis 
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3.1.1.2 Optimization of the Spatial Separation of the Density Profile 
 In order to achieve a better overall spatial separation of the lipoprotein particles, 
extending the total length of separation was deemed necessary.  This meant that the 
optimum spin volume needed to be established.  A base volume of 1200µL of H2O was 
spun under standard conditions similar to that used for lipoprotein profiling.  Each tube 
was weighed prior to and after the spin.  By measuring the weight loss, the total volume 
loss was able to be calculated using the density of H2O.  It was discovered that an 
average of 3.5% by weight or 40µL of H2O was lost per tube during the spin.  This loss 
was due to overflow from the sample tube into the angled rotor when samples are spun 
in the ultracentrifuge.  To compensate for this loss, the maximum spin volume was set at 
1150µL.  A second sample loss study was carried out to confirm that no sample loss 
would occur using this volume.  Results from this study showed that the sample loss 
using the 1150µL spin volume was an average of 0.173% or 2µL.  This loss was uniform 
for all samples and was deemed to have minimal effect on the final analysis.  Therefore, 
the 1150µL spin volume was confirmed as the optimal volume to allow for best spatial 
resolution. 
 The change in spin volume meant that the initial concentration of the solution 
had to be adjusted.  Based on density gradient theory, increasing the overall volume spun 
inherently increases the total number of moles of the EDTA salt that is present.  This 
meant that the initial concentration of the NaBiEDTA had to be lowered in order to 
optimally spread the lipoprotein profile over the whole tube. At the same time, the 
saturation concentration of NaBiEDTA must be avoided and spatial separation on the 
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HDL subclasses must occur away from the curvature at the bottom of the UC tube.  The 
optimum concentration that allowed for the identification of all lipoprotein subclasses 
was found to be 0.1800M NaBiEDTA. 
 
3.1.1.3 Density Gradient Development over Time 
 Measuring the formation kinetics of the density gradient made possible the 
mapping of a lipoprotein profile based on density as well as a determination of the 
density resolution of the measurements.  Figures 6 and 7 shows the formation of the 
density curve over time measured at 2, 4, 6, and 8 hours. (Figures 6A&B, Figures 
7A&B).  As can be observed from the formation of the density curve, and through 
comparison of the R
2
 value for curve fit, for full exponential curve formation to occur, it 
takes 6 hours.  Before 6 hours, the lower density region of the gradient is still not fully 
formed and does not fit an exponential curve, i.e the R
2 
values of 0.955 for a 2 hours 
spin.  Development of the exponential form of the gradient can be seen as the R
2
 
approaches 1.0 over time.  After 6 hours, the curve shows an R
2
 value of 0.9897 and a 
density profile that is close to exponential.  After 8 hours, the R
2
 value increases to 
0.99095.  The 6 hour spin time was chosen as it gives an acceptable exponential gradient 
while minimizing the spin time.   
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Figure 6: Gradient Formation over Time (2 and 4 Hours).  (A) 2 hour spin, (B) 4 
hour spin 
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Figure 7: Gradient Formation over Time (6 and 8 Hours).  (A) 6 hour spin, (B) 8 
hour spin 
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As the gradient forms, the progression of the lipoprotein profile, portrayed in 
Figure 8, shows that the lipoproteins are resolved at the higher densities first and then 
propagates down the tube as the density gradient becomes steep enough to reach the 
same density at the lower portion of the sample tube.  As the exponential gradient forms, 
the lower density lipoproteins are then separated by their respective densities in a similar 
fashion.  This shows that the lipoproteins density relatively do not change during 
ultracentrifugation.  Any change in the lipoproteins would have to happen immediately. 
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Figure 8: Overlaid Serum Profiles at 2-8 hours 
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For the density profile to be applied to clinical studies, the density gradient 
formation must be repeatable and precise as well.  To test the repeatability of the 
gradient formation, the density gradient was measured for 3 different ultracentrifuge 
spins.  It was found that the average error in the density curve was minimal.  The 3 
density curves are graphed together in Figure 9.  When comparing the 3 different 
exponential equations, the largest error was in the multiplicative constant applied to the 
exponential function.  The %RSD was calculated to be 2.44%.  The other constants in 
the equation had errors no greater than 0.4%.  This data showed that the gradient 
formation was highly repeatable and very precise.  This feature of the density profile is 
an important contribution to the application of this method to clinical studies and the risk 
classification.  Precision in the measurements will lead to more precise classification. 
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Figure 9: Replicate Density Gradients for 0.1800M NaBiEDTA Spun for 6 hours 
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3.1.1.4 Precision of Density Measurements Using Nano-spheres 
With the density gradient now mapped and spin time identified, the next step was 
to measure the inherent resolution of the particle density.  To carry out this 
measurement, a mono-dispersed fluorescent tagged nanoparticle was employed.  The 
objective of this study was to identify how the peak for the mono-dispersed nanoparticle 
forms and what is the inherent resolution of the density measurement based on the 
exponential density curve.  Figure 10 shows the progression of the fluorescent 
nanoparticle based on the spin time.  By measuring the full width half maximum 
(FWHM) of the peak intensity, it was observed that the peaks from the nanoparticles 
become sharper as spin time increases.  Looking at peak resolution in terms of the 
 
 
Figure 10: Fluorescent Nanoparticle Profile Based on Spin Time 
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percent change in density at the FWHM in relation to the average peak density of the 
nanoparticle (Table 3), it is seen that this percentage gets larger as the spin time 
increases.  This makes sense in terms of the nature of an exponential curve.  The change 
in density increases rapidly when the peak is portrayed further into the sample tube due 
to the rate of density change in relation to the exponential curve.  The resolution change 
is insignificant as the percent change is no more than 0.20% even at an 8 hour spin. 
 
Table 3: Nanoparticle Density Measurements and Resolution 
Spin 
Time 
(Hrs) 
Avg 
Density 
(g/mL) 
Std. 
Dev. 
%RSD 
Avg. 
FWHM 
(mm) 
Avg. Δ 
Density 
(g/mL) 
Avg. 
Resolution 
(%) 
2 1.0562 0.0001 0.0118 1.2563 0.0012 0.1124 
4 1.0544 0.0003 0.0237 0.6845 0.0014 0.1304 
6 1.0524 0.0004 0.0411 0.5861 0.0019 0.1782 
8 1.0552 0.0003 0.0319 0.5462 0.0021 0.1979 
 
According to the manufacturer, the reported density of the nanoparticle is 
between 1.040 and 1.060 g/mL.  Using the density curve formation for each time spin, 
the density of the nanoparticle was shown to be 1.0545 +/- 0.0016 g/mL on average for 
all spin times and propagates with the density gradient formation similar to the way 
serum was shown to in Figure 8.  The percent relative standard deviations (%RSD) of 
the density measurement ranged from 0.01-0.04% with an average of 0.027% over all 
spin times measured.  This observation suggests that the nanoparticles propagate from a 
homogeneous solution, before it is spun, to a focused band within 2 hours that matches 
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the density of the nanoparticles.  For larger spin times, the nanoparticle propagation 
follows the formation of the density gradient as it approaches equilibrium.  By balancing 
the resolution with the gradient curve formation, a 6 hour spin was chosen because it 
allows for optimal gradient formation while maximizing the resolution.     
 
3.1.1.5 Polar Layering with H2O vs. Non-Polar Layering with Hexane 
The initial method described previously by Johnson et al. used deionized water 
(DI H2O) as a layering medium for separation of the chylomicrons and TRLs that are 
less dense than 1.00g/mL from the VLDL and TRLs that have a greater density than 
1.00g/mL.  This method of layering creates a large amount of experimental error.  The 
DI H2O can readily mix with the gradient at the meniscus due to turbulence which will 
induce mixing of the VLDL/TRL layers with the LDL.  There is also an added factor of 
creating an error in the fluorescent intensity of the VLDL/TRL layers due to the 
meniscus scattering light at the wavelength for NBD emission.  To counter this effect, a 
method of using a non-polar layering medium that is less dense than the lipoproteins was 
developed.  The use of hexane was chosen as the layering medium.  Hexane’s density is 
0.68g/mL which means it will trap all of the TRLs, VLDL, and chylomicrons into one 
peak while at the same time, removing the error due to meniscus light scattering by 
separating the meniscus from the TRL/VLDL layer being measured. 
The effects of the two different layering techniques can be seen in Figure 11.  
Figure 11A shows the original lipoprotein separation using 0.20M NaBiEDTA and DI 
H2O as a layering medium.  The fluorescent layer near the top of the sample tube is due 
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to scattered light from the meniscus and a small amount of the low density TRLs.  This 
feature can also be seen in Figure 11B where the lipoprotein separation was carried out 
using 0.1800M NaBiEDTA without any layering.  The intense band at the top of the 
image is mainly from the meniscus and VLDL/TRL fluorescence.  This interpretation is 
supported by comparing the image to Figure 11C where the sample has been layered 
with hexane to remove the meniscus effect and leave the VLDL/TRL band exposed.  In 
Figure 11C, the hexane volume was chosen in order to shift the meniscus created from 
the hexane from the illumination area, and therefore remove any false fluorescent 
intensity that would be due to the scattered light from the meniscus.  Consequently, the 
TRL and VLDL form a single band without affecting the measurement since the hexane 
will trap all TRL’s based on their densities in relation hexane’s (0.68g/mL). 
The use of hexane not only eliminates the meniscus reflection problem, but it 
also removes the error that occurs due to the diffusion of the DI H2O into the aqueous 
gradient.  Figure 11D shows a comparison of the two layering techniques through 
overlaid lipoprotein profiles.  As can be distinguished from the graph, when DI H2O is 
used as the layering medium, the peak at the lower tube coordinates broadens due to 
diffusion of the DI H2O which then causes error in the lipoprotein profile.  Selecting 
hexane as the layering medium means that there is no diffusion as the polar properties of 
the aqueous gradient and the non-polar properties of hexane prevents the two layers from 
mixing. 
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Figure 11: Layering Medium Comparison. (A) DI H2O as a layering medium, (B) 
no layering medium, (C) hexane as a layering medium, (D) Lipoprotein profile 
comparison of DI H2O layering and hexane layering.  Note: (A) does not represent 
the same serum used in (B) and (C). 
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3.1.1.6 Effects of Ultracentrifugation Spin Temperature 
With the general ultracentrifugation spin conditions such as EDTA concentration 
and spin time established, a more detailed study of other variables was undertaken.  
When considering the potential of applying lipoprotein profiles to clinical studies, it is 
important to take into account the viability of the lipoprotein profile over time.  With a 6 
hour spin necessary for the gradient formation, it becomes important to understand the 
effect the temperature at which the samples are spun has on the profile.   
For this study, the temperatures of 5°C, 15°C, and 25°C were chosen to test a 
broad range of possible settings.  Figure 12 shows the effect of spin temperature on the 
lipoprotein profiles.  Figures 12A shows the overlaid lipoprotein profiles for the three 
selected temperatures.  Figures 12B shows relationship between the average %RSD in 
the lipoprotein profiles as it relates to the spin temperature.  This %RSD was calculated 
based on 10 replicate samples that were spun at the designed spin temperature.  The 
profile subclasses were integrated and the %RSD was calculated.  Figures 13A and 13B 
map the peak shifts observed for both LDL and HDL distributions as a function of spin 
temperature.  As temperature increases, the LDL and HDL peaks shift to a lower tube 
coordinate.  This does not mean that the lipoprotein density has changed, just that the 
density gradient profile has changed due to the spin temperature.  Temperature influence 
on density gradient formation was previously discussed in Section 1.4.1.1.  According to 
density gradient theory, temperature is a component of the diffusion forces acting in situ.  
Increase in temperature will increase the rate of diffusion and therefore accelerate the  
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Figure 12: Effect of Spin Temperature on Lipoprotein Profiles. (A) Overlaid 
lipoprotein profiles for 5, 15, and 25C, (B) Average Repeatability Error vs. Spin 
Temperature 
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Figure 13: Effect of Spin Temperature on Lipoprotein Peak Orientation. (A) LDL 
peak orientation vs. Spin Temperature, (B) HDL peak orientation vs. Spin 
Temperature 
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change in the resolved density range.  It is important to note that repeatability error of 
the profiles based on integration of the subclass intensities increases as the spin 
temperature increases (Figure 12B).  This means that to reduce the error in the profiling 
of lipoproteins, the samples must be spun at low temperatures.  Lower spin temperatures 
slow the formation of the gradient and therefore minimize the error in profiling while 
keeping the serum sample viable. 
 
3.1.1.7 Tube Orientation for Imaging 
 With the optimal UC spin conditions now established, the next step was to 
reduce the error contributed by imaging and analysis of the sample.  To investigate these 
factors, the influence of the sample tube’s orientation was studied by marking each 
sample as it related to the center of the UC rotor and imaging the sample by rotations of 
90
o
 from the initial orientation point.  The orientation of the tube was found to have an 
effect on the resulting profiles due to a circular particulate deposit on the inside surface 
of the sample tube relating to its initial orientation in the UC rotor.  This particle deposit 
and the resulting profiles can be viewed in Figure 14.  Without the rotation, this stain can 
result in false intensity peaks in the lipoprotein profile (Figure 14E, 0° rotation).  These 
peak errors appear in the range of the LDL region of the density profile (12mm-15mm).  
Rotating the tube away from the camera still portrayed the deposit in the image 
background.  Rotating the tube’s orientation towards the light source resulted in light 
scattering and uneven intensity of the excitation light source.  Rotation of the sample 
tube by 90°, so that the particulates faced away from the light source and were not in the   
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Figure 14: Tube Orientation for Imaging.  (A) 0° rotation, (B) 90° rotation, (C) 180° 
rotation, (D) 270° rotation, (E) Overlaid Lipoprotein Profiles. Images are of 6uL of 
Serum in 0.20M NaBiEDTA based density gradient after being spun in the 
Ultracentrifuge.  Sample was spun for 6 h at 120,000rpm and 5 °C.  Initial image is 
oriented so that the part of the tube facing the camera is the same part that was 
facing the center of the UC rotor.  The red rectangles signify the area of the image 
used to create the lipoprotein density profiles. 
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center of the image, was found to remove this effect on the lipoprotein profile.  For this 
study, layering methods were not implemented. 
 
3.1.1.8 Stability of the Density Profile after UC Spin 
 The next factor studied in order to limit the error in the imaging process of the 
lipoprotein profiles was stability of the profile over time.  The stability of the lipoprotein 
profile over time will have a direct effect on the use of the profile for clinical studies.  
With use of the EDTA salt gradients, there will be a slow diffusion of the gradient back 
to a homogeneous concentration.  The profiles must be imaged prior to this diffusion.  
For this study, profiles were imaged every 30 minutes after the initial image in order to 
map the change in the lipoprotein profile due to time.   
 Figure 15 shows how the profile changes over time after the sample was spun 
and layered.  Figure 15A shows the resulting profiles overlaid on the same graph while 
Figure 15B shows the profiles staggered based on the amount of time after the UC spin 
that the sample was imaged.  The figures showed that it was the high density range of 
the profile that was more affected by time.  The protein peak separated at the high 
density section of the lipoprotein profile began to merge with the HDL3 density range 
after just 30 minutes and continued over time.  The rest of the lipoprotein profiles stay 
relatively stable during the tested time periods.  This was most likely due to the gradient 
starting to diffuse back to the homogeneous state of the aqueous solution before the UC 
spin.  For repeatability and quality of the lipoprotein profile, the results show that the  
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Figure 15:  Stability of the Lipoprotein Density Profile over Time.  (A) Overlaid 
lipoprotein density profiles, (B) Staggered lipoprotein density profiles 
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images must be taken within the first 30 minutes after the UC spin to minimize the 
influence of gradient diffusion. 
 
3.1.1.9 Precision of the Density Profiles after Optimization 
After incorporating these improvements in the measurement of the lipoprotein 
density profiles, an error analysis of the new lipoprotein profiling method was 
completed.  By comparing the average %RSD of the lipoprotein subclasses for each 
method, and the overlaid lipoprotein density profiles, a significant reduction in error was 
observed.  For the initial method described by Johnson et al, the average %RSD was 
found to be 23.39%.  Applying the enhancements that were identified to create the High 
Performance Lipoprotein Density Profiling method (HPLDP), the average %RSD was 
reduced to 5.28% +/- 0.88.  All subclasses of the lipoprotein profile showed reduction in 
error.  The %RSD of the TRL and low density LDL regions of the profile were the most 
significantly reduced.  This feature can be linked to the change in layering methods.  The 
polar/non-polar relationship of the aqueous gradient to the hexane prevents diffusion of 
the layering medium and therefore reduced the %RSD layering had on the lipoprotein 
profiles.  Figure 16A shows the overlaid sample profiles of 10 replicate measurements 
using the original method.  Figure 16B is the overlaid sample profiles of 10 replicate 
measurements using the HPLDP method.  The HPLDP method shows a much more 
congruent overlay of lipoprotein profiles compared to the original method.  This 
observation corresponds to the reduced error that was calculated from the average 
%RSD of the subclasses. 
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Figure 16: Repeatability of Lipoprotein Density Profiles for 10 Replicate Samples. 
(A) Overlaid profiles for original method of density profiling, (B) Overlaid profiles 
Using HPLDP method of density profiling 
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3.1.1.10 Normalization of Density Profile Data 
An analysis of the lipoprotein profiles for light source related errors was 
performed by calculating the percent intensity of the lipoprotein subclass in relation to 
the total intensity of the lipoprotein density profile.  The rationale behind this study was 
to reduce any error present due to the pipetting of serum or NBD fluorophore as well as 
due to possible fluctuations in the light source over time.  Since the classification 
analysis is based on the fluorescence intensities of the lipoprotein subclasses, factors that 
influence the fluorescence intensity are sources of systematic error. 
The initial method of measuring the total intensity of each lipoprotein subclass 
(Mode 1) showed the average %RSD to be 5.28% +/- 0.88 as previously reported.  Using 
the percent intensity of each subclass in relation to the total intensity of the profile 
(Mode 2), the average error of the lipoprotein profiling method was reduced to 3.69% 
+/- 1.41.  Figure 17 illustrates this difference in error between Mode 1 and Mode 2 
analysis when applied to profiles that were taken using different exposure settings on the 
camera (53.3ms versus 100ms exposure) to simulate possibly fluctuations in light 
intensity.  As can be observed from Figure 17A, the total intensities are near double for 
the higher exposure.  However, when applying the Mode 2 analysis, the two different 
exposure times show similar values for each lipoprotein subclass; effectively reducing 
any error due to the excitation source or preparative variation.   
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Figure 17: Application of Mode 2 Analysis for Density Profile Normalization. (A) 
Total Intensity (Mode 1), (B) Percent Intensity (Mode 2).  Black Bars Represent 
Data Measured at 53.3ms Exposure.  Red Bars Represent Data Measured at 100ms 
Exposure. 
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Not only was the RSD improved by the normalization of the lipoprotein profiles, 
but it also offered the possibility of considering that the population of lipoprotein 
subclasses is a coupled system instead of just individual measurements. This realization 
has the potential for a new systematic approach to the use of the lipoprotein density 
profile in clinical applications.  This application will be discussed later in Clinical 
Applications Section 3.2. 
 
3.1.1.11 Profiling HDL/LDL Commercial Standards 
 The final phase of the optimization involved the measurement of HDL and LDL 
subclass intensities through serial dilutions of commercial standards.  This study was 
necessary so that the relationship between HDL and LDL integrated fluorescence 
intensities could be related to the concentration of the lipoproteins present in the spin.  
For this study, commercial standards of HDL and LDL were obtained through Sigma-
Aldrich.  The concentration of these standards was reported by the manufacturer in terms 
of amount of total protein (µg/dL).  These standards were diluted in situ and the resulting 
fluorescent profiles were obtained.   
 The resulting profiles have been overlaid and are shown in Figures 18A and 18B.  
The HDL peak was prominent for the largest concentration showing a peak intensity of 
near 2000.  The LDL peak however showed very little intensity with a peak of only 125 
for the highest concentration.  HDL’s concentration was 3.25 times higher than that of 
LDL, but this relationship did not translate to the total intensities.  This data leads to  
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Figure 18: LDL and HDL Density Profiles Using Commercial Standards.  (A) LDL 
Density Profiles of Serial Dilutions.  (B) HDL Density Profiles of Serial Dilutions.  
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Figure 19: LDL and HDL Calibration Curves Using Commercial Standards.  (A) 
LDL Calibration Curve Relating Concentration to Integrated Intensities.  (B) HDL 
Calibration Curve Relating Concentration to Integrated Intensities. 
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the realization that the LDL and HDL particles interact with the NBD fluorophore based 
on their individual composition rather than in a uniform relationship.    
 By integrating the total fluorescence intensity for each lipoprotein density class, 
calibrations curves were generated comparing the concentration to the corresponding 
intensity.  These calibration curves are shown in Figures 19A and 19B.  This study 
showed that for standard samples, there is a linear relationship between the lipoprotein 
concentration and the resulting fluorescent intensities.  These findings will be used to 
compare the fluorescent intensities for each lipoprotein density class for the clinical 
subjects to determine whether similar relationships exist. 
 
3.1.2 Cs2CdEDTA-Based Gradients for Isolation of LDL and HDL 
 With the successful error reduction and implementation of the NaBiEDTA-based 
density gradient system, the results led to the possibility that enhancing the baseline 
separation of the lipoproteins, especially the HDL region, would allow for a more 
detailed characterization of lipoprotein profiles that could result in a more accurate risk 
assessment when applied to the clinical studies.  There was also the added benefit that 
this enhanced separation would aid in the preparatory techniques previously applied in 
order to isolate specific areas of the lipoprotein profile for further analytical analysis.   
 Because of NaBiEDTA’s relatively low solubility, its use in forming the density 
gradient was limited to profiling the entire density range of serum lipoproteins in a 
singular spin.  The use of Cs2CdEDTA as the solute has previously shown to have a 
higher solubility which in turn would allow for greater control over the density gradient.  
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This meant that through use of the Cs2CdEDTA solute, initial concentrations could be 
manipulated in order to isolate the LDL density range and the HDL density range 
through individual spins designed for this purpose.  The objective of this study was to 
identify the solute concentrations necessary for implementation of a dual spin system to 
isolate LDL and HDL separately, measure the repeatability and error in these solute 
systems, and to compare the resulting profiles to the profiles found when using 
NaBiEDTA as the solute in the density gradient. 
 
3.1.2.1 Cs2CdEDTA Gradient Measurement and Optimization 
 With the optimum conditions for gradient development during the UC spin and 
for profile imaging having been previously studied and identified, the first step toward 
application of Cs2CdEDTA as a solute system was the identification of the ideal 
concentrations of solute needed to form gradients that would separate the LDL and HDL 
subclasses respectively.  To carry this out, the first step was to use different 
concentrations of solute ranging from 0.05M-0.30M Cs2CdEDTA with serum to 
measure the resulting lipoprotein profiles.  The resulting lipoprotein profiles are 
displayed in Figure 20.  It was anticipated that lower concentrations of the solute would 
result in a narrow range of densities that can be resolved once the density gradient is 
formed.  Taking this effect into account when observing the different peak movement 
compared to the concentration of solute used, the results clearly show the LDL peak 
moving to the lower tube coordinates with increasing initial concentration of the solute 
as was expected.  The concentrations of 0.0500M and 0.1000M Cs2CdEDTA provided 
81 
 
 
 
the best conditions for resolving the LDL over the full length of the tube while the 
concentration of 0.2500M Cs2CdEDTA was shown to spread out the HDL region of the 
profile.   
 
6 9 12 15 18 21 24 27 30
0
550
1100
1650
2200
0.3M
0.25M
0.2M
0.15M
0.1M
0.05M
HDL
Tube Coordinate (mm)
In
te
n
s
it
y
C
s
2 C
dE
D
TA
 C
oncentratoin (M
)
LDL
 
Figure 20:  Lipoprotein Density Profiles for Varying Cs2CdEDTA Concentrations 
 
These solute concentrations were then mapped for density gradient formation in 
order to assess the resolution of the density regions.  The 0.2500M Cs2CdEDTA was 
found to resolve the LDL5 subclass and all HDL subclasses over the optimum length of 
the UC tube.  For the LDL region, it was found that the 0.0500M Cs2CdEDTA resolved 
all LDL subclasses over the optimum length of the UC tube and also resolved the density 
range of IDL as well.  The resulting density gradient curves are portrayed in Figure 21A 
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and 21B.  The average error between the constants from the exponential equation for the 
0.2500M Cs2CdEDTA-based density gradient was calculated to be 15.73%.  The 
average error between the constants from the exponential equation for the 0.0500M 
Cs2CdEDTA-based density gradient was calculated to be 7.55%.  This increased error 
was associated with the fact that the Cs2CdEDTA gradients are synthesized versus 
simply using a commercially available salt like NaBiEDTA.  The error associated with 
the synthesis of the Cs2CdEDTA compounds the overall %RSD on the gradient 
formation.   
 To assess the extent this factor influences the clinical samples, the %RSD was 
then calculated for the resolution of the lipoprotein subclasses based on the tube 
coordinates for each density cut-point between subclasses using the corresponding 
exponential equation.  The %RSD or for the density cut-points for HDL subclasses was 
found to be 3.87%.  The lower density cut-points were associated with the highest 
%RSD at 15.58%.  The %RSD for the density cut-points for LDL subclasses was found 
to be 6.24%.  The lower density cut-points were again associated with the highest %RSD 
at 15.98%.  This %RSD at the lower density subclass of each spin is most likely due to 
the smaller slope at the beginning of an exponential curve.  The %RSD is reduced in the 
higher density regions due to the increased slope.  While the %RSD was higher for the 
Cs2CdEDTA based gradients when compared to the NaBiEDTA based gradients, the 
average %RSD in subclass definition was still small enough to qualify the gradient 
system for further evaluation of the systematic error when applied to the clinical serum  
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Figure 21: Cs2CdEDTA Density Gradient Formation. (A) 0.2500M Cs2CdEDTA 
(B) 0.0500M Cs2CdEDTA 
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samples based on the definition of error required for clinical testing previously identified 
in Section 1.2.1. 
 
3.1.2.2 Precision of Density Profiles Using Cs2CdEDTA Gradients 
 Before applying the dual Cs2CdEDTA-based gradients to clinical samples, the 
systematic error must be low enough to ensure repeatability of the analysis similar to 
that of the NaBiEDTA-based gradients.  This error was again measured by running a 
standard serum sample in 10 replicates and calculating the error between lipoprotein 
density profiles.  The resulting lipoprotein density profiles and error analysis are 
displayed in Figure 22 and Figure 23, respectively.  As can be observed from the figure, 
the lipoprotein density profiles again have low error overall.  The average %RSD for the 
LDL profile was calculated to be 11.00%.  The average %RSD for the HDL profile was 
calculated to be 7.06%.  While this error is higher than the error found for the 
NaBiEDTA-based density profiles, it is still within an acceptable range for application to 
clinical studies. 
 When comparing the lipoprotein density profiles of the dual Cs2CdEDTA-based 
spins to the NaBiEDTA-based spin, some interesting observations can be made.  First, in 
the NaBiEDTA gradient, LDL’s most prominent peak is portrayed between LDL4 and 
LDL5 (1.049g/mL).  The most prominent peak in the Cs2CdEDTA gradient for LDL was 
portrayed at a higher density inside the density range of LDL5 (1.061g/mL).  The 
difference in density, based on the measured density gradients, is 0.012g/mL.  As for the 
HDL, in the NaBiEDTA based gradient, the density peak was found at 1.098g/mL.  For  
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Figure 22: Dual Concentration Cs2CdEDTA-Based Gradient Density Profiles. (A) 
0.0500M Cs2CdEDTA LDL Profiles Overlaid, (B) 0.2500M Cs2CdEDTA HDL 
Profiles Overlaid 
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Figure 23: Dual Concentration Cs2CdEDTA-Based Gradient Profile Error 
Analysis. (A) 0.0500M Cs2CdEDTA LDL Subclass Error, (B) 0.2500M 
Cs2CdEDTA HDL Subclass Error 
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the Cs2CdEDTA-based gradient, the density of the HDL peak was found to be 
1.100g/mL; a difference of only 0.002g/mL.  Similar differences in the lipoprotein 
density for LDL have been reported by Johnson et al
12
 who first studied the application 
of different EDTA salt-based gradients.  However, a larger difference in HDL density 
was reported between the two gradient solutes by Johnson et al
12
 where only a small 
density change was recorded in this study.   
 The reason for this density shift in the different EDTA solutes could be due to a 
cation-interaction between the phospholipids on the outer shells of the lipoprotein 
particles and the different metal cations.  Through reviewing sedimentation theory, it 
was documented that the use of Cs
+
, which has a high affinity to bind to phosphate 
groups, can alter the density of DNA when studied.
72
  Na
+
 has the same effect but it is 
less due to the mass difference between the Cs
+
 and Na
+
.  Similarly, this would affect the 
monolayer of lipoproteins since phospholipids can be found there.  When referencing 
Krilov et al for FT-IR spectra on lipoproteins, it is reported that an LDL particle has 724 
phospholipids where HDL2 and HDL3 particles have 137 and 51, respectively.
118
  This 
increase in active sites could explain why the LDL is affected more than the HDL.  With 
the use of Cs2CdEDTA, there is the potential for more metal cations to bind with the 
phospholipids on the monolayer of the LDL due to the fact that the CdEDTA-complex 
has a -2 charge and therefore there are twice as many Cs
+
 cations in the solution as there 
are Na
+
 cations in the NaBiEDTA solution.  The potential for unassociated 
phospholipids would be decreased with the enhanced number of Cs
+
 cations present in 
solution.  Despite this density changing effect, the dual concentration Cs2CdEDTA-
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based gradients were shown to have high repeatability as well as the ability to spread out 
the density profiles for the LDL and HDL density ranges.  The effect that the metal 
cation has on the density profile will be further studied in clinical samples to test on 
multiple subjects.  It is possible that this effect could be subject dependant and therefore 
could contribute as a risk marker for CVD classification. 
 
3.1.3 Serum Viability Studies 
 With the analytical methods for lipoprotein density profiling optimized, the only 
other source of possible error was the viability and stability of serum samples.  
Understanding the way that serum is affected by being thawed multiple times and how 
serum is affected through the length of exposure it has to room temperature will serve as 
a guide in how clinical samples should be treated.  These studies were designed to 
understand these effects so that the optimum method of serum treatment could be 
employed when studying clinical samples in order to minimize sample degradation.  The 
NaBiEDTA-based density gradient was used for all studies in order to compare results. 
 
3.1.3.1 Density Profiles Relative to Time Serum Spent at Room Temperature 
 The goal of this study was to examine the effect that serum being stored at room 
temperature has on the lipoprotein profile over time.  To carry out this study, the same 
serum sample was aliquotted into several identical fractions and stored at room 
temperature for 0.5hr, 2hr, 4hr, and 24hr. The fractions were then profiled in 5 replicate 
measurements.  The resulting lipoprotein density profiles are depicted in Figure 24A.  As 
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can be observed from the overlaid profiles, there is relatively no change in the TRL, 
HDL, or Protein peaks in the serum profiles.  There is, however, a distinct change in the 
LDL peak of the lipoprotein density profile.  This peak shift has been mapped by 
studying the peak density as a function of exposure time at room temperature as shown 
in Figure 24B.  This graph shows a direct relationship between the peak density and the 
exposure time in the form of an exponential decay.  This relationship indicates that the 
density change is a process which slows and reaches an endpoint over time.  The change 
in LDL density can possibly be attributed to increased enzymatic activity as time elapses 
or loss of lipids from the lipoproteins.  Regardless of the reason for the change, in order 
to evaluate lipoprotein density profiles for clinical applications, the exposure to 
increased temperature must be minimal.  For this reason, a 30 minute thaw time for 
serum was selected to reduce the temperature effect. 
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Figure 24: Effects of Exposure at 23°C on Serum over Time.  (A) An Overlay of 
Lipoprotein Density Profiles Obtained from Serum Exposed at Different Times, (B) 
Density Change in LDL based on Exposure Time at 23°C 
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3.1.3.2 Effect of Multiple Freeze/Thaw Cycles of Serum on Density Profiles 
 With the thaw time identified for viability of the lipoprotein density profile, the 
next factor studied was the stability of the profile over freezer storage time and multiple 
freeze/thaw cycles.  The goal of this study was to identify any effect that these multiple 
freeze/thaw cycles could have on the lipoprotein density profile.  To study this factor, a 
serum sample was thawed for 30 minutes and then flash-frozen using liquid nitrogen 
several times.  After each thaw, an aliquot of the serum was withdrawn for profiling.   
 The %RSD between freeze/thaw cycles was calculated and compared to the 
baseline %RSD for ten replicates previously reported as the systematic error of the 
enhanced lipoprotein profiling method.  This error was previously identified at 5.28% 
+/- 0.88 for Mode 1 and 3.69% +/- 1.41 for Mode 2.  For the 12 different thaw cycles, 
the %RSD was calculated to be 7.05% +/- 1.59 for Mode 1 and 5.77% +/- 1.10 for Mode 
2.  The profiles are shown in Figure 25.  Only small differences in the profiles were 
observed showing that the relative error due to thaw cycles was insignificant for 12 
cycles.  This number of cycles is more than a standard clinical sample would undergo. 
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Figure 25: Effect of Multiple Freeze/Thaw Cycles on Density Profiles 
 
3.1.4 Optimization of Preparative Techniques for HDL Apolipoprotein Mass 
Spectrometry  
 Differences between control and CVD samples in the mass spectra of HDL 
apolipoproteins have been identified through previous work in the Macfarlane research 
group.  These differences have been identified as a possible biomarker for the presence 
of CVD.  Specifically, a difference in the mass of Apo C-I was found in a small cohort 
of CVD samples that was not present in a small cohort of control samples. Application 
of mass spectrometry to HDL was previously performed on the HDL2 and HDL3 
subclasses.  This separate analysis of the major subclasses of HDL identified that the 
93 
 
 
 
modified Apo C-1 was present in both HDL subclasses.  For this reason, it was decided 
that mass spectra analysis of the full HDL fraction would be studied. 
 Before performing this analysis on a large scale cohort of clinical samples, it 
was necessary to identify the proper methods for sample preparation that allow for the 
optimum recovery of the apolipoproteins off of HDL.  Multiple methods of sample 
purification have been previously studied and applied to serum to isolate HDL including 
dextran sulfate precipitation of the Apo B containing lipoproteins and UC density 
separation for isolation of HDL.
115
  To delipidate the HDL fraction, reverse phase solid 
phase extraction has been shown through previous studies as a simple and efficient 
method for removing the lipids.
117
  In order to verify the efficiency of these methods, 
commercially available ELISA kits were used to measure the recovered Apo A-I-
containing lipoproteins taking advantage of the one-to-one relationship between Apo A-I 
and the HDL particles.  The BCA protein analysis was also used to quantify the total 
protein recovery.  The objective of these studies was to determine the optimal method 
for recovery of the proteins associated with HDL with the highest percent recovery of 
the full spectrum of HDL-related protein, realizing this feature of the protocol 
maximizes the probability of discovering new CVD-related biomarkers. 
 
3.1.4.1 Optimizing Recovery of HDL and HDL Apolipoproteins  
   In order to identify the optimum method of sample preparation for mass 
spectra analysis, a comparison of the preparative protocols was made using the resulting 
mass spectra as the criteria for optimization.  The three protocols studied were 1) UC 
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density preparation with the 0.25M Cs2CdEDTA-based density gradient to recover the 
HDL fraction, 2) dextran sulfate precipitation to isolate HDL, and 3) the combination of 
dextran sulfate precipitation followed by density gradient separation to isolate HDL.  
Each recovered HDL fraction was then desalted and delipidated by SPE.  The resulting 
mass spectra for the three protocols are shown in Figure 26.  When comparing the total 
intensities of the peaks for each of the preparative methods, it was found that the highest 
Apo C-I peak intensities were observed in the dextran sulfate treated serum.  However, a 
more complete coverage of the mass spectrum was achieved with a combination of the 
use of preparative ultracentrifugation and dextran sulfate precipitation (Figure 26C).  In 
order to establish the most information-rich recovery method, further investigation was 
needed to determine the reason why there were such noticeable differences. 
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Figure 26:  Mass Spectra of HDL Apos for Different Preparative Methods. (A) 
HDL Isolated through UC Preparation, (B) HDL Isolated through DS Preparation, 
(C) HDL Isolated through Combining UC and DS preparation 
A 
B 
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3.1.4.2 Protein Recovery of Delipidated HDL   
 In order to understand the differences in the mass spectra between preparative 
methods, additional analytical methods were implemented to obtain quantitative data 
using Apo A-I specific ELISA and the BCA assay for total protein measurement.  The 
products of the dextran sulfate precipitation were first tested to measure the total 
recovery both before and after solid phase extraction was performed.   Initial 
concentrations of multiple serum samples were measured and then compared to the 
concentration recovered after dextran sulfate precipitation and after solid phase 
extraction.  The average recovery after dextran sulfate precipitation was 95.20 +/- 
3.24%.  This result showed that use of dextran sulfate precipitation had little influence 
over the resulting mass spectra due to the high recovery rate of the dextran sulfate 
precipitation method.  On the other hand, after the sample was run through solid phase 
extraction to collect the free apolipoproteins, the recovery was calculated to be only 
11.43 +/- 2.84%.  When testing the wash sample used to remove the salts from the 
sample in the SPE cartridge, the total concentration of Apo A-I was calculated to be 
90.59 +/- 4.59%.  This high recovery yield indicated that the signal loss previously found 
in the mass spectrometry analysis of HDL apolipoproteins was due to the solid phase 
extraction technique.   
 To understand this loss, previous research into the method of reverse phase 
solid phase extraction for delipidation of lipoproteins was reviewed.  The previous 
research had shown recoveries of up to 90% on pure protein samples.
117
  However, when 
lipids were present, there was a reduced functionality that limited the loading capacity of 
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the SPE cartridge to no more than 150µg of total protein.  When limiting the sample load 
to 100µg of protein with the presence of lipids, the total recovery found was 80%.  In 
reference to the methods performed in this study, 200µL of serum were used.  With the 
average concentration of protein in human serum ranging from 60-83mg/mL, this range 
translates into a total range of 14,000-16,600ug of total protein present in the initial 
serum sample.  Since dextran sulfate precipitation only removes the proteins that are 
related to LDL, the HDL proteins and the free proteins, such as globulin and albumin, 
are present in the sample when loaded onto the SPE cartridge.  This overload of protein, 
combined with the presence of lipids, explains the sample loss that was found in the 
wash step of the SPE method.   
 With total protein content being the controlling factor in the amount of 
apolipoproteins recovered from HDL, it was now possible to explain why the 
combination of dextran sulfate precipitation and preparative ultracentrifugation resulted 
in the best mass spectra total signal.  The preparative ultracentrifugation technique adds 
a secondary purification process in isolating HDL that removes abundant globulins and 
albumin.  The removal of these proteins minimized the total amount of protein that was 
loaded onto the SPE cartridge and in turn improved the total recovery of the HDL 
apolipoproteins.   
 The total amount of protein present in HDL is primarily due to the Apo A-I 
concentration since it is present on every HDL particle.  Other apolipoproteins are 
present, but only in small concentrations relative to the concentration of Apo A-I.  The 
average concentration of Apo A-I in a normal human’s HDL is 130 mg/dL.48  Coupled 
98 
 
 
 
with the other apolipoproteins present, the average concentration of the HDL-related 
proteins is approximately 200mg/dL.  For an average human serum samples, this 
concentration translates into a total protein content of 400µg for HDL in 200µL of 
human serum.  With the maximum loading capacity of the SPE cartridge being reported 
at 150ug of protein when lipids are present, this means that the SPE extraction cartridge 
would have been overloaded.  In order to test this possibility, multiple recovered protein 
samples were measured for their total protein content.  While total protein content varied 
between subjects, all samples tested at an average recovery of 387 +/- 119µg.  These 
recovered protein values show an increased recovery from that previously reported when 
using the SPE cartridge and confirm that the majority of the apolipoproteins present in 
HDL are being recovered. 
 With the large spread in HDL-protein concentrations, it became necessary to 
identify the reproducibility of the full preparative method.  To measure the 
reproducibility of the protein recovery when combining the dextran sulfate precipitation 
method and the ultracentrifugation preparative method, the use of the BCA assay to 
measure the total protein recovered from HDL was implemented in order to measure all 
protein content instead of just the Apo A-I.  To test the reproducibility, a volunteer 
serum sample was run through the method in triplicate and the %RSD was calculated.  
%RSD was found to be 15.54%.  This low value suggests that the variation in protein 
recovery previously found in patient samples was due to patient variability and not error 
in the preparative methods.  These results show that by combining dextran sulfate 
precipitation with preparative ultracentrifugation, a viable technique has been developed 
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for HDL apolipoprotein isolation and recovery that can be combined with mass 
spectrometry techniques in order to assess the application of the mass spectra in terms of 
the risk assessment for CVD. 
 
3.1.4.3 Optimizing Mass Spectra Signal for Clinical Applications 
 With the apolipoprotein recovery methods now established, a standard serum 
sample was prepped using dextran sulfate precipitation and preparative 
ultracentrifugation.  The sample was then reconstituted to different levels of 
concentration based on the initial serum volume used.  The goal of this study was to find 
an optimum concentration for which the mass spectra would show strong peaks in all 
mass regions.  For application of the mass spectrum data to the LDA/SIR analysis, there 
must be enough signal strength to distinguish peaks in the mass ranges for the lower 
abundant apolipoproteins such as Apo A-II, Apo C-II, Apo C-III, etc. 
  The apolipoprotein concentrations chosen for this study were 1x, 2x, and 4x 
more concentrated than what is in the serum sample.  For the 200µL of serum used for 
each concentration, the recovered apolipoproteins were evaporated to dryness and 
reconstituted to 200µL, 100µL, and 50µL to provide samples with increasing protein 
concentrations.  The resulting mass spectra are shown in Figure 27A-27C.  The signal 
intensities for all mass ranges show close to double the intensity when comparing the 2x 
and 1x concentrated samples.  However, the 4x concentrated sample shows a large signal 
drop for all mass ranges except between 7000Da and 11000Da.  For this mass range, the  
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signal intensity is roughly twice as large as the intensities seen for the 2x concentrated 
sample.  All other mass ranges show even less peak intensity than the 1x concentrated 
sample.  This difference in peak intensity is larger than any error that might be present in 
MALDI-TOF experiments due to the preparation techniques.  The decrease in signal for 
the most concentrated HDL apolipoprotein sample could indicate that there is some form 
of sample aggregation that is suppressing the signal.  Based on these results, the 2x 
concentrated sample was shown to allow for clean mass spectra with sufficient peak 
intensities for application of the results to the LDA analysis.  For this reason, the 2x 
concentration was selected as the method for measuring the mass spectra of all clinical 
samples in future studies. 
 
3.2 Clinical Applications of High Performance Lipoprotein Profiling Methods 
 
3.2.1 Lipoprotein Density Profiles and LDA/SIR Analysis for CVD Risk Assessment  
 The objective of these studies was to assess the influence of the improved 
lipoprotein profiling method for use in CVD risk analysis.  Previous research had shown 
the potential for the use of advanced statistical analysis of the lipoprotein profiles in the 
assessment of CVD risk.
14
  The previous study research was limited by the small sample 
library and the precision of the methods used.  With the more precise method of the 
lipoprotein density profiling developed in this thesis work, the application of this method 
to a broader library with better clinical definitions of control (CTRL) and CVD was 
expected to yield a more accurate CVD risk assessment.  The studies described here 
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include the original results of the lipoprotein profiles and LDA/SIR analysis found by 
R.Henriquez
14
 in comparison to the more precise lipoprotein profiles and LDA/SIR 
analysis to show improvement in the classification, as well as the implementation of the 
methods to a normal lipidemic cohort of samples, a cohort of hypercholesterolemic 
children, and, finally, to the comprehensive serum library to test for a universal risk 
assessment. 
 
3.2.1.1 Improving the Predictive Power of the Original Pilot Study through Application 
of HPLDP Method 
 The initial pilot study, prior to improving the precision of the method, was 
performed on a small sample cohort of subjects to assess the use of LDA/SIR in 
application to the lipoprotein density profiles.  LDA/SIR is a multivariate analysis that 
produces an equation that classifies CVD and CTRL groups.  The subjects for this study 
were selected based on having normal to elevated levels of HDL cholesterol, normal 
levels of LDL cholesterol, and their individual CVD status.   
 The importance of each lipoprotein subclass in the LDA/SIR multivariate 
analysis equation, relative to CVD prediction, was reflected in the coefficients of the 
equation.  The equation generated for the original method of lipoprotein profiling is 
shown in Equation 9.  In the equation, the natural log of the integrated intensities for 
each subclass is used to normalize the data.  Positive subclass coefficients (red) indicated 
that the subclass was weighted towards risk of CVD while a negative coefficient (green) 
was weighted towards being a CTRL.  For the pilot study, the HDL-3c, LDL-4, and  
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LDL-2 subclasses were found to be the most important factors for a prediction of CTRL.  
The HDL-3b, dTRL, and LDL-5 subclasses were found to be the most important factors 
for prediction of CVD.  Figure 28 highlights each lipoprotein subclass relative to its 
coefficient polarity (CVD or CNTL).  Seven of the twelve subclasses were weighted 
towards CVD classification.  To better visualize the relative importance of each 
subclass, the coefficients from the equation are graphed in Figure 29.  LDL-1 was found 
to not be as important relative to the other lipoprotein subclasses. 
 
                                                          
                                                      
                                                     
                                                    (Eq. 9) 
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Figure 28: Influence of Lipoprotein Subclasses Based on Pilot Study Algorithm: 
Red = CVD factor, Green =CTRL Factor 
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Figure 29: Pilot Study LDA/SIR Coefficients for Lipoprotein Subclasses Using 
Original Lipoprotein Profiling Method 
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 The separation found using the LDA/SIR calculated values for the initial 
method, prior to improvement, is shown in Figure 30.  Of the 16 CVD subjects, 3 
subjects were found to have negative LDA/SIR values which indicated that they were 
misclassified as controls based on the LDA/SIR equation.  Of the 14 CTRL subjects, 3 
subjects were found to have positive LDA/SIR values which indicated that they were 
misclassified as CVDs based on the statistical model.  Based on the total number of 
correct classifications, the baseline prediction potential was found to be 80% accurate.   
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Figure 30: Pilot Study LDA/SIR Separation of CVD/CTRL Using Original Method 
 
 The standard method of evaluating the significance of a statistical model would 
be to test the predictive power of the LDA/SIR equation on a set of subjects, for which 
the classifications of CVD and CTRL are known.  These samples would not have been 
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used to develop the statistical model in order to assess the model’s viability.  This set of 
samples is called a hold out set.  Because the sample size was limited, a hold out sample 
set was not available and therefore the method of cross validation (X-Val) was used as a 
substitute evaluation of the method.  Cross validation is a method of testing the bias of 
the model in terms of the subject dependency (Section 1.5).  X-val is a method of 
removing one random sample from the sample set and then rerunning the analysis.  The 
resulting equation is tested on the full sample set; including the sample that was 
removed.  The difference between the new prediction accuracy and the original accuracy 
represents the level of dependence that the model has on the sample data that was 
removed.  The X-Val score for the pilot study was found to be 60%.  This low X-Val 
score indicated that the LDA/SIR classification accuracy is sensitive to the sample set 
size based on the difference in prediction power being 20% relative to the prediction 
accuracy using the full sample set.  While the prediction accuracy showed the potential 
of combining lipoprotein density profiles with LDA/SIR analysis, the X-Val prediction 
indicated that the prediction accuracy was not statistically significant.   
 To study the effect that the more precise lipoprotein density profiling method 
has on CVD risk assessment, the initial pilot study sample library was profiled using the 
high precision method.  The LDA/SIR analysis of the enhanced method lipoprotein 
profiles produced a prediction equation that was 92.7% accurate with an X-Val accuracy 
of 63%.  Through use of the high precision method of lipoprotein density profiling, only 
one subject each were misclassified for the CVD and CTRL groups.  The resulting  
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Figure 31: Pilot Study LDA/SIR Separation of CVD/CTRL Using HPLDP Method 
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Figure 32: LDA/SIR Coefficients for Lipoprotein Subclasses Using HPLDP Method 
  
  
108 
 
 
 
separation between CVD and CTRL subjects is shown in Figure 31.  The coefficients for 
the LDA/SIR equation are graphed in Figure 32.   
 These coefficients differed from the original analysis in many ways.  Five of 
the 11 subclasses changed in their polarity from being a factor towards CVD to being a 
factor towards being a CTRL and vice versa. Most notably, the majority of the LDL 
subclasses were now factors for CVD and the majority of the HDL factors were now 
factors for CTRL classification.  The changes in these coefficients changed the 
classification of the previously misclassified samples from an incorrect classification to a 
correct classification.  The change also changed one subject from each of the CVD and 
CTRL cohorts to being misclassified.  The increase in prediction accuracy between the 
original pilot study data and the data obtained from application of the enhanced method 
can be directly related to the change in the subclass coefficients.  The improved 
classification confirmed that the enhanced method increased the risk assessment of CVD 
and therefore was an improvement over the original method.  However, the X-Val 
accuracy still showed a high subject bias. 
 
3.2.1.2 Effect of Redefining the Definition of CTRL 
 To investigate the reason for the subject bias, the definitions of CTRL were 
questioned.  The initial method of CTRL definition was that the subject had no risk 
factors for CVD and no history of disease.  This definition did not account for subjects 
that might be in the pre-stages of atherosclerosis.  For this reason, a new cohort of CTRL 
subjects was acquired for the study.  These CTRL samples were identified through 
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angiography based on the level of arterial blockage.  Any subject who showed less than 
10% blockage through angiography was identified as a CTRL and a serum sample was 
collected.   
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Figure 33: LDA/SIR Separation of CVD/CTRL Using Redefined CTRL Library 
 
 Of the new CTRL samples collected to build the redefined library, a subset of 
this new library fit the design profile for inclusion to the original pilot study CVD 
samples.  In this study, LDA/SIR analysis was performed the same CVD samples as 
used in the pilot study but using the more accurately defined CTRL samples from the 
new library.  The LDA/SIR separation of this new library is depicted in Figure 33.  The 
prediction accuracy for this library was found to be 100%.  The X-Val for this library 
110 
 
 
 
was found to be 84%.  This X-Val score showed that the new LDA/SIR separation was 
statistically significant.   
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Figure 34:  LDA/SIR Coefficients for the Separation of the Pilot Study CVD 
Samples and Angiography-Defined CTRL Samples 
 
 The LDA/SIR constants for the prediction equation are depicted in Figure 34.  
When comparing the constants for the newly defined library to the constants from the 
original pilot study found in Figure 29, there were some significant differences that were 
observed.  The relative value of each subclass coefficient between the two libraries was 
compared in order to identify the relative contributions of each subclass when compared 
to the other subclasses.  The LDL-3 coefficient changed in polarity, i.e. the LDL-3 
weighted subjects towards a CVD classification in the original pilot study and a CTRL 
classification in the new library study.  Another difference found when the CTRL 
subjects were better defined was observed in the relative importance of the subclasses.  
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Several subclasses, most notably LDL-2 and HDL-2b, changed their relative 
contribution to the LDA/SIR value.  The overall improvement in classification can be 
attributed to having a more precise protocol of lipoprotein density profiling as well as 
having a better defined CTRL population. The enhancement of both the prediction 
accuracy and X-Val accuracy proved that the newly defined CTRL library better 
identified what is a true control by using a medically defined test rather than the 
subjective appearance of no disease.  While the X-Val score did improve in comparison 
to the original study, there still was a large subject bias with a difference of 16% 
between the prediction equation accuracy and the X-Val accuracy.  For this reason, a 
larger serum library was deemed to be necessary to test the overall validity of this 
methodology of CVD risk assessment. With a larger serum library to test the accuracy of 
the prediction equation, the hold out sample set protocol can be utilized as the ultimate 
test of the utility of the method in a clinical setting. 
 
3.2.1.3 LDA/SIR Analysis Applied to Normal Lipidemic Patient Samples for CVD Risk 
Assessment 
 With the improvements in CVD risk assessment for the original pilot study, 
application of the enhanced lipoprotein density profiles and LDA/SIR analysis was 
applied to specific cardiovascular risk studies to better assess the methods potential in 
the clinical setting.  The first study was to explore whether this methodology could be 
used to identify risk for those subjects that showed none of the traditional risk factors, 
i.e. normal lipidemic subjects.  While other CVD risk assessment methods have been 
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shown to be applicable to patients with identified risk factors
7
, these methods are still 
inaccurate for the normal lipidemic subject population.  The results presented here 
summarize the application of LDA/SIR to lipoprotein density profiles in order to 
distinguish between normal lipidemic subjects with documented CVD and those without 
CVD.  The sample population size for this study was 26 subjects and was composed of 
14 CVD subjects and 12 CTRL subjects. 
 In order to assess the level of improvement that lipoprotein density profiles has 
over tradition methods, traditional lipid cholesterol and triglyceride measurements 
acquired through a standard lipid panel were compared to the lipoprotein profiles as the 
accepted standard for lipoprotein measurement.   The effect of sample size versus 
number of measurements was also explored by separating the lipoprotein profiles by 
density in three ways: 3 lipoprotein subclasses, 5 lipoprotein subclasses, and 11 
lipoprotein subclasses.  The 3 lipoprotein subclasses are the integrated intensities based 
on the lipoprotein profile identified as TRLs (ρ<1.019g/mL), LDL 
(1.019g/mL<ρ<1.063g/mL), and HDL (1.063g/mL<ρ<1.179g/mL).  These subclasses 
are further broken down by density into the 5 lipoprotein subclasses defined as TRLs 
(ρ<1.019g/mL), low-density LDL (1.019g/mL<ρ<1.039g/mL, LDL-1 through LDL-3), 
high-density LDL (1.039g/mL<ρ<1.063g/mL, LDL-4 through LDL-5), low-density 
HDL (1.063g/mL<ρ<1.110g/mL, HDL2), and high-density HDL 
(1.110g/mL<ρ<1.179g/mL, HDL3).  Finally, the lipoprotein subclasses are broken down 
into the 11 density subclasses as defined in Section 1.3.3.
9,68
  A sample of the lipoprotein 
density profile and the different methods of fractioning the profile is shown in Figure 35.  
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Though examining the effects that increasingly more distinct lipoprotein subclasses have 
on the LDA/SIR analysis, the benefits of lipoprotein density profiles over the traditional 
lipid panel measurements were established.  The results of the LDA/SIR analysis for 
these different data sets are summarized in the following sections. 
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Figure 35: Lipoprotein Density Profile Fractioned into 3, 5, and 11 Subclasses 
 
3.2.1.3.1 LDA/SIR Results of Lipoprotein Measurements 
 Table 4 summarizes the accuracy of LDA/SIR analysis on each of the four data 
sets: traditional lipid panel measurements, 3 lipoprotein subclasses, 5 lipoprotein 
subclasses, and 11 lipoprotein subclasses.  Because of the small number of samples 
available for this study, X-val was selected to test the subject dependency of the 
analysis.  As shown from the reported accuracy values for each lipoprotein measurement  
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Table 4: LDA/SIR Analysis Summary for Normal Lipidemic Serum Library of 
Different Lipoprotein Measurements 
Lipoprotein Measurement 
LDA/SIR Accuracy 
(%) 
X-validation 
(%) 
p-value 
Traditional Lipid Panel 73.1 53.8 NA 
3 Lipoprotein Subclasses 69.2 69.2 NA 
5 Lipoprotein Subclasses 88.5 73.1 0.0186 
11 Lipoprotein Subclasses 92.3 69.2 0.0952 
 
method in Table 4, the accuracy of the LDA/SIR prediction increased with respect to the 
number of subclasses that were included in the lipoprotein profile.  The traditional lipid 
panel measurements used in standard medical dianostics showed a low accuracy rate of 
73.1% when using LDA/SIR analysis.  This approach was further influenced by the  
patient dependency represented by the X-Val value of 53.8%.  For the small number of 
subjects included in the study, the use of the 5 lipoprotein subclasses gave the best 
relationship of prediction accuracy and X-Val indicating a low subject bias with values 
of 88.5% and 73.1%, respectively.  Use of all 11 possible subclasses increased the 
accuracy of the prediction to 92.3%.  However, the increase in the number of subclasses 
also increased the subject dependency seen through the lower X-Val score.  With more 
variables included in the LDA/SIR analysis, a larger subject population is required to 
strengthen the statistical significance of the classification.  When using the p-value to 
distinguish the statistical significance the LDA/SIR separation, it was found that the 5 
subclass method of analysis gave a statistically significant separation while the other 
methods did not.  This statistical significance is represented by a p-value of 0.0186 
which is lower than the required value of 0.05 to distinguish a significant difference 
between groups.  The p-value is larger when the 11 lipoprotein subclass data method is 
115 
 
 
 
used due the calculation of the p-value being related to the number of sample variables 
and sample population size.  The results found in this study emphasized the need for a 
larger sample population relative to the number of variables applied to the LDA/SIR 
analysis and the benefits that can be obtained through use of lipoprotein density profile 
data in the LDA/SIR analysis in comparison to tradition lipid measurements used in 
current medical practices.   
 
3.2.1.3.2 LDA/SIR Separation and Coefficients Using 5 and 11 Lipoprotein Subclasses 
With the optimum risk assessment for CVD in normal lipidemic subjects found 
using the 5 and 11 lipoprotein subclass methods, further analysis was performed in order 
to assess the differences between the LDA/SIR analysis when 5 and 11 subclasses were 
used.  Figure 36 illustrates the separation of CVD and Control subjects through 
LDA/SIR analysis of 5 lipoprotein subclasses.  LDA/SIR separates the CVD and CTRL 
samples based on the mathematical equation developed in the statistical analysis.  The 
two CVD samples with negative LDA/SIR values are considered misclassified, i.e they 
were incorrectly identified by this method as not having CVD.  The CTRL sample with 
the positive LDA/SIR values was also considered misclassified. 
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Figure 36: LDA/SIR Separation of CVD/CTRL of Normal Lipidemic Library 
Using 5 Lipoprotein Subclasses 
 
Figure 37 shows the graphical representation of the coefficient strength found 
through the LDA/SIR analysis of the 5 subclasses included in the analysis.  The 
coefficients with negative values identify subclasses that increase the chance of being 
classified as a healthy control, and the coefficients with positive values identify 
subclasses that increase the chance of being classified as CVD.  As can be seen from the 
coefficients, the low density LDL (LDL1-LDL3) and TRL subclass values are identified 
as control factors, and the high dense LDL (LDL4-LDL5) and HDL3 subclasses are 
identified as CVD factors.  The HDL3 subclass has a very small positive coefficient, 
which could be an indication that there are some properties of low dense HDL that are 
atherogenic.   
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Figure 37: Normal Lipidemic LDA/SIR Coefficients for 5 Lipoprotein Subclasses 
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Figure 38: Normal Lipidemic LDA/SIR Separation of CVD/CTRL Using 11 
Lipoprotein Subclasses 
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Figure 38 represents the LDA/SIR separation of the CVD and CTRL subjects 
using the 11 subclasses.  The classification is similar to Figure 36 in that the negative 
values represent the classification as a CTRL and the positive values represent 
classification as a CVD.  The difference between Figure 36 and Figure 38 is that one less 
CVD subject was misclassified.   
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Figure 39: Normal Lipidemic LDA/SIR Coefficients for 11 Lipoprotein Subclasses 
 
 Figure 39 shows the coefficients found using LDA/SIR analysis on the 11 
lipoprotein subclasses.  When compared to the coefficients found for the 5 subclass 
separation, it can be seen that the smaller, more defined subclasses alter the coefficient’s 
strength and sign.  LDL-1 is part of the low density LDL subclass in the 5 subclass 
separation, which had a sign indicating it to be a CTRL factor.  However, when using the 
small subclasses, LDL-1 was assigned a positive coefficient indicating it as a factor 
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towards CVD identification.  It has also been observed that the HDL subclasses change 
sign as well.  HDL-2b, the lowest density HDL subclass, and HDL-3c, the highest 
density HDL subclass, are identified as a CTRL factors while HDL-2a, 3a, and 3b are 
identified as factors toward CVD classification. 
 This analysis shows the advantage of using the 11, more detailed subclasses of 
lipoproteins coupled with the advanced statistical methods of LDA/SIR in order to 
distinguish risk for CVD in normal lipidemic subjects.  As the lipoprotein subclasses 
became more defined, the LDA/SIR analysis increased the accuracy of its prediction.  
When compared to the standard lipid panel values used by practicing physicians, the 
lipoprotein density profile was better able to distinguish between those normal lipidemic 
subjects with CVD and those that are without CVD as defined through angiography.  
The only limitation of this method was in the requirement of having a large enough 
sample size in order to reduce the patient dependency of the analysis identified through 
X-Val. 
 LDA/SIR analysis of the lipoprotein subclasses goes further in prediction of 
CVD by identifying the subclasses that lead to high risk.  For the most part, this analysis 
fits into the current medical literature that low dense LDL and HDL are healthy and the 
high dense LDL and HDL are not.  This analysis, along with the previously described 
pilot study, indicates that there could be specific subclasses of the HDL that are 
atherogenic.  This is a new feature of HDL that is gaining support in recent studies.
58,119-
126
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3.2.1.4 Advanced Statistical Analyses Applied to the Comprehensive Patient Library for 
CVD Risk Assessment 
 As a result of the success in application of the LDA/SIR analysis to small 
libraries, it was determined that the lipoprotein density profiles and statistical analysis 
protocols would be more rigorously tested using a larger library that included a more 
comprehensive spectrum of subjects.  This study was designed to answer questions that 
had previously been unanswered, such as the accuracy of the method when used on a 
hold out sample, what effect patient demographics have on the analysis, how the 
fluorescent intensity for lipoproteins is affected by presence of CVD, and what method 
of analysis is best for the risk assessment of CVD.  For this study, the CVD patients 
were defined as having been diagnosed with CVD through angiography or cardiac event.  
The CTRL patients were defined as having a clear angiogram with less than 10% arterial 
blockage.  Traditional lipid panels for measurement of triglycerides and cholesterol for 
each subject were performed at Scott & White Hospital.  To assess the best method of 
analysis, Modes 1 and 2 data sets were analyzed using the LDA/SIR and QDA statistical 
analyses.  The comprehensive library consisted of 100 CVD subjects and 58 CTRL 
subjects.  Of these subjects, 70 CVD and 40 CTRL were selected as the training set for 
generating the LDA/SIR equation.  The remaining subjects were used as a holdout 
sample set to test the accuracy of the method on samples not used to create the LDA/SIR 
prediction equation. 
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3.2.1.4.1 Relation of HDL/LDL Cholesterol Measurements to Lipoprotein Density 
Profile Integrated Intensities 
 Before application of the statistical analyses to the lipoprotein density profiles, 
the relationship between the profiles and the traditional lipid measurements used for 
current risk assessment was explored.  Using commercial standards of HDL and LDL, a 
linear relationship between protein concentration and integrated fluorescence intensities 
was found.  These relationships are graphed in Figure 40.  However, when comparing 
cholesterol measurements with integrated fluorescence intensities for clincal subjects, a 
varied relationship was observed.  For the CVD subjects, the relationship was a scatter 
plot that showed little linearity.  When fitting the data to a linear equation, the R
2
 value 
was found to be 0.30 for LDL cholesterol measurements and 0.42 for HDL cholesterol 
measurements for the CVD subjects, indicating a poor fit.  These relationships are 
graphed in Figures 41 A and B.  By comparison, for the CTRL subjects, the relationship 
between the cholesterol measurements and the integrated fluorescence intensities 
showed a much more improved fit to the linear equation.  The R
2
 values for the CTRL 
measurements were found to be 0.69 for the LDL measurements and 0.67 for the HDL 
measurements.  This improved relationship between cholesterol measurements and 
fluorescence intensities for CTRL subjects is graphed in Figures 42 A and B.  A possible 
explanation for the difference between the CVD and CTRL libraries is that the NBD 
fluorophore interacts differently with the lipoprotein particles from a CVD subject when 
compared to the lipoprotein particles that are associated with the healthy controls.  This  
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Figure 40: Calibration Curve of Protein Concentration vs. Integrated Intensities of 
Commercial Lipoprotein Standards.  (A) LDL Calibration Curve (B) HDL 
Calibration Curve 
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Figure 41: Traditional Lipid Measurements in Relation to Integrated Intensities 
Found Using Lipoprotein Density Profiles for CVD Subjects. (A) LDL 
Measurements for CVD Library, (B) HDL Measurements for CVD Library 
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Figure 42: Traditional Lipid Measurements in Relation to Integrated Intensities 
Found Using Lipoprotein Density Profiles for CTRL Subjects. (A) LDL 
Measurements for CTRL Library, (B) HDL Measurements for CTRL Library 
 
A 
B 
125 
 
 
 
inherent difference may be contributing to the reason why the LDA/SIR analysis has 
been able to distinguish classification better than the tradition lipid measurements.  The 
interaction of the NBD-ceramide with the lipoprotein particles may be a sensitive probe 
of the morphology of these particles. 
 
3.2.1.4.2 Statistical Comparison of Lipoprotein Measurements between CVD and CTRL 
Sample Libraries 
 
Table 5: Comparison of Statistical Analysis for Traditional Risk Factors between 
CVD/CTRL Groups for the Comprehensive Library 
 
Factor P-value 
Patient Data 
Age 0.564 
Weight 0.368 
Standard Lipid 
Measurements 
TC 0.595 
TG 0.352 
HDL 0.628 
LDL 0.692 
Lp(a) 0.519 
 
 In order to assess the differences in the traditional lipid measures and patient 
background information between CVD and CTRL libraries, a 2-sample T-test was 
applied to compare the two groups using the comprehensive library.  Table 5 shows the 
results of the 2-sample T-tests applied to the patient’s background data and comparing 
the CVD group to the CTRL group.  The p-values from the T-tests were used to assess 
whether or not there were differences between the two groups.  A p-value of greater than 
0.05 meant that at a 95% confidence interval, the two groups were not statistically 
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different.  As can be seen from Table 5, there was no statistical difference between the 
CVD and CTRL groups for background data selected or the standard lipid 
measurements.  This leads to two conclusions: (1) the age distribution between the 
samples is similar and therefore differences are not due to age and (2) no difference can 
be detected using standard lipid measurements.  The findings presented here suggest that 
any improvements found in the risk assessment of CVD when applying the lipoprotein 
density profiles developed in this thesis to the comprehensive library of samples 
represent a significant improvement over the standard lipid measurements.  Current 
studies have indicated that there are significant relationships between cholesterol 
measurements for lipoproteins and CVD mortality rates.
42,57,122
  For example, elevated 
HDL cholesterol was correlated with a reduced level of CVD risk and mortality.  These 
studies were not able to identify a relationship between lipoprotein levels and the 
mortality rate for healthy subjects.  When compared to the data presented in this thesis, 
this relationship was not seen as no statistical difference could be found when using the 
cholesterol measurements for the subject population. 
Table 6 summarizes the results when the T-test analysis of the lipoprotein 
subclasses was applied to the lipoprotein density profiles.  The analysis was carried out 
on the total intensities of the subclasses (Mode 1) and the percent intensities of the 
subclasses (Mode 2).  For those lipoprotein subclasses with a p-value of <0.05, a 
statistically significant difference was found between the CVD and CTRL values for the 
respective subclass.  By comparing the p-values for each subclass with the standard lipid 
measurements, some conclusions were reached. First, the lipoprotein subclasses found 
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by density profiling showed statistical differences where the standard lipid 
measurements did not.  Second, there are differences in the statistical significance of the 
lipoprotein subclass that were detected when using the Mode 1 data analysis in 
comparison to Mode 2 data analysis.  These differences indicated that the method of data 
analysis could have an effect on the outcome of the LDA/SIR predictive outcome due to 
the quantitative measurement of the lipoprotein subclass calculated in Mode 1 analysis 
versus the measurement of relative contribution to the total lipoprotein density profile 
calculated in Mode 2 analysis.   
 
Table 6: Comparison of Statistical Analysis for Lipoprotein Density Profiles 
between CVD/CTRL Groups 
  
P-value from 2-Sample t-test 
 
Subclass Mode 1 Mode 2 
Lipoprotein Subclass 
TRL 0.000 0.000 
LDL1 0.000 0.024 
LDL2 0.002 0.070 
LDL3 0.000 0.005 
LDL4 0.019 0.490 
LDL5 0.309 0.000 
HDL2b 0.499 0.210 
HDL2a 0.008 0.877 
HDL3a 0.043 0.313 
HDL3b 0.031 0.000 
HDL3c 0.245 0.347 
 
3.2.1.4.3 LDA/SIR Analysis on Lipoprotein Measurements 
 With the differences between CVD and CTRL groups that were found through 
lipoprotein density profiling, application of the LDA/SIR analysis allowed for enhancing 
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the individual differences into a prediction model using the full lipoprotein density 
profile.  In order to identify the improvement in risk assessment that the lipoprotein 
density profiles had over the traditional lipid measurements, the traditional 
measurements were also analyzed using LDA/SIR.  Mode 1 and Mode 2 data from the 
lipoprotein density profiles were also compared to assess the best method for CVD risk 
assessment.   
 
Table 7: LDA/SIR Prediction Summary for Traditional Lipid Measurements and 
Lipoprotein Density Profiles 
Statistical Output 
Traditional 
Lipid 
Measurements 
Mode 1 Mode 2 
Prediction Accuracy (%) 58.5 81.8 81.8 
X-Val Accuracy (%) 50.0 76.4 77.3 
Holdout Accuracy (%) 50.0 72.9 72.9 
p-value 0.613 2.72 E-07 3.62 E-07 
 
For each data set, the total prediction accuracy, X-Val value, and efficiency of 
the model on a hold out sample were tested.  The results of these analyses are 
summarized in Table 7.  The p-values were calculated for the separations between CVD 
and CTRL groups that showed the most accurate prediction.  As can be seen from Table 
7, the traditional lipid measurements were only able to obtain 58.5% accuracy and an X-
Val and hold out sample score of 50.0%, indicating that the measurements did not allow 
for significant risk assessment.  However, the lipoprotein density profiles were able to 
obtain 81.8% accuracy with significant X-Val and hold-out sample scores.  The p-values 
were calculated for the LDA/SIR separations using just the Mode 1 and Mode 2 data and 
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showed that both data sets gave statistically significant separations between the CVD 
and CTRL groups.  Therefore, it was not evident which method of data analysis was 
preferred based on the similar predictive power between the methods of analysis.  
Further investigation into the nature of the LDA/SIR prediction equation was necessary 
to study the similar outcome found between Mode 1 and Mode 2 data analysis versus the 
different outcomes found when using the T-test. 
To further investigate the LDA/SIR predictive similarities between Mode 1 and 
Mode 2 data analysis, the coefficients for these analyses were studied for comparison 
between Modes 1 and 2 and between the previous studies reported.  The coefficients are 
graphed in histogram form in Figure 43.  The coefficients show similar polarities 
between the Mode 1 and Mode 2 data sets with slightly varied importance measured by 
the relative size of the coefficients.  The strength of each coefficient does not directly 
represent the differences found between subclasses in the 2-samples T-test.  For 
example, the HDL-2b subclass was found to be statistically similar between CVD and 
CTRL groups using the T-test analysis, but was given a larger coefficient in the 
LDA/SIR prediction equation when compared to other subclasses that were shown to be 
statistically different.  The reason for this lack of congruence between the LDA/SIR 
prediction equation and the T-test results is most likely due to the multivariate nature of 
the LDA/SIR analysis and how it includes the relationship of variables inside the CVD 
and CTRL groups and not just between the CVD and CTRL groups.  When comparing 
these coefficients of the comprehensive library study to the coefficients found from the 
normal lipidemic library study, the most significant observation is that the alternating 
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polarities of the HDL subclasses found from the normal lipidemic library study are 
present in the comprehensive library study with the exception of the HDL-3a subclass.  
The alternating HDL subclass polarities again gave evidence to support the existence of 
atherogenic forms of HDL as suggested in recent studies.  
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Figure 43: LDA/SIR Coefficients for Prediction of CVD for the Comprehensive 
Serum Library Using Mode 1 and Mode 2 Data Sets. 
 
  
131 
 
 
 
The graphical separation of CVD and CTRL for the traditional lipid 
measurements and each Mode of the training set data are depicted in Figure 44.  From 
Figure 44, it can be seen that the traditional lipid measurements were not able to separate 
the CVD and CTRL groups through a generated LDA/SIR equation.  Mode 1 and Mode 
2 data for lipoprotein subclasses were able to separate the two groups by using the 
respective LDA/SIR equations generated for each data set.  Slightly different 
distributions can be seen between Modes 1 and 2, but there was no difference in 
prediction accuracy between Modes 1 and 2.  There was a small increase in the X-Val 
score for Mode 2.  This increase in X-Val in Mode 2 represented the correct 
classification of one additional subject when compared to the X-Val of Mode 1.  The 
correct classification of one subject did not represent a significant change between 
Modes 1 and 2 and therefore it was unclear which method of data analysis was best for 
risk assessment.  It was clear from the analyses that lipoprotein density profiles did allow 
for better risk assessment of CVD in comparison to the traditional 
cholesterol/triglyceride measurements. 
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Figure 44: LDA/SIR Separations for the Comprehensive Serum Library for 
Lipoprotein Measurement Methods.   
(A) Tradition Lipid Measurement Data, (B) Mode 1 Data, (C) Mode 2 Data  
A 
B 
C 
133 
 
 
 
The separation of CVD and CTRL groups for the Mode 1 data of the holdout 
sample set based on the calculated LDA/SIR values using the generated LDA/SIR 
equation is graphed in Figure 45.  The subject samples in the hold out set were not used 
to develop the LDA/SIR equation.  Therefore, the separation/accuracy of the holdout 
sample indicated that the LDA/SIR values can be used to assess risk for clinical samples.   
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Figure 45:  LDA/SIR Separations for the Hold Out Sample Set of the 
Comprehensive Serum Library Using Mode 1 Data 
 
In order to apply this prediction analysis to clinical samples, the error in 
classification needed to be studied further.  To study the precision of the LDA/SIR 
classification, the LDA/SIR analysis was carried out on the 10 replicate measurements 
used to assess the lipoprotein density profiling method repeatability.  Based on the 
LDA/SIR value, this sample was classified as at risk due to the positive value.  Using the 
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LDA/SIR prediction equation, the average LDA/SIR value for Mode 1 analysis was 
calculated to be 0.124 +/- 0.030.  The error represented by the standard deviation of the 
measurement represented a 23.61% spread in the LDA/SIR value.  For Mode 2, the 
average LDA/SIR value was calculated to be 0.152 +/- 0.030.  The standard deviation of 
this measurement represented a 19.74% spread in the LDA/SIR value.  This reduction 
was attributed to the reduced error due to the light source and serum volume when using 
the normalized Mode 2 analysis of the data.  Further reduction of this error was possible 
by using three sets of three replicate measurements and comparing the average data 
calculated for each set of three profiles.  The average %RSD for this method was 
calculated at 11.13% and 9.46% for Modes 1 and 2, respectively, when applying the 
LDA/SIR equations to the averages of three replicates.  This reduction of the error in the 
LDA/SIR values qualified the analysis for clinical assessment of risk as previously 
defined.  
To further improve in the prediction accuracy of the LDA/SIR analysis, patient 
histories and background information were added as additional variables.  The 
traditional risk factors for CVD that were included in the analysis include tobacco use, 
family history of disease, presence of hypertension, presence of diabetes, subject age, 
and body mass index.  For the factors that had a yes/no answer as a response, they were 
included into the analysis using a 1 for yes and 2 for no.  The summaries of the 
LDA/SIR analyses on the Mode 1 and Mode 2 data sets are shown in Tables 8 and 9, 
respectively.  The results for the LDA/SIR analyses are expressed in terms of the 
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prediction accuracy, X-Val accuracy, and accuracy on a holdout sample when each 
individual factor was added to the lipoprotein density profile information.   
 
Table 8: Influence of Tradition Risk Factors on the LDA/SIR Analysis of Mode 1 
Data of Lipoprotein Density Profiles for the Comprehensive Library 
Risk Factor 
Prediction 
Accuracy 
(%) 
X-Val 
Accuracy 
(%) 
Holdout 
Accuracy 
(%) 
Density Profile Data (DP) 81.8 76.4 72.9 
DP + Age 80.9 76.4 75.0 
DP + BMI 82.1 75.5 77.1 
DP + Diabetes 80.6 77.8 70.8 
DP + Tobacco Use (T) 82.7 78.2 77.1 
DP + Hypertension (HT) 85.2 75.0 75.0 
DP + Family History (FH) 83.5 77.1 75.0 
DP + HT/FH 86.9 77.6 75.0 
DP + T/HT/FH 84.1 79.4 72.9 
 
Table 9: Influence of Tradition Risk Factors on the LDA/SIR Analysis of Mode 2 
Data of Lipoprotein Density Profiles for the Comprehensive Library 
Risk Factor 
Prediction 
Accuracy 
(%) 
X-Val 
Accuracy 
(%) 
Holdout 
Accuracy 
(%) 
Density Profile (DP) 81.8 77.3 72.9 
DP + Age 81.8 74.5 72.9 
DP + BMI 83 76.4 75 
DP + Diabetes 80.6 76.9 75 
DP + Tobacco Use (T) 80.9 77.3 75 
DP + Hypertension (HT) 84.3 78.7 75 
DP + Family History (FH) 82.6 75.2 75 
DP + HT/FH 86 80.4 72.9 
DP + T/HT/FH 84.1 78.5 72.9 
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Of the six risk factors added to the LDA/SIR analysis, only three showed 
improvement in the accuracy of the method.  These factors were tobacco use, 
hypertension, and family history.  The largest improvement was seen when applying the 
history of hypertension in subjects.  The prediction accuracy increased from 81.8% to 
85.2% and 84.3% for Modes 1 and 2, respectively.  Limited improvement was realized 
in the X-Val scores, but there was an increase of the accuracy of the model when testing 
the holdout sample sets.  Combinations of the factors which showed the best 
improvement were also tested as indicated in Tables 8 and 9.  The combination of 
hypertension and family history, in addition to the lipoprotein subclasses, was found to 
have the best accuracy at 86.9% for Mode 1 and 86.0% for Mode 2.  There was also an 
increase in the accuracy of the X-Val and holdout sample scores.  These results indicate 
that the best prediction method was when the lipoprotein density profiles were combined 
with the factors relating to hypertension and family history. 
Subject age, BMI, and presence of diabetes were included as factors in the 
analysis but there were no significant improvements in the LDA/SIR prediction 
accuracy.  These results showed that the LDA/SIR analysis on lipoprotein density 
profiles for risk assessment of CVD was not improved by the addition of the age, BMI, 
or presence of diabetes in the subjects.  The hypothesis that the lipoprotein density 
profiles may be time dependent fingerprints that represent the status of CVD in a patient 
at the time that the serum sample was collected would explain the lack of improvement 
with the additional risk factors.  The effects of age, BMI, and diabetes could be 
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inherently represented in the lipoprotein density profiles.  The effects these factors have 
on the lipoprotein density profiles require further research. 
To examine the effect of adding the traditional risk factors to the statistical 
analyses, the coefficients of the LDA/SIR prediction equation formed from using the 
Mode 1 data coupled with the traditional risk factors were compared to the coefficients 
found using just the Mode 1 data set.  The coefficients for the addition of traditional risk 
factors are depicted in Figure 46.  The polarity of the coefficients for family history and 
presence of hypertension were both found to be negative, indicating that the risk factors 
influence the risk assessment towards being a CTRL.  To understand this finding, the 
method of applying these values to the LDA/SIR analysis was explored.  The presence 
of the risk factor was given the value of 1 and the lack of presence of the risk factor was 
given the value of 2.  With the larger value indicating that the subjects did not have the 
the risk factor, the negative value of the LDA/SIR coefficient indicates that the lack of 
risk factors increased the probability of being classified as a CTRL.  This finding is 
consistent with the established risk factors and gives support to the premise that the 
LDA/SIR coefficients have the potential for augmenting the risk assessment panel.  
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Figure 46: LDA/SIR Coefficients for Lipoprotein Subclasses with the Addition of 
Tradition Risk Factors. (FH=Family History, HT=Hypertension) for the 
Comprehensive Library 
 
3.2.1.4.4 QDA Analysis of Lipoprotein Measurements 
 A more advanced statistical analysis that can be applied to the patient libraries is 
Quadratic Discrimination Analysis (QDA).  QDA is closely related to LDA in that it 
creates a classification equation based on the variables for the CVD and CTRL goups.  
QDA does not hold to the initial assumption that the covariance between groups is 
identical.  The model for QDA analysis takes into account the covariance differences 
and can be a more comprehensive analysis.  For this reason, a larger number of subject 
samples are required to achieve statistical significance when using QDA.  Consequently, 
the comprehensive serum library was utilized for the QDA study.  Since the sample size 
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was not increased, an increase in sample bias was expected in the form of a lower X-Val 
score. 
 With the results from the LDA/SIR analysis of the comprehensive serum library 
showing that application of traditional risk factors can improve the CVD risk 
assessment, the same factors were studied using the QDA analysis.  Mode 1 and Mode 2 
data sets were both used to further explore and identify the best method with which to 
represent the data.  The summaries of these analyses can be found in Tables 10 and 11 
for Modes 1 and 2, respectively.   
The best accuracy for CVD risk assessment previously reported using LDA/SIR 
was 81.8% for the lipoprotein subclasses and 86.9% with the addition of family history 
and hypertension to the Mode 1 data set.  Based on the results found when implementing 
the QDA analysis, improvements were realized in the prediction accuracy and the 
accuracy when testing the holdout sample set.  The total prediction accuracy for the 
lipoprotein subclasses increased to 84.5% and the addition of the family history and 
hypertension risk factors further improved the analysis to 89.7% accuracy.  The best 
result previously seen for the holdout sample set was 75% accuracy.  Using the 
lipoprotein subclasses coupled with the risk factors of family history and hypertension, 
the holdout sample set accuracy was improved to 85.4%.  There was a reduction in the 
X-Val score, but this was anticipated due to the nature of the statistical analysis in 
relation to the sample size.  A larger sample library would improve the X-Val score. 
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Table 10: Influence of Tradition Risk Factors on the QDA Analysis of Mode 1 Data 
of Lipoprotein Density Profiles for the Comprehensive Library 
Risk Factor 
Prediction 
Accuracy 
(%) 
X-Val 
Accuracy 
(%) 
Holdout 
Accuracy 
(%) 
Density Profile (DP) 84.5 70.9 83.3 
DP + Age 84.5 70.9 81.3 
DP + BMI 88.7 70.8 77.1 
DP + Diabetes 87.0 67.6 79.2 
DP + Tobacco Use (T) 86.4 68.2 85.4 
DP + Hypertension (HT) 87.0 70.4 77.1 
DP + Family History (FH) 89.0 70.6 83.3 
DP + HT/FH 89.7 68.2 85.4 
DP + T/HT/FH 89.7 64.5 72.9 
 
Table 11: Influence of Tradition Risk Factors on the QDA Analysis of Mode 2 Data 
of Lipoprotein Density Profiles for the Comprehensive Library 
Risk Factor 
Prediction 
Accuracy 
(%) 
X-Val 
Accuracy 
(%) 
Holdout 
Accuracy 
(%) 
Density Profile (DP) 85.5 70.0 79.2 
DP + Age 85.5 68.5 72.9 
DP + BMI 84.0 69.8 81.3 
DP + Diabetes 88.0 67.6 79.2 
DP + Tobacco Use (T) 87.3 66.4 83.3 
DP + Hypertension (HT) 87.0 70.4 75.0 
DP + Family History (FH) 89.9 70.6 83.3 
DP + HT/FH 88.8 70.1 79.2 
DP + T/HT/FH 88.8 67.3 75.0 
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 The improvements seen through the application of QDA statistical analysis 
proved to show the best classification accuracy for CVD.  There were significant 
improvements over the LDA/SIR analysis.  For both the LDA/SIR and QDA statistical 
analyses, the lipoprotein density profiles have shown to provide a more accurate CVD 
risk assessment than traditional lipid measurement or traditional risk factors.  Based on 
the results in this study, the optimum method of CVD risk assessment for application to 
clinical studies was found using the QDA analysis of the lipoprotein density profile data 
with the addition of the tradition risk factors hypertension and family history of CVD.  
Future directions in the improvement of this methodology include increasing the size of 
the library and incorporating the correct epidemiology of the sample library.  In addition, 
incorporation of novel risk markers will be included to increase the accuracy 
determining whether an individual has risk of developing CVD.   
 
3.2.1.5 LDA/SIR Analysis Applied to Hypercholesterolemia 
 The next sample library in which the lipoprotein density profiles and LDA/SIR 
analysis was applied was a library of children’s serum samples for which there were 
subjects with and without hypercholesterolemia.  Hypercholesterolemia is a disease that 
involves abnormally high levels of cholesterol in a subject’s serum.  This disease can 
also be a precursor to the onset of CVD.  Early risk assessment of this disease in children 
would be a first step in utilizing the potential for using the lipoprotein density profiles as 
a CVD risk assessment tool.  Preventative measures could then be applied to reduce the 
subject’s risk of CVD.  The hypercholesterolemic subjects from this library were also 
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monitored over a period of time as they were treated with statin therapies or placebos to 
measure the effectiveness of the therapy.  The goal of this study was to use the LDA/SIR 
analysis to develop a prediction algorithm for hypercholesterolemia and then in case 
studies to assess the effectiveness of using the LDA/SIR algorithm to monitor the 
influence of statin treatment. 
-0.4 -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 0.4
no
yes
H
y
p
e
rc
h
o
le
s
te
ro
le
m
ia
 P
re
s
e
n
c
e
LDA Value
 
Figure 47: LDA/SIR Separation for Hypercholesterolemic Subjects 
 
3.2.1.5.1 LDA/SIR Analysis for Risk Assessment of Hypercholesterolemia 
 The LDA/SIR analysis proved effective in the risk assessment of 
hypercholesterolemia.  For this study, all 11 lipoprotein subclasses were included.  The 
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prediction accuracy of this study was found to be 97.6% with an X-Val value of 92.7%.  
The LDA/SIR separation is depicted in Figure 42.  Only one subject from the sample 
library was misclassified using the LDA/SIR analysis.  The difference in the prediction 
accuracy and the X-Val score was only 4.9% which indicated that there was very little 
sample dependency for this analysis, even though the total sample size was only 41 
subjects.  This study showed a robust statistical significance based on the X-Val test 
despite the small number of subjects in the library.   
 The low sample dependency for detection of hypercholesterolemia could 
indicate that the separation between the two groups in this study was more readily 
detected due to the nature of the hypercholesterolemia and the elevated lipoprotein 
cholesterol content related to the disease.
127
  This elevated cholesterol level affected the 
fluorescence intensities in the lipoprotein profiles.  When comparing the total integrated 
fluorescence intensities for the TRL, LDL, and HDL between groups, it was found that 
the intensities for the TRL and LDL of the hypercholesterolemic subjects were almost 
double that of the non-hypercholesterolemic subjects.  The average HDL intensities 
between groups were relatively similar and did not show any difference between groups.  
The elevated fluorescence intensities throughout the TRL and LDL subclasses more 
readily distinguished between sample groups and reduced the sample dependency of this 
study. 
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Figure 48: LDA/SIR Coefficients for Prediction of Hypercholesterolemia in 
Children 
 
 To access the effect of the lipoprotein subclasses with respect to the prediction 
analysis, the coefficients of the prediction algorithm were studied.  These coefficients 
are depicted in Figure 48.  The majority of the coefficients for the hypercholesterolemia 
prediction algorithm have the same polarities as the coefficients for the comprehensive 
serum library.  The coefficients for TRL, LDL-1, and LDL-5 are the only variables that 
change polarity between the studies.  The constant that is included in the algorithm also 
changes.  The constant for the hypercholesterolemic study was found to be -1.353.  The 
constant for the comprehensive serum library was found to be 2.054.  The polarity 
change for the hypercholesterolemic study means that the samples were weighed 
145 
 
 
 
towards a “healthy” classification and that the classification changed based on the 
increase in fluorescent intensities for the variables with positive coefficients.  When 
compared to the coefficients for the comprehensive serum library, the HDL subclasses 
show a similar pattern of polarities for CVD prediction.  This again is evidence that 
supports the theory of atherogenic forms of HDL.     
 With the similarities in algorithm coefficients between the comprehensive 
serum library and the hypercholesterolemia children’s library, application of the 
hypercholesteremic subject data from the lipoprotein profiles to the LDA/SIR equation 
for the comprehensive serum library was investigated.  The resulting LDA/SIR values 
for the different subjects have been overlaid onto the separation graph from the 
comprehensive library in Figure 49.  Of the 31 hypercholesterolemic subjects, six of the 
subjects were classified as CTRL and 25 of the subjects were classified as CVD based 
on the LDA/SIR calculated values.  For the 10 non-hypercholesterolemic subjects, 9 of 
the 10 subjects were classified as CVD while only one was classified as CTRL based on 
the LDA/SIR calculated values. 
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Figure 49: Classification of Hypercholesterolemia Children's Library Using the 
Comprehensive Serum Library LDA/SIR Algorithm. (HC = Hypercholesterolemia 
Subject, Non-HC = Non-hypercholesterolemia Subject) 
 
 The classification of the hypercholesterolemic subjects as CVD correlated with 
the fact that the disease can be a precursor to the onset of CVD.  The classification of the 
“healthy” children as CVD indicated that the algorithm generated for the adult 
population of the comprehensive serum library was not applicable to the children 
samples since there should be very little, if any, arterial blockage in children.  Current 
studies into the stability of the lipid panels from childhood to adulthood indicate the 
potential changes in lipoprotein profiles during adolescence.
128
  There are also studies 
that have indicated the correlation between lipoprotein levels in childhood and the 
resulting adult levels.
129
  The findings from this research coupled with the ambiguity that 
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has been reported in the correlation of lipid values between childhood and adulthood 
indicate that further investigation is needed into the correlation of the LDA/SIR risk 
assessment and the longitudinal development of CVD. 
  
3.2.1.5.2 Effects of Therapy/Placebo on Risk Assessment of Hypercholesterolemia 
 The next goal of this research was to assess the benefits of implementing the 
LDA/SIR risk analysis in identifying the effects that treatment can have on the subject’s 
risk.  The specific treatment studied in this experiment was the use of statin therapy.  
Statin therapy has been well documented to reduce cholesterol levels and mortality due 
to CVD.
37,38,124
  To test statin therapy’s effectiveness on the hypercholesterolemic 
children, some were given the treatment while others received a placebo.  Treatment was 
applied over a 48 week span with serum samples drawn at the 0, 24, and 48 week point.  
There was also a washout period of 12 weeks applied to this study after the 48 week 
mark.  This washout period halted all therapies and was designed to test the effect that 
halting statin therapy had on the lipoprotein profiles.  In this study, the effects of 
treatment were related to the change in the initial risk assessment for risk of 
hypercholesterolemia. 
 When studying the profiles of subjects treated with statin therapy, results were 
subject-dependent.  While nearly all subjects treated with statins showed changes in 
LDA/SIR values towards the CTRL group at some point during therapy, there were 
some patients whose values fluctuated up and down.  Four patient’s (I-IV) LDA/SIR 
changes over time have been depicted in Figures 50 and 51.  Subjects I and II showed a  
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Figure 50: LDA/SIR Values for Hypercholesterolemia Subjects Treated with Statin 
Therapy (Subjects I and II) 
A 
B 
149 
 
 
 
0 10 20 30 40 50 60
-0.04
-0.02
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
L
D
A
/S
IR
 V
a
lu
e
Week
Statin Therapy on Subject III
 
0 10 20 30 40 50 60
-0.05
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
L
D
A
/S
IR
 V
a
lu
e
Week
Statin Therapy on Subject IV
 
Figure 51: LDA/SIR Values for Hypercholesterolemia Subjects Treated with Statin 
Therapy (Subjects III and IV) 
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general reduction in the LDA/SIR value which indicated a decrease in the risk of 
hypercholesterolemia over the span of statin treatment.  This trend was found in six of 
the eight subjects treated with statin therapy.  Subjects III and IV showed varied results 
including LDA/SIR values that were increased relative to the baseline value at Week 0.  
This result could indicate that there is a patient to patient variability in the effectiveness 
of treatment.  In all statin treated subjects, some form of reduced LDA/SIR value was 
observed throughout the study.  Three of the eight subjects even showed a change from a 
positive LDA/SIR value to a negative LDA/SIR value which would indicate a change in 
CVD risk.  After the washout period (Week 60), seven of the eight statin-treated subjects 
showed an increased LDA/SIR value indicating that when statin treatment was 
terminated, the CVD risk increased.   
 The placebo-treated subject’s LDA/SIR values showed a variety of patterns.  
These patterns are depicted in Figures 52 and 53.  Of the nine subjects treated with 
placebos, three subjects showed varying LDA/SIR values similar to that found with the 
statin treated subjects indicating no significant changes over the study period (Subject V, 
Figure 52A).  Three of the subjects showed increased LDA/SIR value over the study 
period indicating stability in the classification identified through the LDA/SIR analysis 
(Subject VI, Figure 52B).  Finally, three subjects displayed a decrease in LDA/SIR 
values over the study period which would indicate a reduced risk of disease even though 
they were treated with placebos (Subject VII, Figure 53A).  Of these three subjects, only 
one subject (Subject VIII, Figure 53B) showed a reduction in the LDA/SIR value to a  
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Figure 52: LDA/SIR Values for Hypercholesterolemia Subjects Treated with 
Placebos (Subjects V and VI) 
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Figure 53: LDA/SIR Values for Hypercholesterolemia Subjects Treated with 
Placebos (Subjects VII and VIII) 
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negative value indicating a diagnosis change.  These studies suggest that the LDA/SIR 
value for a subject can fluctuate over a period of time, most like due to lifestyle. 
 To understand how the changes in the lipoprotein density profiles affected the 
LDA/SIR value calculated from the algorithm, a comparison of the integrated 
fluorescent intensities and the value of each lipoprotein subclass using the coefficients 
from the LDA/SIR algorithm was carried out.  Figures 54 and 55 compares the 
lipoprotein density profiles for Subject I (statin therapy) and Subject V (placebo) and the 
calculated LDA/SIR contributions by lipoprotein subclass for the baseline draw (Week 
0) and final draw (Week 48) for each treatment.  For Subject I, analysis of the integrated 
fluorescence intensities between week 0 and week 48 showed reduction in LDL-1 
through LDL-4 subclasses and a relative increase in the HDL3 subclasses.  This pattern 
correlated with the reported effects of statin therapy on lipoproteins.  The impact of these 
changes was not as prevalent in the LDA/SIR values for each subclass due to the use of 
natural logs to normalize the data.  An increase in values for three subclasses with 
negative coefficients and decrease in value for one subclass with a positive coefficient 
explained the reduction in the total calculated LDA/SIR value for Subject I between 
week 0 and week 48.  For Subject V, the integrated intensities showed relatively no 
difference between week 0 and week 48 except for a reduction in the LDL-3 and LDL-4 
subclasses.  The calculated LDA/SIR values for each subclass also showed relatively no 
change between week 0 and week 48.  These findings show that slight changes in the 
profile were seen despite using a placebo for treatment.  
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Figure 54:  Comparison of Integrated Fluorescent Intensities and LDA/SIR Values 
for Each Lipoprotein Subclass: Subject I (Statin Therapy).  
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Figure 55:  Comparison of Integrated Fluorescent Intensities and LDA/SIR Values 
for Each Lipoprotein Subclass: Subject V (Placebo Therapy) 
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 To identify whether or not the changes found in the placebo treated subjects 
were insignificant, a study would need to be performed to assess the stability of the 
lipoprotein density profile and the LDA/SIR value over time.  The current study gave 
evidence that the effects of statin treatment can be studied using the lipoprotein density 
profile and the LDA/SIR analysis and that the treatment did reduce the risk assessment 
of hypercholesterolemia.  Other forms of medical treatment must still be studied in order 
to confirm the use of these methods for the assessment of individual treatment 
effectiveness.  Similar studies must also be carried out in order to assess the effect of 
medical treatments on CVD risk assessment. 
 
3.2.2 Further Analytical Methods Applied to the Statistical Analyses to Improve Risk 
Assessment of CVD 
 In order to assess any improvements that changes in methodology or additional 
risk factors might have on the CVD risk assessment, a subset of serum samples were 
selected from the Comprehensive Serum Library to test prior to application to the full 
serum library.  This subset was made up of 36 CVD and 36 CTRL samples which were 
selected based on the LDA/SIR analysis and were a mix of correctly and incorrectly 
classified samples for each condition.  The baseline accuracies for the LDA/SIR and 
QDA analyses on this sample set were found to be 86.1% and 93.1%, respectively.  The 
X-Val scores for the LDA/SIR and QDA analyses were found to be 79.2% and 70.8%, 
respectively.  The LDA/SIR prediction equation coefficient histogram for the 72 subject 
library is shown in Figure 56.  
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Figure 56:  LDA/SIR Coefficients for the 72 Patient Library Using the NaBiEDTA-
Based Gradient System 
 
The goal of these studies was to measure the improvements in risk assessment 
when applying new analytical methods and/or risk factors to the statistical analyses.  The 
methods tested for improvement were the use of Cs2CdEDTA based gradients to expand 
the lipoprotein density profiles and application of mass spectrometry to the 
apolipoproteins present in each subject’s HDL.  
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3.2.2.1 Application of Cs2CdEDTA-based Lipoprotein Density Profiling for CVD Risk 
Assessment 
 With all of the evidence from the previous CVD risk studies pointing to the HDL 
subclasses as the major contributors to the risk assessment, further studies were designed 
to specifically look at the HDL subclasses by expanding this region of the lipoprotein 
profiles using the Cs2CdEDTA solute based systems.  As previously described, the 
Cs2CdEDTA solute-based gradient systems allow for expansion of the HDL or the LDL 
subclasses.  The goal of this study was to explore the effect that expanding the 
lipoprotein profiles have on the statistical analyses for risk assessment.   
 The use of the Cs2CdEDTA-based gradients was analyzed in multiple ways.  
First, the total lipoprotein profile was analyzed by combining the results from the LDL 
and HDL profiles using Cs2CdEDTA.  Next, the use of Cs2CdEDTA for profiling the 
HDL subclasses was studied by combining the HDL data with LDL data from the 
NaBiEDTA-based profiles.  The differences in prediction accuracies and X-Val scores 
were used to assess the advantages of the expanded lipoprotein profiles.  For this 
analysis, Mode 1 data from the NaBiEDTA-based profiles was used as a baseline due to 
it previously showing the best accuracy in terms of risk assessment. 
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Table 12:  LDA/SIR and QDA Statistical Analyses for Cs2CdEDTA-Based 
Gradients of the 72 Subject Data Set 
System 
LDA/SIR Analysis QDA Analysis 
Prediction 
Accuracy 
(%) 
X-Val 
Accuracy 
(%) 
Prediction 
Accuracy 
(%) 
X-Val 
Accuracy 
(%) 
NaBiEDTA 86.1 79.2 93.1 70.8 
Cs2CdEDTA 88.9 83.3 93.1 76.4 
Cs2CdEDTA w/o IDL 86.1 79.2 91.7 77.8 
NaBiEDTA (TRL & LDL) 
and Cs2CdEDTA (HDL)  
87.5 77.8 94.4 77.8 
NaBiEDTA + HT & FH 88.6 78.6 92.9 74.3 
Cs2CdEDTA + HT & FH 90 82.9 98.6 82.9 
Cs2CdEDTA w/o IDL + HT 
& FH 
87.1 78.6 95.7 82.9 
NaBiEDTA (TRL & LDL) 
and Cs2CdEDTA (HDL) + 
HT & FH  
87.1 80 94.3 75.7 
 
 The summary of the LDA/SIR and QDA statistical analyses are displayed in 
Table 12.  The use of Cs2CdEDTA-based lipoprotein density profiles showed minimal 
improvements in the prediction accuracy.  This improvement was found in the form of 
one more subject being correctly classified than when using the NaBiEDTA-based 
density profiles.  This improvement was not clearly defined as significant due to the 
small number of samples in the study.   The application of QDA with the risk factors of 
family history and hypertension to the Cs2CdEDTA density profile data, however, 
showed a very large improvement in the prediction accuracy and the X-Val score.  The 
prediction accuracy was found to be 98.6% with an X-Val score of 82.9%.  The 15.7% 
difference between the X-Val score and prediction accuracy indicates some level of 
patient dependency.  However, this was just a subset of the data tested to confirm the 
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potential of expanding the lipoprotein profiles.  The increased prediction power 
indicated that the Cs2CdEDTA-based gradients for expanding the lipoprotein profiles 
have the potential for improving the risk assessment of CVD. 
 With the best potential for risk assessment of CVD found using the Cs2CdEDTA-
based gradients and patient history, further analysis of how these factors impacted the 
risk assessment by studying the coefficients of the LDA/SIR analysis was performed.  
The coefficients are depicted in Figure 57.  The addition of the IDL subclass to the 
analysis was deemed significant with the large coefficient that was associated with the 
lipoprotein subclass.  The coefficients for the family history and hypertension, 4.53E-4 
and 1.48E-3 respectively, were so small in comparison to the lipoprotein subclasses that 
they are indistinguishable in the figure.  The small size of these coefficients explains 
why the improvement when adding the traditional risk factors only improves the 
accuracy of the analysis by one patient.  The largest difference between the coefficients 
from the Cs2CdEDTA lipoprotein subclasses and the NaBiEDTA subclasses was seen in 
the LDL subclasses.  The LDL2-LDL5 subclasses all switched polarities and relative 
strengths.  The LDL1 subclass did not change in polarity, but the size of the coefficient 
was largely different.  These differences in the LDL subclasses and their application to 
the CVD risk analysis required further study. 
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Figure 57: LDA/SIR Coefficients for Lipoprotein Subclasses and Traditional Risk 
Factors Using Cs2CdEDTA Density Gradient System on the 72 Subject Data Set 
 
 To further understand the changes in how the LDL subclasses contributed to the 
LDA/SIR analysis when applied to the Cs2CdEDTA lipoprotein subclass data, the LDL 
profiles of different subjects were compared when using the two different gradient 
systems.  The change in LDL peak densities between the different solute gradient curves 
was seen for both CVD and CTRL subjects.  Examples of lipoprotein profiles for both 
solute systems are shown for CTRL and CVD subjects in Figures 58 and 59, 
respectively.  When examining the changes in the densities of the prominent fluorescent 
peaks between the CVD and CTRL groups, it was found that the average changes in 
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Figure 58: Comparison of LDL Lipoprotein Density Profiles for CTRL-Patient 052 
between Solute Systems. (A) Cs2CdEDTA for LDL, (B) Cs2CdEDTA for HDL, (C) 
NaBiEDTA 
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Figure 59: Comparison of LDL Lipoprotein Density Profiles for CVD-Patient 169 
between Solute Systems. (A) Cs2CdEDTA for LDL, (B) Cs2CdEDTA for HDL, (C) 
NaBiEDTA
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C 
164 
 
 
 
density were 0.0260 +/- 0.0020g/mL and 0.0276 +/- 0.0020g/mL, respectively.  When 
testing the difference between these two groups with an ANOVA analysis, the p-value of 
the analysis was found to be 0.131, which means that at a 95% confidence level, the two 
groups were not statistically different.  This means that the change in densities was 
uniform between the disease classifications and that it had nothing to do with the type of 
patient tested.  The change in the LDA/SIR equation between solute systems was 
therefore related to the difference in cationic interactions between the solute and the 
phospholipids in LDL. 
 
3.2.2.2 Mass Spectrometry of HDL Apolipoproteins for Application to CVD Risk 
Assessment 
 Through previous work performed in our laboratory for profiling the mass 
spectra of apolipoproteins in the HDL fraction of patient serum, the identification of a 
post translational modification (PTM) of Apo C-I was identified in a small cohort of 
CVD subjects that wasn’t present in the cohort of CTRL subjects.16  This PTM was 
identified as a potential risk factor that could aid in the risk assessment of CVD.  For this 
reason, further analysis of the applications of the mass spectra was performed, 
specifically to incorporate mass spectral data into the LDA/SIR and QDA analyses.  The 
goal of this study was to assess the potential of adding HDL apolipoprotein mass 
spectral data to the statistical analyses in order to improve the CVD risk assessment and 
identify potential risk factors for CVD based on the mass spectra. 
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Figure 60: Mass Spectra of HDL Apolipoproteins for CVD Patient 124 
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Figure 61: Mass Spectra of HDL Apolipoproteins for CVD Patient 148 
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Figure 62: Mass Spectra of HDL Apolipoproteins for CVD Patient 171 
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Figure 63: Mass Spectra of HDL Apolipoproteins for CTRL Patient 013 
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Figure 64: Mass Spectra of HDL Apolipoproteins for CTRL Patient 033 
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Figure 65: Mass Spectra of HDL Apolipoproteins for CTRL Patient 043 
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3.2.2.2.1 Mass Spectra Differences between CVD and CTRL Cohorts 
 Through examination of the mass spectra between the subsets of CVD and CTRL 
samples, differences in the mass spectra for the two groups were identified.  Examples 
for both CVD and CTRL mass spectra are shown in Figures 60-65.  Figures 60-62 
represent mass spectra for CVD samples.  Figures 63-65 represent mass spectra for 
CTRL samples.  Each mass spectrum represents a molecular weight modification 
(MWM) that was observed relative to the CVD or CTRL cohort.  The most easily 
identifiable MWMs found between the CVD and CTRL groups were in the Apo A-I, 
Apo C-I, and Apo A-II mass regions.  These features were easily identifiable due to the 
large mass differences between these apolipoproteins in comparison to each other and 
the other apolipoproteins present in the HDL particles.  A summary of the average 
apolipoprotein masses and the MWMs observed are shown in Table 13.  The high 
standard deviation in masses for the un-modified forms of Apo A-I and Apo A-II could 
indicate further MWMs that were not able to be identified through the small number of 
samples selected for this study.  In the sections following, the differences between CVD 
and CTRL groups for these mass ranges will be further explored. 
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Table 13: Masses of HDL Apolipoproteins between CVD and CTRL Cohorts 
Measured Using MALDI-TOF MS 
Apolipoprotein 
CTRL Cohort CVD Cohort 
Avg. Mass 
(Da) 
Std. 
Dev. 
Avg. Mass 
(Da) 
Std. 
Dev. 
Apo A-I 28051 118 28110 72 
Apo A-I MWM 27558 7 27543 19 
Apo A-II 17275 92 17258 124 
Apo A-II MWM 16999 2 16988 6 
Apo C-I 6631 12 6623 17 
Apo C-I MWM 6729 4 NA NA 
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Figure 66: Apo A-I Mass Distribution between CVD and CTRL Cohorts 
 
 The difference between the CVD and CTRL groups with respect to the 
apolipoprotein Apo A-I mass distribution is depicted in Figure 66.  The documented 
molecular weight for Apo A-I is 28,016Da.
48
  The masses for Apo A-I and its MWM in 
the CVD samples were found to be an average of 28,110 +/- 72 Da and 27543 +/- 19 Da, 
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respectively.  The masses for Apo A-I and its MWM in the CTRL samples were found to 
be an average of 28,051 +/- 118 Da and 27558 +/- 7 Da, respectively.  The difference in 
the Apo A-I masses between groups was examined through an ANOVA analysis.  The p-
value for this analysis was found to be 0.001 which indicated that there was a 
statistically significant difference between the CVD and CTRL cohorts.  The difference 
between groups was attributed to the number of samples in the CVD group with the 
presence of the MWM of Apo A-I.   
The MWM of Apo A-I was present in a large number of samples in the CVD 
cohort in comparison to its presence in the CTRL cohort.  20 of the 36 CVD subjects 
were identified to possess the MWM of Apo A-I.  Figure 60 (Patient 124) shows a CVD 
sample without the Apo A-I MWM.  Figures 61 and 62 (Patients 148 and 171, 
respectively) show CVD samples with the MWM of Apo A-I.  Figure 64 (Patient 033) 
shows a CTRL sample with the presense of the MWM of Apo A-I.  Figure 63 and 65 
(Patients 013 and 043, respectively) show CTRL samples without the Apo A-I 
modification.   
The MWM of Apo A-I identified in this study was attributed to a change in the 
molecular weight of the apolipoprotein by approximately -450Da to a final molecular 
weight of ~27,550Da.  This molecular weight of Apo A-I has previously been identified 
in cows where the Apo A-I is missing two amino acids in comparison to the human form 
of Apo A-I.  It is possible that a loss of two amino acids in the Apo A-I in humans could 
result in an increased risk of CVD due to the changes it causes in the metabolism of 
HDL.  A mass peak for the subjects with the MWM of Apo A-I was present in the mass 
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spectra at the documented molecular weight of Apo A-I; however it was not the 
prominent mass peak of the region.   
Of the 36 CTRL subjects in this study, only four of the CTRL subjects were 
identified as having the MWM of Apo A-I present in their mass spectra.  The presence 
of this MWM in the CTRL samples indicated that while the MWM could be a risk 
factor, having the MWM of Apo A-I does not mean that a subject will have CVD.  The 
presence of the MWM did show the potential for the application of Apo A-I mass 
spectral data to the LDA/SIR and QDA analyses as an added risk factor in the 
multivariate analyses. 
 The results of comparing the Apo C-I mass spectra between CVD and CTRL 
groups led to an unexpected observation.  Previous analysis of the Apo C-I mass spectra 
indicated that there was a MWM present for all eight CVD subjects tested while there 
was no MWM present in the eight CTRL subjects tested.
16
  This MWM presented itself 
in the form of an additional 90-100Da to the documented molecular weight of 6630Da 
for Apo C-I.  The results found using the subset of 72 patients, 36 CVDs and 36 CTRLs, 
differed from this observation in that the only subjects for whom a MWM was present 
were the CTRL subjects.  The distribution of the Apo C-I masses for each group is 
shown in Figure 67. 
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Figure 67: Apo C-I Mass Distribution between CVD and CTRL Cohorts 
 
Of the 36 CTRL subjects in this study, eight showed the presence of the Apo C-I 
MWM that was previously identified for the CVD subjects in the pilot study.  For the 
CTRL subjects that did not show the presence of the MWM, the average mass was found 
to be 6631 +/- 12 Da.  The MWM of Apo C-I was identified with the average mass of 
6729 +/- 12 Da.  Figure 65 (Patient 043) represents the mass spectrum of a subject with 
the MWM of Apo A-I.  The MWM was not present in any of the 36 new CVD subjects 
tested in this study.  The average mass for all of the 36 CVD subjects was found to be 
6623 +/- 17 Da.  While the Apo C-I mass between the CVD and CTRL groups was 
found to be statistically significant through ANOVA analysis, the relative error in the 
MALDI-TOF instrument for this mass region was reported to be +/-10Da which 
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indicated that the mass difference between the two groups is indistinguishable except for 
those subjects with the MWM of Apo C-I. 
 The presence of the MWMM in the Apo C-I for the CTRL subjects is counter to 
the pilot study data that identified the MWM of Apo C-I is a biomarker for CVD.  Of the 
36 CTRL subjects in this study, seven of the subjects tested were also used for the pilot 
study.  For all seven subjects, the results of the current mass spectra correlated with the 
results found in the pilot study.  This indicated that the MWM presence in the CTRL 
subjects was not experimental error, but a real observation.  The observation that none of 
the 36 CVD subjects tested in this study had the reported MWM for Apo C-I was also 
counter to the pilot study.  The variation between the pilot study results and the results 
found in the current study could be related to the design of each study.  The pilot study 
was specifically designed to study subjects based on their likelihood to have atherogenic 
HDL.  The 72 subjects selected for the current study were selected based on their 
LDA/SIR classification in the comprehensive library study.   
In order to explain the presence of the Apo C-I MWM in CTRL subjects and the 
lack of the MWM presence in CVD subjects, the subjects’ medical records were put 
under further review.  When comparing the subject histories between those subjects with 
the MWM of Apo C-1 and the subjects without the MWM of Apo C-I, no correlation 
could be made to the available patient histories to explain the presence of the MWM.  
While the majority of the subjects with the MWM of Apo C-I had the presence of 
hypertension in their medical histories, there were many of the subjects without the 
MWM of Apo C-I that also had the presence of hypertension.  While the MWM of Apo 
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C-I could still be a risk factor for CVD, further exploration into the nature of the MWM 
is necessary to understand its influence on CVD risk. 
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Figure 68: Apo A-II Mass Distribution between CVD and CTRL Cohorts 
 
The third apolipoprotein that portrayed a difference in the mass spectra between 
CVD and CTRL groups was Apo A-II.  Apo A-II’s presence in HDL is primarily in the 
form of a homodimer with the molecular weight of 17,414Da.
48
  The distribution of Apo 
A-II masses is shown in Figure 68.  When comparing this region of the mass spectra 
between the CVD and CTRL groups, 14 of the 36 CVD subjects portrayed a MWM with 
primary peaks in the Apo A-II mass region at 16,988 +/- 6 Da (Figures 61 and 62, 
Patients 148 and 171, respectively).  The other 22 CVD subjects were found to have the 
average Apo A-II mass of 17,258 +/- 124 Da (Figure 60, Patient 124).  For the CTRL 
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subjects, only two of the 36 subjects portrayed a similar MWM for their primary peak in 
this mass region with an average mass of 16999 +/- 2 Da (Figures 64, Patient 033).  The 
average mass of Apo A-II for the remaining 34 CTRL subjects was calculated to be 
17,275 +/- 92 Da (Figures 63 and 65, Patient 013 and Patient 043, respectively).  The 
large deviation in masses for the “unmodified” Apo A-II could indicate the presence of 
further MWMs that were not distinguishable due to the sample size of this study. 
The mass region of 16,990 Da was identified as a possible MWM due to the 
population of CVD samples with this mass as the primary peak in the region.  There 
were also satellite peaks with masses less than 16,990Da that were primarily present in 
the CVD samples.  The presence of these peaks could indicate a truncated form of the 
Apo A-II dimer or the presence of a hetero dimer.  The distinction of this mass peak 
between the CVD and CTRL groups showed potential for application of this Apo A-II 
PTM to the LDA/SIR and QDA analyses. 
 
3.2.2.2.2 Application of Mass Spectral Data to Statistical Analyses 
 With the identification of potential mass spectra data that could be used in the 
statistical analyses in order to enhance the accuracy of CVD risk assessment, these 
factors were now added systematically to study the individual and combined potentials 
of the mass spectrum data as an addition to the lipoprotein density profiles for CVD risk 
assessment.  These factors were also tested separately to explore the potential of the 
mass spectra as an individual method of risk assessment when applied to the LDA/SIR 
and QDA analyses.  The mass spectral data for the apolipoproteins was added to the 
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statistical analyses in terms of the natural log of the masses for the most prominent peak 
in the mass regions of Apo A-I, Apo A-II, and Apo C-I.  
The summary of the results when applying the mass spectrum data to the 
statistical analyses can be found in Table 14.  The statistical analyses were carried out 
using both the NaBiEDTA-based lipoprotein density profile data and the Cs2CdEDTA-
based lipoprotein density profile data.  For the NaBiEDTA-based lipoprotein density 
profiles, the addition of Apo C-I and Apo A-I mass spectra data to the statistical analyses 
was shown to improve the classification.  The Apo A-II data only enhanced the 
prediction analysis when applied to QDA.  The best accuracy for the NaBiEDTA-based 
profiles was found when combining the data for Apo C-I and Apo A-I for both LDA/SIR 
and QDA.   
For the Cs2CdEDTA-based lipoprotein density profiles, the addition of Apo C-I 
and Apo A-I mass spectra data was shown to best improve the classification similar to 
the improvement seen with the NaBiEDTA density profiles.  The Apo A-II data showed 
limited improvement for both QDA and LDA.  Through the combination of 
Cs2CdEDTA-based lipoprotein density profile data and Apo A-I and Apo C-I data, the 
prediction analysis was increased to 93.1% for the LDA/SIR analysis and 100% for the 
QDA analysis.  The low X-Val score for the QDA analysis indicated that there was a 
large subject dependency inherent to the analysis.  This subject dependency was to be 
expected due to the nature of the QDA analysis in that there is no assumption that the 
covariance matrices are equal between groups like in the LDA/SIR analysis.  The 
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addition of more risk factors without the addition of more subjects directly affected the 
subject dependency. 
 
Table 14: Application of Mass Spectra Data to the LDA/SIR and QDA Analyses for 
CVD Risk Assessment Using the 72 Subject Data Set 
System 
LDA/SIR Analysis QDA Analysis 
Prediction 
Accuracy 
(%) 
X-Val 
Accuracy 
(%) 
Prediction 
Accuracy 
(%) 
X-Val 
Accuracy 
(%) 
NaBiEDTA DP 86.1 79.2 93.1 70.8 
NaBiEDTA + Apo A-I 84.5 78.9 94.4 72.2 
NaBiEDTA + Apo C-I 86.1 77.8 93.1 73.6 
NaBiEDTA + Apo A-II  84.7 76.4 95.8 70.4 
NaBiEDTA + Apo A-I + 
Apo C-I 
87.5 77.8 93.1 70.8 
NaBiEDTA + Apo A-I + 
Apo C-I + Apo A-II 
84.7 79.2 93.1 73.6 
Cs2CdEDTA DP 88.9 83.3 93.1 76.4 
Cs2CdEDTA + Apo A-I 91.7 86.1 97.2 80.6 
Cs2CdEDTA + Apo C-I 93.1 86.1 97.2 76.4 
Cs2CdEDTA + Apo A-II  90.3 83.3 94.4 79.2 
Cs2CdEDTA + Apo A-I 
+ Apo C-I 
93.1 86.1 100.0 75.0 
Cs2CdEDTA + Apo A-I 
+ Apo C-I + Apo A-II 
93.1 86.1 98.6 77.8 
Apo A-I + Apo C-I + 
Apo A-II 
70.8 68.1 56.9 51.4 
 
With the improvements in CVD risk assessment through the application of the 
mass spectrum data to the lipoprotein subclass data, the use of the mass spectrum data as 
a singular method of CVD risk assessment was further examined.  When using only the 
mass spectrum data for the three apolipoproteins identified, the LDA/SIR analysis was 
shown to be 70.8% accurate.  While the mass spectrum data did not improve the 
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prediction accuracy, it did show the potential for use of mass spectrometry of 
apolipoproteins for CVD risk assessment.  The current preparative methods only isolated 
the HDL apolipoproteins for study.  Future applications of the mass spectra include the 
study of the lower concentration apolipoproteins in HDL such as Apo C-II and C-III.  
The mass region for these apolipoproteins in the MALDI-TOF spectra is 8,000Da-
10,000Da.  Due to the multiple peaks in this mass region and the closely related masses 
of these apolipoproteins, identification of any potential risk factors for CVD would 
require further isolation of the specific apolipoproteins before the analysis of these 
apolipoproteins. 
The prediction equation coefficients of the LDA/SIR analyses with the addition 
of the mass spectral data were further studied to identify the influence that the mass 
spectrum data had on the CVD risk assessment.  The coefficients for each variable used 
in the LDA/SIR analysis are graphed for the different density gradient systems in 
histogram form in Figures 69 and 70 (NaBiEDTA and Cs2CdEDTA, respectively). 
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Figure 69: LDA/SIR Coefficients for Lipoprotein Subclasses Using NaBiEDTA-
Based Density Gradients and Mass Spectrometry Data for the HDL 
Apolipoproteins when Applied to the 72 Subject Library 
 
When comparing the coefficients found for the NaBiEDTA density profiles of 
the 72 subject library (Figure 56) to the coefficients found for the addition of the mass 
spectral data, the primary change was in the magnitude of the coefficients.  The 
coefficients for the apolipoproteins were very large in comparison to the coefficients of 
the lipoprotein subclasses.  The lipoprotein subclass coefficients were also smaller with 
the addition of the mass spectral data when compared to the coefficients found using the 
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lipoprotein subclasses alone.  The majority of the lipoprotein subclasses retained their 
polarities toward CVD or CTRL except for the LDL-5 and HDL-2a. 
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Figure 70: LDA/SIR Coefficients for Lipoprotein Subclasses Using Cs2CdEDTA-
Based Density Gradients and Mass Spectrometry Data for the HDL 
Apolipoproteins when Applied to the 72 Subject Library    
  
When comparing the coefficients found for the Cs2CdEDTA density profiles of 
the 72 subject library (Figure 57) to the coefficients found for the addition of the mass 
spectral data, a few differences were observed.  First, the coefficient value for each 
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lipoprotein subclass was reduced with the addition of the mass spectral data similar to 
what was observed with the NaBiEDTA density profiles.  Only the LDL-5 subclass 
changed in polarity to being a factor towards CVD classification when coupled with the 
mass spectrometry data.  Second, the apolipoprotein variables were again associated 
with the largest variables using the Cs2CdEDTa lipoprotein subclass data.   
The polarity of the mass spectrometry variables for both density systems 
indicated the Apo A-I and Apo C-I as variables for classification as CTRL and Apo A-II 
as a variable for CVD.  The implication on the mass spectrometry data indicates that the 
higher masses of Apo A-I and Apo C-I would weigh the subject towards a CTRL 
classification.  This observation for the Apo C-I mass is contrary to the Apo C-I data 
reported in the initial pilot study of 16 subjects.  Further exploration into the nature of 
the Apo C-I MWM is necessary due to the uncertainty present with respect to the nature 
of the Apo C-I MWM and how it relates to CVD.  The higher masses of Apo A-II would 
weigh the subject towards a CVD classification based on the LDA/SIR coefficients.  
This coefficient of Apo A-II was contrary to the data for Apo A-II which indicated that 
the lower masses are more prevalent for the CVD subjects.  This contradiction could 
only be accounted for by the fact that the LDA/SIR analysis inter-relates all the variables 
used to generate the equation and does not just compare the differences of single 
variables between the defined groups. 
The optimum separation of CVD and CTRL subjects through use of the 
LDA/SIR equation that was generated with the lipoprotein subclasses and mass 
spectrometry data is displayed in Figure 71.  The p-value for the LDA/SIR separation of 
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CVD and CTRL was calculated to be 1.14E-05.  This p-value indicated that the 
distinction found between CVD and CTRL groups using the LDA/SIR equation was 
statistically significant.  Based on the prediction accuracy of the LDA/SIR and QDA 
analyses and the statistical significance of the separation between CVD and CTRL 
groups, the coupling of the mass spectrometry data with the lipoprotein subclasses was 
decidedly the best method for CVD risk assessment. 
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Figure 71: LDA/SIR Separation for the 72 Subject Library Using Lipoprotein 
Subclasses and Mass Spectrometry Data 
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3.2.3 Case Studies for Monitoring CVD Therapies 
 With the potential for the use of lipoprotein density profiles in the assessment of 
CVD risk established and the evidence seen in the hypercholesterolemia study that 
therapy effectiveness could be monitored using the LDA/SIR equation, further studies 
into the sensitivity of the lipoprotein density profiles and risk analysis were carried out 
with respect to the effects of further medical treatment and the increase of exercise.  For 
the use of the LDA/SIR risk assessment to be valuable in clinical applications, methods 
of medical treatment must be able to be monitored using the LDA/SIR equation for CVD 
risk when applied to subjects undergoing drug therapy or lifestyle modifications.  The 
goal of these studies was to show that lipoprotein density profiles, in conjunction with 
the LDA/SIR analysis, are sensitive enough to monitor the effectiveness of medical 
treatment and lifestyle modification with respect to their impact on CVD risk. 
 
3.2.3.1 Case Study Monitoring the Effects of Niacin Therapy 
 The effects of statin therapy on lipoprotein density profiles were previously 
studied with respect to the hypercholesterolemic children.  Another medical treatment 
related to the reduction of CVD symptoms is niacin.  Niacin has been thought to reverse 
atherosclerosis by reducing total cholesterol, triglycerides, very-low-density lipoprotein 
(VLDL), and low-density lipoprotein (LDL), and increasing high-density lipoprotein 
(HDL).
39-41,130
  There are also studies relating niacin therapy with the reduction of 
lipoprotein (a) (Lp(a)).
131
  In this study, the effects of increasing the dosage of niacin 
therapy were examined with respect to the effects it had on the lipoprotein profiles.  
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HDL cholesterol and Lp(a) protein concentrations in relation to the niacin dosage were 
also examined.  The LDA/SIR values for the sequential serum draws were calculated 
using the LDA/SIR equation found for the comprehensive library study using the 
NaBiEDTA-based gradient system in order to examine any effects niacin had on the 
CVD risk assessment.   
The subject in this study was treated with increasing amounts of niacin from 0mg 
to 2000mg using increments of 500mg.  Serum samples for this subject were drawn over 
a period of five months with a baseline sample of the subject having no treatment and a 
washout sample one week after the last treatment was taken.  Each serum sample was 
tested for HDL cholesterol content, Lp(a) protein concentration, and lipoprotein density 
profiles.  The increase in niacin treatment and the results of the serum tests are graphed 
in Figure 72.  The traditional HDL cholesterol measurements showed a general increase 
in relation to the niacin treatment dosage (Figure 72B).  With respect to the Lp(a) protein 
concentration, an inverse relationship was observed in relation to the increasing niacin 
dosage.(Figure 72C)  These results concur with the current literature on the effects of 
niacin treatment on lipoproteins.  Using the lipoprotein density profiles, fluctuation in 
the integrated fluorescence intensities for the TRL and total LDL fractions (Figures 72D 
and 72E, respectively) of the lipoprotein density profiles led to no specific conclusions 
with respect to the effects of the niacin treatment.  However, the integrated fluorescence 
intensities for the total HDL fraction of the profiles showed a surprising result.  There 
was an inverse relationship between the total HDL fluorescence intensity and the niacin 
dosage. (Figure 72F)  This result is contrary to the relationship previously documented   
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Figure 72: Niacin Dosage Effects on Lipoprotein Measurement Methods. (A) Niacin 
Dosage over Time, (B) HDL Cholesterol Concentration over Time, (C) Lp(a) 
Protein Concentration over Time, (D) TRL Fluorescence Intensity over Time, (E) 
LDL Fluorescence Intensity over Time, (F) HDL Fluorescence Intensity over Time 
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between the HDL cholesterol concentration and niacin dosage.  This discontinuity 
between HDL measurement methods further supported the hypothesis that the NBD-
ceramide fluorescence can be influenced by the morphology and chemical content of the 
HDL particles.  
The effect that the niacin treatment had on the lipoprotein profiles was further 
examined in order to understand its effect on the HDL subclasses.  The overlaid 
lipoprotein density profiles are shown in Figure 73.   The HDL peak at the density 
~1.117g/mL steadily decreased in intensity as the niacin dosage increased.  The decrease 
of the fluorescence intensity in this density range explained the decrease in the total 
HDL fluorescence intensity previously observed.  There was also a peak at ~1.049g/mL 
in the baseline serum draw on 05/07/2010 that was not apparent in the serum draws 
taken after niacin treatment.  This peak reappeared in the final serum draw after a one 
week washout period of no niacin.  The density range for this peak indicates that it is 
possibly the result of an increase in Lp(a) concentration. 
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Figure 73: Lipoprotein Density Profiles by Draw Date/Niacin Dosage 
 
 With niacin’s effect on the lipoprotein density profile showing significant 
changes in the HDL fraction; this effect was now studied in terms of its influence on the 
LDA/SIR risk assessment for CVD.  The change in the LDA/SIR value over time is 
graphed in Figure 74.  While niacin treatment is supposed to reduce the risk of CVD, the 
LDA/SIR value showed a general increase over time with respect to the niacin dosage.  
As previously discussed in Section 3.2.1.4, the HDL subclasses were attributed with the 
largest coefficients in the LDA/SIR equation.  The change in HDL fluorescence intensity 
found in relation to the niacin treatment was identified in the HDL-3a subclass.  This 
subclass was attributed with the largest coefficient for classification of a CTRL.  
Reduction of the HDL fluorescence intensity in this region explains why the LDA/SIR 
191 
 
 
 
value, and therefore the CVD risk, was found to be increased with the increase in niacin 
dosage. 
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Figure 74: LDA/SIR Value in Relation to Draw Date/Niacin Dosage 
 
 While the effects of statin therapy were identified to reduce the risk of 
hypercholesterolemia in children, this case study indicates that the effects of niacin 
therapy have an adverse effect on the CVD risk assessment through the lipoprotein 
density profiling and LDA/SIR statistical analysis.  Further investigation is required to 
ascertain the true effect of niacin on CVD risk assessment in terms of the methods of this 
thesis.  This was only one case study and it could have been affected by uncontrolled 
factors.  A larger study which includes more subjects, a variety of dosages, and a control 
arm is recommended. 
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3.2.3.2 Case Study Monitoring the Effects of Lifestyle Modification 
 With the various methods of medical therapy currently being studied for CVD 
risk reduction, the most universal and available way for a person to lower risk is through 
lifestyle modifications including exercise and diet change.  Lifestyle modification can 
also be performed prior to any presentation of CVD risk.  With the methodology 
developed in this thesis, the idea of monitoring the effect of lifestyle modification 
through a standard test without the use of more invasive methods became possible.  The 
case study described here involved a subject that underwent an exercise program that 
was made up of three to five 30 minute runs every week for 16 weeks.  The program was 
designed to keep the heart rate down to an optimal range for burning fat (60-70% of 
maximum heart rate).  After 16 weeks, the regime was increased to include an extra 30 
minute run each day at a pace that was set for cardiovascular training (70-80% of 
maximum heart rate) in addition to the fat burning run.  Serum draws were performed 
each week to monitor the change in the lipoprotein density profiles.   
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Figure 75: Lipoprotein Density Profiles Comparison Based on the Increase of 
Physical Exercise – NaBiEDTA-Based Density Gradient 
 
A comparison of the lipoprotein density profiles over every four weeks is 
graphed in Figure 75.  The baseline draw (Red) shows a dual peak in the LDL density 
range that is not present for the next three sequential draws.  The dual peak was again 
present after Week 16 where the cardiovascular run was added to the exercise regime.  
There was also an apparent density shift in the primary LDL peak over the exercise 
period to a lower density.  As for the HDL, the total intensity of the HDL fraction 
seemed to increase over the exercise period.  Increase in HDL content and the shift of 
LDL to a lower density concur with the current theories and trends for healthy 
lipoproteins. 
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To further study the changes in the lipoprotein density profiles, the integrated 
fluorescence intensities for the TRL, total LDL, and total HDL subclasses were graphed 
in relation to the exercise week in Figure 76.  The total HDL fluorescence intensity 
generally increased over time.  The total LDL fluorescence intensity decreased initially 
and then balanced out to a range similar to the baseline value.  The TRL fluorescent 
intensities fluctuate but do not change in a significant manor relative to the exercise 
program. 
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Figure 76: Fluorescence Intensities for Major Lipoprotein Fractions Found 
through Lipoprotein Density Profiling with Respect to Increase in Physical 
Exercise 
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Figure 77: LDA/SIR Values in Relation to Increased Physical Exercise 
 
 To assess how the changes in the lipoprotein density profiles affect the LDA/SIR 
risk assessment for the subject of this case study, the LDA/SIR equation generated was 
used to calculate the LDA/SIR value for each week.  The resulting LDA/SIR values are 
graphed in Figure 77 with respect to the week of the exercise program.  Surprisingly, the 
LDA/SIR values generally increased over the first 13 weeks of exercise.  The increase in 
the LDA/SIR values indicated an increase in CVD risk after exercise.  After Week 13, 
there was a steep drop in LDA/SIR values which would indicate a reduction in CVD risk 
for the subject.  There was also a brief increase in LDA/SIR values after the change in 
the exercise program.  This increase only lasted three weeks this time and then LDA/SIR 
values decreased to lower than the baseline value and stabilized at this low LDA/SIR 
value for the rest of the study.  Both increases in the LDA/SIR values occurred directly 
after the increase of physical activity.  The increase in CVD risk at the beginning of the 
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exercise program can be related to the drop in the low density LDL subclasses.  It is 
possible that the increase in metabolism related to exercise increased the subject’s 
catabolism of these low density LDL subclasses and resulted in the increased LDA/SIR 
score by reducing the fluorescent intensities of lipoprotein subclasses that were 
associated with the classification of CTRL in the LDA/SIR equation.  The reduction in 
LDA/SIR values at the end of the exercise program indicated that exercise can be used 
for reduction of CVD risk.  With the case study subject not having a definitive definition 
of CVD or CTRL, further studies involving subjects that have been diagnosed with CVD 
and the effects that exercise can have on the lipoprotein density profiles are necessary to 
establish this methodology not only as a risk assessment tool but also as a tool for 
monitoring the effectiveness of risk reduction through lifestyle modification.   
This case study and the previous case study involving the niacin therapy show 
the sensitivity of the lipoprotein density profiles and how they can fluctuate based on 
day-to-day factors.   With this sensitivity, the risk assessment for CVD when using the 
lipoprotein density profiles is a mobile snapshot of a subject’s health at the time the 
serum sample was extracted.  Further investigation into the stability of the lipoprotein 
density profile when no outside factors like medical therapy or change in physical 
activity are involved is necessary in order to assess the use of this methodology in a 
longitudinal CVD risk assessment. 
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4. CONCLUSIONS 
 
The overall objective of this research was to develop and enhance analytical 
techniques and methods which, when combined, could be used to assess the risk an 
individual has of developing cardiovascular disease.  This objective was achieved 
through use of high precision lipoprotein density profiling, mass spectrometry of HDL 
apolipoproteins, and the application of advanced multivariate statistical analyses.  
Through application of these methods to clinical studies, an equation was developed 
using the method variables to accurately identify subjects with and without CVD.  For 
clinical studies, the definition of a healthy control was redefined from the lack of patient 
history and risk factors to having a clean angiogram of less than 10% arterial blockage.  
This new definition of CTRL was able to increase the distinction between the CVD and 
CTRL groups in the applied clinical studies for both CVD risk assessment and 
lipoprotein characterization.  These clinical studies showed the feasibility of this 
methodology as a novel method of risk assessment that has the potential for early 
detection of CVD prior to the onset of the disease. 
Through studies designed to increase the precision of the lipoprotein density 
profiles using heavy metal EDTA complexes for density gradient formation, a better 
understanding of the optimal conditions necessary for creating a high precision method 
of separating lipoproteins was attained.  This high precision method was able to be used 
as a profiling method as well as a preparative method for further analysis of the 
lipoproteins and their content.  Future use of these EDTA complexes and high precision 
198 
 
 
 
lipoprotein density profiles includes the use of larger UC tubes and modifications of the 
density gradient in order to isolate specific lipoprotein subclasses for further studies. 
The SPE method of isolation of apolipoproteins was studied using quantitative 
ELISAs and protein analysis techniques in order to optimize recovery of the 
apolipoproteins so that comparative studies between CVD and CTRL cohorts were 
possible.  The combination of preparative ultracentrifugation techniques and dextran 
sulfate precipitation was found to optimally isolate the HDL prior to applying the SPE 
method.  Through quantitative analysis of the protein content in the recovered fraction, 
improved recovery of the apolipoproteins over the previously documented SPE 
capabilities was obtained. 
Through the use of preparative ultracentrifugation, SPE, and MALDI-TOF MS, 
multiple differences in the apolipoprotein content of HDL fractions were identified when 
comparing CVD and CTRL groups.  The Apo A-I mass spectra for multiple CVD 
subjects showed a change in mass of ~450Da when compared to the CTRL subjects.  
The Apo A-II mass spectra for CVD subjects showed the presence of peaks at a m/z of 
<16,900Da that were not present for the majority of CTRL subjects.  Finally, the PTM 
for Apo C-I that was identified in CVD subject from prior research(ref) was present in 
multiple CTRL subjects while not present in the CVD subjects studied in this research.  
Future research into the nature of these modifications and their causes can illuminate 
methods of medical treatment and the role these modifications play as risk factors for 
CVD.  Future research into the lower abundant apolipoproteins, such as Apo C-II and 
Apo C-III, also showed potential.  However, further separation of these compounds 
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would be necessary due to their similar mass characteristics in order to identify any PTM 
or truncated form that might be associated with CVD risk. 
Application of the high precision lipoprotein density profiling method developed 
in this thesis, in conjunction with LDA/SIR analysis, was able to generate equations 
using the lipoprotein subclasses to accurately assess which subjects were at risk in the 
different clinical studies.  Compared to the accuracy of the LDA/SIR analysis when 
using traditional lipid measurements performed by medical practitioners, the lipoprotein 
density profiles were found to have significant increases in the accuracy of risk 
assessment.  The method was successfully applied to subjects with normal lipidemic 
characteristics with a prediction accuracy of up to 92.7%.  When applied to the 
prediction of hypercholesterolemia in children, the prediction accuracy was found to be 
97.6%.  These results indicated the potential for lipoprotein density profiles over 
traditional methods of lipid measurement.   
Further investigation into a sample library with an increased number of samples 
was necessary to investigate the subject dependency found in these studies.  For the large 
comprehensive library of subjects, the prediction accuracy was found to be 81.8%.  A 
reduction in the subject dependency was observed that was related to the increase in 
subjects relative to the number of variables used in the LDA/SIR analysis.  Through 
inclusion of specific traditional risk factors: the presence of hypertension and family 
history of CVD, an increased prediction accuracy of 86.9% was attained.  Through 
examination of the LDA/SIR equation generated, evidence was found to support the 
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existence of atherogenic forms of HDL due to multiple subclasses being coupled with 
coefficients weighting them towards a CVD classification. 
Further research into the LDA/SIR analysis was designed to increase the 
accuracy in CVD risk assessment by identifying characteristics that could distinguish 
between CVD and CTRL groups through alternate analytical techniques.  This research 
included identification of the differences in mass spectrometry between the two groups 
and the use of Cs2CdEDTA as the solute for density gradient formation to further 
separate the lipoproteins through density profiling.  The additional lipoprotein subclass 
resolved when using the new solute (IDL) and the differences in the mass spectra 
between CVD and CTRL groups showed the potential for increasing the prediction 
accuracy of the LDA/SIR analysis to 93% in a subset of samples from the 
comprehensive library.  This result proved the feasibility of adding mass spectra 
information to the LDA/SIR analysis for enhanced CVD risk assessment. 
In an effort to identify the optimal method of multivariate statistical analysis to 
be used for CVD risk assessment, the method of QDA was applied to the comprehensive 
library and the 72 patient subset of the comprehensive library. QDA showed an increase 
potential of risk assessment through the increased prediction accuracy for every data set 
for which it was applied in comparison to the prediction accuracy of the LDA/SIR 
analysis.  The optimal prediction accuracy was found when using QDA on the data set 
that included the lipoprotein density profiles with the addition of HDL apolipoprotein 
information from mass spectrometry.  With this data the prediction accuracy for the 72 
patient subset of the comprehensive library using QDA was found to be 100%.  There 
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was a large subject dependency that was seen through the X-Val score relative to this 
analysis.  Increasing the subject size was hypothesized to remove this dependency. 
The results presented in this thesis identified the potential for enhanced CVD risk 
assessment through the combination of analytical methods for lipoprotein profiling and 
characterization with advanced multivariate statistical techniques.  Use of these 
techniques showed potential for an increased accuracy in risk assessment relative to 
current methods such as the Framingham and Reynold’s Risk Score.  Further application 
of the lipoprotein profiles and the algorithms generated through the statistical analyses 
was seen in the sensitivity of the methods for monitoring the effectiveness of medical 
therapies designed to reduce a subject’s cardiovascular risk.  Through further 
characterization of the lipoproteins, potential atherogenic subclasses of HDL and novel 
potential risk factors in the HDL apolipoproteins were identified.  These novel factors 
were shown to improve the CVD risk assessment when added to the integrated 
fluorescence intensities from the lipoprotein density profiles. These methods represent 
the potential for a more “personalized” view of medical therapy and for monitoring the 
effectiveness of such therapies. 
In the future, this methodology should be applied to larger libraries of serum 
samples for which epidemiological data has been accumulated in order to assess the 
differences in risk assessment when applied as a longitudinal risk study and due to 
factors like gender, ethnicity, etc.  One such serum library is the Framingham Heart 
Study.  This would allow for direct comparison between the different methods and for 
comparison of the results to the current medical standard. 
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